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The use of visible light for promoting chemical reactivity has far-reaching implications in 
providing access to otherwise challenging bond constructions in drug discovery, as well as 
minimizing the environmental impact of industrial pharmaceutical production. Along with 
harnessing a more sustainable energy source (e.g. sunlight), photocatalysis presents a means to 
circumvent the use of toxic reagents and hazardous conditions classically employed for promoting 
free radical chemistry in the synthesis of biologically active compounds.  This thesis focuses on 
the development of visible light-mediated methods for the late-stage functionalization of 
heterocyclic drug scaffolds, as well as the design of a droplet microfluidics platform for the high-
throughput optimization of photocatalytic reactions.  
Chapter 1 provides a detailed summary of visible light-driven methodology that have been 
developed to enable the C–H alkylation of biologically relevant (hetero)arenes.  The application 
of photoredox catalysis for alkyl radical generation has given rise to a multitude of methods that 
feature enhanced functional group tolerance, generality, and operational simplicity. This chapter 
will highlight examples of visible light-driven Minisci alkylation strategies that represent key 
advancements in this area of research. The scope and limitation of these transformations will be 
discussed, with a focus on examining the underlying pathways for alkyl radical generation. 
Chapter 2 focuses on a method for the photoredox (perfluoro)alkylation of heteroarenes using 
alkyl carboxylic acid derivatives. Late-stage introduction of alkyl and perfluoroalkylated groups 
onto unfunctionalized positions on a drug scaffold holds significant potential for accelerating the 
drug discovery process.  As such, the development of a visible light-driven heteroarene alkylation 
 xxi 
strategy, including optimization studies, elucidation of scope, and mechanistic studies, is 
described. 
Chapter 3 describes our efforts in developing a droplet microfluidics-based, nanoelectrospray 
ionization-mass spectrometry (nESI-MS) platform for screening photoredox catalysis reactions.  
Both the time and resource-efficient principles governing this technology underscore its 
anticipated impact on providing accelerated access to an array of diversified drug scaffolds using 
sustainable, visible light-driven synthetic methods.  Application of this system towards the high-
throughput late-stage diversification of complex pharmaceutical scaffolds is established in this 
chapter.   
Chapter 4 continues to explore the utility of droplet microfluidics as a platform for screening 
photoredox reactions in continuous flow.  Here, we describe the development of a droplet 
microfluidic photoreactor setup that combines ESI-MS analysis to enable high-throughput reaction 
discovery on picomole scale.  This platform is anticipated to enable the direct optimization of flow 
reaction parameters (e.g. flow rate, residence time) and in turn, expedite the translation of 
discovery scale flow conditions to pilot scale continuous flow operations.   
Chapter 5 discusses a microwave heating strategy for streamlining the synthesis and 
diversification of Ir(III)+ polypyridyl complexes for applications in photoredox catalysis. This 
method is envisioned to help accelerate future developments in visible-light mediated chemistry.  
Additionally, the synthesis of novel nanohoop ligand-bearing Ir(III)+ polypyridyl complexes is 
described, along with the photophysical and electronic characterization of these complexes. 
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Chapter 1: Photoredox Catalysis in (Hetero)arene Alkylation 
* Portions of this chapter have been published in Sun, A. C.; McAtee, R. C.; McClain, E. J.; 
Stephenson, C. R. J. Advancements in Visible Light-Enabled Radical C(sp)2–H Alkylation of 
(Hetero)arenes; Synthesis 2019, 51(5), 1063–1072. 
 
1.1 Introduction: Photocatalysis Background and Design Principles 
 Since the first reported synthesis of tris(bipyridine)ruthenium(II) chloride (Ru(bpy)3Cl2) in 
1936,1 visible light-active metal complexes have been extensively investigated for applications in 
water splitting,2 photovoltaic cells,3 and energy storage.4  Until 2008, these complexes had only 
been employed sporadically as photocatalysts for radical processes in organic synthesis.  In the 
past decade, however, a renewed interest in photoredox catalysis across the synthetic organic 
chemistry community has led to the development of a diverse array of novel synthetic 
methodologies.5,6  In addition to enabling unprecedented bond constructions and new modes of 
reactivity, visible light photoredox catalysis offers significant benefits over traditional methods for 
redox chemistry.  For example, photoredox catalysis provides an optimal platform for performing 
redox neutral reactions, as both oxidants and reductants can be transiently generated in the same 
reaction vessel.   
The photochemical processes pertaining to the excited state species of iridium and ruthenium 
photocatalysts have been extensively studied (Figure 1.1A).7,8,9  Upon the complex's absorption 
of a photon in the visible region (λmax=375–455 nm), a metal-to-ligand charge transfer (MLCT) 
event occurs, followed by intersystem crossing to generate the lowest-energy and longer-lived 
triplet excited state species.   This species is "bipolar" in nature, having the ability to either undergo 
a single-electron reduction (reductive quenching) or a single-electron oxidation (oxidative
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quenching).  Additionally, the species resulting from either oxidative or reductive quenching are 
 
Figure 1.1. Simplified molecular orbital depiction of Ru(bpy)32+ photochemistry 
themselves strong oxidants and reductants, respectively (Figure 1.1B).  Upon altering the 
electronic properties of the redox-active pyridyl/bipyridyl ligands, the redox potentials of these 
photocatalysts can also be fine-tuned (Figure 1.1C) to mediate the reduction/oxidation of a variety  
of organic substrates.    
The use of visible light for promoting chemical reactivity has far-reaching implications in 
minimizing the environmental impact of the chemical industry. While traditional photochemistry 
has generally utilized ultraviolet light as chemical energy, visible light is a more desirable energy 
source due to an increased level of selectivity and control of reactivity. Visible light is absorbed 
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by relatively few organic molecules and can be used to selectively activate specific molecules or 
even transient species in solution. In addition to the promise of reduced waste streams, the use of 
a more sustainable energy source (e.g. sunlight), and the avoidance of the hazardous and/or toxic 
reagents classically-employed for carbon-centered radical formation (e.g. AIBN, Bu3SnH, 
BEt3/O2), photoredox catalysis has gained meaningful traction due to its ability to integrate with 
continuous flow technology.10-13 The enhanced light penetration available in flow can lead to 
order(s) of magnitude improvements in material throughput, and the applicability of these 
combined strategies will only increase as methods for in-line manipulation of material continue to 
improve.10  Importantly, photoredox catalysis is already exerting a significant influence on 
industrial chemistry by enabling otherwise infeasible bond disconnections and aiding 
sustainability efforts. Given the ever-increasing industrial investment (e.g. Merck10,11 Eli Lilly,13-
17AbbVie10), photoredox catalysis promises to be the most enabling synthetic technology since Pd-
based cross-coupling, which happens to be the only methodology invented in the last few decades 
to dramatically impact industrial synthesis.18 
1.2 Radical Functionalization of Unactivated Heteroarenes 
Nitrogen-containing heterocycles constitute the backbone of natural products, medicinally 
valuable small molecules and agrochemicals (Figure 1.2A).19,20 Methodologies for the direct C–
H alkylation and perfluoroalkylation of N-heteroarenes enable both the late-stage modification of 
clinical leads and rapid diversification of drug-like libraries. 21 , 22  These strategies allow for 
expedient access to unexplored chemical space and circumvent conventional de novo chemical 
syntheses.23 Notably, the medicinal chemistry community has placed growing interest on late-
stage functionalization technologies, as they allow for rapid  modulation of drug metabolism and 
pharmacokinetic profiles of lead compounds.21-23 Thus, synthetic approaches which are not 
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dependent on strong oxidants/reductants, high reaction temperatures, or pre-functionalized 
substrates are of high-value to both academic and industrial sectors.  
 
Figure 1.2. The Minisci alkylation of N-heteroarenes 
The addition of open-shell alkyl and perfluoroalkyl radical intermediates to heteroarenes is 
referred to as the Minisci reaction (Figure 1.2B).24-27 Minisci's original protocol relied on free 
radical formation from carboxylic acids via formation of their corresponding silver salts, followed 
by oxidative decarboxylation upon treatment with a persulfate oxidizing agent.  Addition of an 
alkyl radical intermediate onto a protonated heteroarene, followed by rearomatization, yields the 
desired alkylated heterocyclic product (Figure 1.2C). Based on Studer and Curran's mechanistic 
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studies, rearomatization is proposed to occur via deprotonation and sequential single electron 
oxidation of the functionalized heteroarene upon radical addition. 28  Since Minisci's seminal 
contributions, this reactive paradigm for the alkylation of (hetero)arenes has been a stalwart 
foundation for modern drug discovery and development.29 Furthermore, renewed interest in the 
mild and operationally simple generation of radical intermediates has spurred rapid evolution in 
the area of (hetero)arene alkylation.30-32 In part, the driving inertia for this interest has been the 
emergence of visible light-mediated photoredox catalysis, which facilitates exceptionally mild 
single electron transfer (SET) events with organic substrates.33-35 Importantly, the pharmaceutical 
industry has recognized the transformative impact of photoredox catalysis, 36 , 37  as it has far 
reaching implications in harnessing sustainable energy sources, reducing waste streams, and 
avoiding hazardous and/or toxic reagents classically employed for carbon-centered radical 
formation (e.g. Bu3SnH, BEt3/O2).  
1.3 N-Heteroarene Functionalization with Carboxylic Acids and Carboxylic Acid 
Derivatives 
 
Alkyl carboxylic acids are versatile feedstock chemicals that are ubiquitous throughout nature 
and have been widely used as chemical building blocks.38,39 Owing to their low cost, stability, 
minimal toxicity, and commercial availability, alkyl carboxylic acids have been widely utilized 
across a variety of synthetic transformations and represent preeminent building blocks for 
combinatorial chemistry (e.g. amide bond formation).  In recent years, the radical decarboxylation 
of aliphatic carboxylic acids and their activated derivatives has emerged as a powerful strategy for 
the Minisci functionalization of bioactive organic molecules.   
A broad selection of methods has been developed to promote the decarboxylation of alkyl 
carboxylic acid derivatives through a reductive pathway. In the context of photoredox catalysis, 
the formation of alkyl radicals via a reductive pathway would enable a net redox neutral catalytic 
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cycle, thereby eliminating the need for a terminal oxidant. At the same time, a reductive alkylation 
strategy has the potential to expand upon the scope of alkylation reagents, allowing access to 
compounds with significantly higher oxidation potentials.40  Pioneering studies on the reductive 
decarboxylative generation of alkyl radicals were conducted by Barton and co-workers in the 
1960s. 41 , 42  Barton et al. utilized N-hydroxypryidine-2-thione in the reductive activation of 
carboxylic acids for applications such as carbonyl reduction and reductive halogenation. In 1991, 
Oda and Okada disclosed the use of N-(acyloxy)phthalimides (NAP) as redox auxiliaries to enable 
the decarboxylative generation of alkyl radicals upon single electron reductive fragmentation (E1/2  
= -1.26 to -1.39 V vs. SCE (saturated calomel electrode)), using visible light-mediated photoredox 
catalysis.43    
 
Figure 1.3. Enantioselective synthesis of α-heterocyclic amines using a Brønsted acid/photoredox  
catalytic platform 
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Since 2017, NAP esters have been employed in several visible light-driven Minisci alkylation 
protocols to promote reductive alkyl radical generation.44-48 Notably, Phipps and co-workers have 
reported an enantioselective variant of the Minisci reaction (Figure 1.3) which utilizes a 
combination of asymmetric Brønsted acid catalysis and photoredox catalysis.46  The use of a chiral 
phosphoric acid catalyst provides both stereo- and regiocontrol in the direct addition of prochiral 
α-amino alkyl radicals to the 2-position of a variety of pyridine and quinoline-based substrates. 
This strategy elegantly facilitates the synthesis of enantioenriched α-heterocyclic amines through 
an efficient late-stage functionalization approach. Jiang and co-workers have also designed an 
alternative, organocatalytic approach for constructing α-isoquinoline-substituted secondary 
amines in an enantioselective manner.47  Nonetheless, the use of NAP esters for photoredox 
Minisci alkylations typically necessitates a separate isolation step following ester formation, 
resulting in an overall two-step procedure. In 2018, Sherwood and co-workers at Bristol-Meyers 
Squibb developed an operationally simple, one-pot protocol for the in situ generation of NAP 
esters, which obviates the need for isolating the pre-functionalized alkyl partner and facilitates the 
rapid generation of analog libraries.48 
With the goal of designing a Minisci alkylation strategy for the late-stage functionalization of 
advanced pharmaceutical intermediates, DiRocco and co-workers at Merck disclosed the 
innovative use of stable organic peroxides as alkylating reagents under photoredox conditions 
(Figure 1.4).49 Reaction parameters were optimized using a high-throughput experimentation 
platform, and the use of cyclometallated Ir(III)+ photocatalysts [Ir(dF{CF3)ppy}2(dtbbpy)]PF6 and 
[Ir(ppy)2(dtbbpy)]PF6 provided access to methyl, ethyl and cyclopropyl radical intermediates from 
bench-stable and inexpensive alkyl peracetates. The methodology was shown to be amenable to 
the late-stage alkylation of an array of complex medicinal and agrochemical agents bearing both 
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6- and 5-membered heterocyclic scaffolds. Most importantly, the transformation proceeded 
smoothly in the presence of functionalities such as basic amines, alcohols, amides, and esters, 
without the need for protecting groups. With respect to methyl radical generation, the authors 
propose a mechanistic pathway involving the activation of tert-butylhydroperoxide through a 
reductive proton-coupled electron transfer (PCET) process. The resulting α-peroxy radical 
subsequently undergoes homolytic O–O bond cleavage to afford acetic acid and a tert-butoxy 
radical species. The authors hypothesize that methyl radical formation arises from β-scission of 
the tert-butoxy radical, thereby producing acetone as a byproduct.    
 
Figure 1.4. Late-stage functionalization of biologically active heterocycles using alkyl peracetates  
 
In 2014, MacMillan et al. reported the first use of photoredox catalysis for the oxidative 
decarboxylation of alkyl carboxylic acids in the arylation of α-amino acids.50 In 2017, Glorius and 
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co-workers disclosed a Minisci alkylation strategy that enables access to alkyl radical 
intermediates through the oxidative decarboxylation of carboxylic acids.51 Sodium persulfate is 
used as an external oxidant to mediate alkyl radical formation, as well as facilitate photocatalyst 
turnover. The authors propose that the generation of desired alkyl radicals occurs through a 
hydrogen-atom transfer (HAT) event between a reduced sulfate radical anion species and a 
carboxylic acid precursor, resulting in oxidative decarboxylation. This reaction manifold enables 
the expedient functionalization of heterocyclic scaffolds, including pyridine, quinoline, and 
quinazoline cores. A range of primary, secondary, and tertiary alkyl radicals could be accessed 
from their corresponding alkyl carboxylic acid and amino acid precursors. The following year, 
Genovino and Frenette disclosed a separate visible light-driven Minisci alkylation protocol using 
hypervalent iodine reagents and organophotocatalysis to facilitate alkyl radical generation from 
carboxylic acids.52 
1.4 N-Heteroarene Functionalization with Alkyl Boronic Acids 
Over the past decade, aryl/alkyl-boron reagents have been identified to serve as radical 
precursors for C−C bond forming processes via oxidative C−B bond cleavage.53-60  In 2016, Chen 
and coworkers disclosed the Minisci C–H alkylation of N-heteroarenes with primary and 
secondary alkyl boronic acids using the photocatalyst Ru(bpy)3Cl2 and acetoxybenziodoxole as a 
sacrificial oxidant (Figure 1.5). Diversely substituted primary and secondary boronic acids (e.g., 
alkyl bromide, aryl iodide, ester, amide, carbamate, terminal alkyne, and benzyl chloride) were 
well tolerated. Pyridines, pyrimidines, and a purine riboside substrate were all efficiently 
functionalized. It should be noted that more electron-rich heteroarenes, including benzothiazole 
and benzoimidazole, could also be successfully alkylated. The authors propose that the reaction is 
initiated by a single-electron reduction from the photoexcited Ru(II)* to acetoxybenziodoxole, 
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providing an oxygen-centered radical intermediate. This radical species is then proposed to react 
with the alkyl boronic acid reagent to form the desired alkyl radical via a radical “ate” transition 
state. DFT calculations support that this is a facile and highly exothermic process at room 
temperature. 
 
Figure 1.5. Photoredox Minisci alkylation using boronic acid alkylating reagents  
1.5 N-Heteroarene Functionalization with Alkyl- and Alkoxymethyltrifluoroborates 
Potassium organotrifluoroborates are considerably more attractive radical precursors than their 
corresponding boronic acids, given their lack of an empty p-orbital, which increases their overall 
stability and robustness toward harsh reaction conditions.61,62 In 2011, Molander and coworkers 
reported the first use of potassium alkyl- and alkoxymethyltrifluoroborates as radical precursors 
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in the direct C−H alkylation of (hetero)arenes employing manganese(III) acetate as an oxidant in 
the presence of trifluoroacetic acid.63,64 Under the optimized reaction conditions, the authors were 
able to functionalize several nitrogen-containing heterocycles all in good to excellent yields.  
 
Figure 1.6. Organophotocatalytic Minisci alkylation using alkyltrifluoroborate radical precursors  
 
In 2017, the Molander group reported an impressive advance from their earlier manganese(III) 
acetate-mediated Minisci chemistry by showcasing that alkyltrifluoroborates (many of which are 
commercially available) can be activated by an inexpensive, sustainable organophotocatalyst 
(Figure 1.6). 65  Following reaction optimization, the authors found the utility of a mesityl 
acridinium photocatalyst, potassium persulfate (as a sacrificial oxidant), and trifluoroacetic acid to 
be the optimal  reagent combination for the C–H functionalization of heteroarenes. Under the title 
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reaction conditions, medicinally important cores including quinolines, isoquinolines, indazoles, 
pyridines, and quinazolinones, could all be functionalized with an impressive scope of primary, 
secondary, and tertiary alkyltrifluoroborates in good to excellent yields. As expected, electron-rich 
cores such as benzimidazole, were unreactive toward these Minisci alkylation conditions. These 
conditions proved tolerant of a diverse array of functional groups including aryl halides, 
unprotected amines, thioethers, and amides. Notably, quinine, which features a free alcohol, 
terminal alkene, and a tertiary amine (which has a known propensity for competitive photocatalytic 
oxidation) was efficiently (54% yield) and selectively (C2-) functionalized. To showcase the late- 
stage functionalization utility of their developed protocol, the authors successfully functionalized 
camptothecin, an anti-cancer drug candidate, at the C7-position. Mechanistically, the authors 
propose single electron oxidation of the alkyltrifluoroborate reagent, which leads to generation of 
the desired alkyl radical intermediate and BF3. 
1.6 N-Heteroarene Functionalization with Alkyl Halides 
Alkyl halides are among the most widely used materials in organic chemistry. However, their 
application as radical precursors has been hindered because of the harsh conditions required for 
radical generation, such as the use of highly toxic trialkyltin hydrides.66 The advent of modern 
photoredox catalysis provided a solution to this problem, as photoredox catalysts can be readily 
employed for the reductive dehalogenation of alkyl halides, resulting in the formation of free alkyl 
radicals. In 2010, the Stephenson group reported the seminal application of photoredox catalysis 
for the intramolecular alkylation of heteroarenes through reductive dehalogenation of activated 
alkyl bromides (Figure 1.7A).67 This report represented a significant milestone, as it was the first 
Minisci alkylation that was promoted by photoredox catalysis. The authors' proposed mechanism 
involved generation of a Ru(I) species through reductive quenching of the excited state 
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photocatalyst. This Ru(I) species could then reduce malonyl bromides to produce a carbon-
centered radical; subsequent trapping of the radical intermediate by electron rich indoles and 
pyrroles afforded the functionalized products. Following this initial report, the Stephenson group 
extended this methodology to access intermolecular C–H alkylations, 68  as well as the 
intermolecular construction of quaternary centers (Figure 1.7B).69 
 
Figure 1.7. Visible light-driven dehalogenative alkylation of heteroarenes 
Two recent reports have highlighted the continued expansion of Minisci protocols featuring 
dehalogenative radical generation. First, a group at Vertex Pharmaceuticals demonstrated the 
ability to predictably access C3- and C5-functionalized products by performing the Minisci 
reaction under basic conditions.70 This report featured the reductive dehalogenation of unactivated 
alkyl iodides and demonstrated the ability to predict the site of alkylation based upon the 
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electronics of a heteroaryl substrate. Additionally, the Wang group has reported a separate Minisci 
alkylation protocol which utilizes a halogen atom abstraction event to promote radical 
generation.71 This work was enabled through the adaptation of conditions concurrently reported 
by the Stephenson72 and MacMillan73 groups for visible light-mediated bromide atom abstraction 
from alkyl and aryl bromides, facilitated by a tris(trimethylsilyl)silane radical [(Me3Si)3Si•] 
species generated in situ. The use of a halogen atom abstraction approach allowed Wang and co-
workers to access a diverse scope of alkyl halides and heteroarenes.  
 
Figure 1.8. Photoredox trifluoromethylation of unactivated (hetero)arenes 
The incorporation of trifluoromethyl groups onto (hetero)arenes represents an important 
transformation in medicinal chemistry applications. As such, dehalogenative Minisci alkylations 
have also been expanded upon to include the trifluoromethylation of heteroarenes. In 2011, the 
MacMillan group developed the first reported method for the visible light-driven radical 
trifluoromethylation of (hetero)arenes (Figure 1.8). 74  In this report, reduction of 
trifluoromethanesulfonyl chloride by a ruthenium photocatalyst induced the loss of sulfur dioxide, 
affording the reactive trifluoromethyl radical species. This species could be effectively trapped by 
a number of (hetero)arenes, resulting in C–H trifluoromethylation. This method demonstrated the 
applicability of photoredox catalysis in medicinal chemistry, as a number of trifluoromethylated 
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pharmacophores could be easily accessed. Following this report, a collaborative effort by the 
Fukuzumi, Cho, and You groups described the use of a platinum(II)acetylacetonate (acac) 
photosensitizer for the reduction of trifluoromethyl iodide.  The resultant trifluoromethyl radical 
was utilized in the subsequent C–H trifluoromethylation of heteroarenes.75 
In the aforementioned examples, catalysis is promoted by engaging the photosensitizer in outer 
sphere electron transfer events. At the same time, dehalogenative radical generation has also been 
demonstrated to be driven by non-canonical photocatalysts that engage the halide substrate through 
inner sphere electron transfer or direct halogen atom abstraction events. In 2015, the Barriault 
group described the use of gold photoredox catalysis for the application of unactivated alkyl 
bromides to the alkylation of N-heteroarenes through an intramolecular cyclization (Figure 1.9).76 
This methodology was extended to intermolecular radical additions in 2016. In this more recent 
study, the Barriault group proposed a mechanistic pathway involving an excited state exciplex 
which could undergo an inner-sphere electron transfer to furnish the alkyl radical species (Figure 
1.9).77 The development of these methods has provided mild conditions for accessing primary 
alkyl radical fragments. Recently, a group from Pfizer reported the use of manganese decacarbonyl 
(Mn2CO10) for the alkylation of heteroarenes utilizing simple alkyl iodides as substrates.
78 The 
authors proposed that the Mn2CO10 catalyst undergoes Mn–Mn bond homolysis upon irradiated 
with blue light.  The resultant (CO)5Mn• radical species can then abstract an iodine atom from the 
alkyl iodide reagent to enable alkyl radical generation. 
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Figure 1.9. Dehalogenative alkylation using gold photoredox catalysis 
1.7 N-Heteroarene Functionalization with Alcohols and Ethers 
The late-stage incorporation of oxygenated functionality into complex molecules can have a 
significant impact on the physical properties (e.g. solubility) of a compound. For drug discovery, 
the optimization of these properties for a lead compound is vital to the development of clinical 
candidates. 79  Thus, the development of methods for the installation of simple oxygenated 
fragments, such as those derived from alcohols and ethers, is an important point of development 
for the Minisci reaction. 
The application of alcohols in the visible light-driven Minisci alkylation of heteroarenes was 
first reported in 2015 by the MacMillan group (Figure 1.10).80 The authors proposed that the 
methylation of heteroarenes could be achieved through the initial addition of a carbon-centered 
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hydroxymethyl radical onto a heteroarene substrate. The hydroxymethyl group could then be 
converted to the desired methyl fragment through a spin-center shift induced by the concomitant 
loss of water. The subsequent benzylic radical species was proposed to be reduced and protonated 
to furnish the final methylated product. Importantly, the proposed hydroxymethyl radical 
intermediate in this report was generated through C–H abstraction of methanol with a thiol co-
catalyst. This method provided a general manifold for accessing Minisci reactivity, as a variety of 
alcohols, pyridines, quinolines, and isoquinolines were amendable to these alkylation conditions.  
 
Figure 1.10. Visible light-driven Minisci alkylation reaction using alcohols as alkylating agents 
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Following this report, in 2016, DiRocco and co-workers utilized a radical relay reaction to 
promote the visible light-mediated hydroxymethylation of heteroarenes with methanol.81 This 
reaction was proposed to proceed through the generation of a phenyl radical species from the 
Ir(III)-catalyzed reductive decomposition of benzoyl. The phenyl radical intermediate then 
undergoes hydrogen atom abstraction from methanol, thereby generating the active 
hydroxymethyl radical species, which could be trapped by a variety of heteroarenes. This 
hydroxymethylation protocol allows for the late-stage functionalization of an array of 
pharmacophores.  While the above two examples utilize iridium photocatalysts to promote 
reactivity, Minisci reactions featuring alkyl alcohol reagents have also been reported in the absence 
of photocatalysts. In 2017, the groups of Li 82  and Barriault 83  independently reported the 
application of near UV irradiation to promote the methylation of heteroarenes.  
In 2014, the MacMillan group reported the first application of ethers in conjunction with 
photoredox catalysis for Minisci reactivity.84 The developed method utilized persulfate salts as 
both an oxidant and C–H abstraction reagent. From a mechanistic standpoint, oxidative quenching 
of the photocatalyst by the persulfate salt generates an equivalent of sulfate radical anion, which 
readily abstracts a hydrogen atom from the ethereal substrate. This seminal report demonstrates 
the impact of photoredox catalysis on broadening the scope of Minisci reaction protocols, as both 
cyclic and acyclic ethers could be innovatively used as radical alkylating reagents under mild 
conditions. In 2017, the Ryu group described the use of a polyoxometalate potocatalyst 
tetrabutylammonium decatungstate (TBADT) for a visible light-driven Minisci alkylation 
reaction.85 In its excited state, the TBADT photcatalyst enabled the selective, oxidative generation 
of radical intermediates through the direct abstraction of electron-rich hydrogen atoms present 
across ether, alkane, and amide substrates. It is noteworthy that Minisci reactions enabled by the 
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C–H abstraction of saturated molecules are not limited to oxygenated substrates, as this 
mechanistic paradigm has also been reported with the employment of protected amines86 and 
alkanes.85,87 
1.8 Conclusion 
As exemplified in this chapter, the utility of photoredox catalysis for the Minisci alkylation 
reaction provides synthetic chemists with a myriad of opportunities to utilize inexpensive, 
commercially abundant alkylating reagents (e.g. carboxylic acids, alcohols, alkyltrifluoroborates, 
alkyl halides, etc.) for the direct, C–H alkylation of heteroarenes. Notably, visible light-driven 
Minisci alkylation reactions have been demonstrated to proceed under mild reaction conditions 
and are tolerant of a variety of complex functionalities.  In particular, these strategies have been 
shown to hold significant value for late-stage functionalization efforts in drug discovery. The 
continued development of photoredox Minisci alkylation reactions that are amenable to a broader 
scope of complex heterocyclic  compounds, while providing improved regioselectivity, is vital to 
enhancing the synthetic utility and impact of this transformation. Furthermore, demonstrating the 
scalability of photoredox Minisci alkylation protocols (e.g. using continuous flow systems) may 















Chapter 2: Visible Light-Driven Strategies for the Decarboxylative (Perfluoro)alkylation of 
Pharmaceutically Relevant Compounds 
*Portions of this chapter have been published in Alexandra C. Sun, Edward J. McClain, Joel W. 
Beatty, Corey R. J. Stephenson, Org. Lett. 2018, 20(12), 3487-3490. 
2.1 Introduction 
2.1.1 Trifluoromethylation of (Hetero)arenes and Late-Stage Alkylation  
Fluorinated compounds are the subject of powerful interest within the context of agrochemical 
and pharmaceutical development, as the incorporation of fluorine onto an organic scaffold can 
greatly alter pharmacokinetic properties such as metabolic stability, membrane permeability, and 
solubility.88  Fluorine atoms can be found in over 200 approved pharmaceuticals to date,89 and in 
this context fluorinated moieties such as the trifluoromethyl group (CF3) have found fundamental, 
widespread utility (Figure 2.1A).  Industrially, commodity trifluoromethyl derivatives are 
produced through direct halogen-fluoride exchange in anhydrous hydrogen fluoride at elevated 
temperatures (Figure 2.1B);90  while this method is inexpensive to employ, its application is 
limited to thermally and oxidatively robust molecular architectures, and thus not amenable to 
complex molecule synthesis. In other instances, multi-step fluorination protocols are employed. 
For example, a reported synthesis of the ORL-1 antagonist 2 (Figure 2.1C) accomplished the 
benzylic fluorination of the spirocyclic furan 3 through a lengthy 5-step sequence;91 while scalable, 
this route relied upon the use of 23.9 kg of bis(2-methoxyethyl)aminosulfur trifluoride—a fuming 
reagent which produces HF and reacts violently with water—as well as 1.2 kg of shock-sensitive 
AIBN. 
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Due to the immense importance of the trifluoromethyl group to pharmaceutical synthesis, a 
large number of reagents prepossessing C–F bonds has been developed to avoid the forceful, 
hazardous, and/or circuitous requirements of C–F bond formation (Figure 2.2).  
 
Figure 2.1. Fluorinated pharmaceuticals and intermediates 
While the breadth of effective trifluoromethylation reagents is impressive, the relative cost and 
availability of these reagents varies greatly with complexity and molecular weight–a feature which 
is largely ignored in the context of academic methodology development. Conversely, in 
consideration of scalable, financially feasible, and industrially relevant trifluoromethylation 
methodologies, reagent choice is far more limited. A recent discussion in the context of the 
synthesis of the (trifluoromethyl)-nicotinate 2.1 (Figure 2.1A) places this issue in perspective: On 
large scale, “applications of Ruperts reagent (R3SiCF3) are most prominent. However, the large-
scale availability of CF3SiMe3 and higher alkyl variants is still limited, and their cost can be 
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prohibitive for use in commercial pharmaceutical manufacture.”92 In addition, despite the apparent 
variety of trifluoromethylation reagents, the range of starting-materials used for their preparation 
is strikingly limited (Figure 2.2). Bromotrifluoromethane (BrCF3) is the most commonly utilized 
fluorinated material for reagent synthesis, and is a well-known promoter of ozone-depletion with 
a half-life of 110 years in the troposphere. 93  BrCF3 is produced from the greenhouse gas 
fluoroform (HCF3, atmospheric lifetime = 254 yr),
94 and the two constitute the original source of 





2.4, 99  and 2.5 (Figure 2.2). 100 , 101  The remaining alternative CF3 reagents are obtained as 
derivatives of triflic or trifluoroacetic acid, which are produced avoiding the use of 
environmentally harmful gases directly through the electrochemical fluorination of either 
methanesulfonyl fluoride or acetyl fluoride, respectively.90 The sulfinate reagents CF3SO2Na and 
Zn(SO2CF3)2 in particular have garnered significant popularity for medicinal chemistry in industry; 
however, it should be mentioned that beyond their cost and limited availability, the use of these 
reagents requires an excess of both sulfinate (2-6 equiv.) and tert-butyl hydroperoxide (3-10 
equiv.), and occasionally requires multiple additions of reagent.102,103  
 
Figure 2.2. Cost per mole and sourcing of popular trifluoromethylation reagents (Sigma-Aldrich at 
largest quantity available) 
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2.1.2 Perfluoroalkylation Using Electronically Tuned N-Oxides 
In consideration of all relevant factors including safety, environmental impact, material 
availability, ease of handling, and lastly reagent price,104 TFA and its derivatives undeniably 
constitute the ideal source of CF3 in all respects. A particular challenge preventing the widespread 
use of TFA for trifluoromethylation chemistry is the large energetic cost of C–C bond cleavage, 
which can be accomplished thermally in a 2 e– pathway in the presence of copper salts at or above 
140 ˚C.92 Direct oxidative decarboxylation of trifluoroacetate has thus far been shown to be 
incompatible with electron-rich and electron-neutral substrates, as the potentials required for this 
reactivity will oxidize many common organic solvents (F3CO2Na,  E1/2
ox = >2.4 V vs. SCE in 
MeCN) (Figure 2.3A).105  
 
Figure 2.3. Mild photochemical trifluoromethylation with TFAA 
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The convergence of these factors has resulted in the use of TFA as a CF3 source only in very 
limited contexts of thermal 106  or oxidative 107  substrate stability, often in the presence of 
stoichiometric or superstoichiometric metal promoters.92 A direct oxidation of TFA is not feasible 
with photocatalysis, and so the Stephenson group has designed an activation method to promote 
decarboxylation of its anhydride (TFAA) through an initial reaction with pyridine N-oxide (PNO). 
The strategic use of PNO: (1) nucleophilically activates the acid through acylation (2) presents a 
weak N–O bond and low-lying LUMO for facile single-electron reduction (3) produces pyridine 
as an endogenous base necessary to avoid acid buildup and (4) avoids trifluoromethylation of the 
pyridine itself due to poor electronic matching with the electron-poor CF3 radical (Figure 2.3A). 
Mixing of TFAA with one equivalent of PNO results in the formation of a putative adduct which 
undergoes reduction at mild potentials (Ered
1/2
 = –1.10 V vs SCE in MeCN), forming the CF3 
radical within the redox-window of Ru(bpy)3
2+. Our group has demonstrated the efficacy of this 
design in the C–H trifluoromethylation of a number of electron-rich heterocyclic and aromatic 
substrates, a selection of which are shown in Figure 2.3B. This chemistry is compatible with a 
number of Lewis-basic functionalities, and a number of heterocycles with functionality useful for 
further cross-coupling reactions have been trifluoromethylated. Significantly, the utility of this 
chemistry has been demonstrated in the synthesis of intermediates such as chloropyridine 2.6, an 
intermediate of significant interest to Boeringher-Ingelheim for an anti-infective program.92 
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2.1.3 Perfluoroalkylation Using Electronically Tuned N-Oxides 
The reductive decarboxylation of acid derivatives using heterocyclic N-oxides offers many 
opportunities for customizability, including choice of photocatalyst, N-oxide, and reagent counter 
ion.  Of these factors, N-oxide substitution offers the most control over the reaction outcome. 
Among the issues encountered in the activation of TFAA with PNO, we identified the reduction 
potential of the TFAA adduct (E1/2
red = –1.10 V vs SCE) as potentially problematic as the reducing 
power of photoexcited Ru(bpy)3Cl2 (Ered
1/2 = –0.81 V vs SCE) is too positive for efficient reduction 
of this species.108 Of the wide array of pyridines available for investigation, 4-phenylpyridine N-
oxide (4-Ph-PNO) was expected to both stabilize the immediate product of reduction through 
additional conjugation, as well as present a lower LUMO due to the electron-withdrawing nature 
of the phenyl substituent (Figure 2.4A).  
 
Figure 2.4. Tunable N-oxide properties for decarboxylative photochemistry 
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Indeed, reduction of the 4-Ph-PNO/TFAA adduct was shifted 200 mV in the positive direction 
(Ered
1/2
 = –0.91 V vs SCE) as compared to the reduction of PNO/TFAA, suggesting that this 
alteration of N-oxide electronics is capable of promoting the decarboxylation of TFAA under even 
more mild conditions.  Electron transfer from photoexcited Ru(bpy)3Cl2 (as indicated by 
fluorescence quenching) is accomplished roughly 7 times faster with the 4-Ph-PNO adduct, and 
the observed quantum yield (Φ, yield of product per incident photon)109 is also increased (Figure 
2.4A). Significantly improved yields of trifluoromethylation products were obtained for an array 
of electron-rich substrates, many of which display significant further utility in the context of cross-
coupling and unnatural amino acid synthesis (Figure 2.5).  
 
Figure 2.5. Select scope of photoredox (hetero)arene trifluoromethylation 
The efficacy of 4-Ph-PNO in this manner represents a clear proof of principal for the 
importance of N-oxide functionalization. Much in the same way that ligand design is understood 
to influence the efficacy of transition-metal mediated cross-coupling reactivity, pyridine identity 
in this decarboxylation chemistry can have a significant effect on reaction mechanism and outcome 
(Figure 2.4B). The mechanistic underpinnings of the effects of pyridine substitution will result in 
more effective reagent choice, resulting in improved yields and reaction efficiencies. Beyond 
improved yields of trifluoromethylated products, this understanding of N-oxide reactivity will 
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contribute to the generality and efficiency of our method for cross-coupling of heterocycles with 
a variety of carboxylate radical precursors.   
We have investigated this cross-coupling strategy in the context of the synthesis of 
alternative fluorinated derivatives due to the associated interest in these fluorinated materials by 
the pharmaceutical industry. Without the need for multi-step reagent synthesis, our method offers 
inexpensive, scalable, operationally-simple C–H functionalization chemistry which dramatically 
reduces the environmental footprint of reagent preparation.  In our initial studies, we have 
accomplished the perfluoroethylation (Fig. 2.6A) and perfluoropropylation (Fig. 2.6B) of a 
number of electron rich heterocycles and arenes.  
 
Figure 2.6. Coupling of electron-poor perfluoroalkyl radicals with unfunctionalized heteroarenes 
 
Current methods available for performing these transformations are limited, while the 
corresponding acid derivatives are readily available for investigation.110 The generality of this 
process is cause for optimism, as the yields are good to excellent for electron rich substrates. As 
the acid-derivative coupling partner increases in size, the use of symmetrical anhydrides becomes 
less desirable, and acid chlorides have been found to provide equally good yields of product. It 
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should be noted that the industrial process of fluoride-halogen exchange used to synthesize 
trifluoromethylated arenes (Fig. 2.1B) cannot be applied for the synthesis of these functionalities, 
and these products are generally constructed through cross-coupling methods often requiring 
super-stoichiometric copper.111  
Despite early success with these electron-poor radical precursors, a number of challenges 
present themselves in the expansion of substrate scope and utility. In particular, subtle electronic 
changes to the intermediate radical can have a dramatic effect on reaction outcome; for example, 
switching from the per-halogenated acid derivatives above to difluoroacetic anhydride changes the 
radical character (CF2H radical) from purely electrophilic to significantly more nucleophilic.
112 
The above insight into direct difluoromethylation reactivity has served as early validation of our 
design principles for Phase 2 of our cross-coupling methodology, as the more nucleophilic 
character of the difluoromethyl radical results in preferential addition to electron-poor pyridine in 
solution.  
 
Figure 2.7. Coupling of electron-rich alkyl radicals with heteroarenes 
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One of the ultimate goals for this cross-coupling chemistry is to apply it to complex, high-
value fluorinated acid derivatives such as outlined in Figure 2.7A, which may display ambiphillic 
radical character upon decarboxylation. In order to fully realize this goal, further understanding of 
reactivity for more simple systems will be needed. The decarboxylation of electron-rich acid 
anhydrides and chlorides through reduction of electron-poor N-oxides forms an electronically 
matched pair of reactants, which can combine and provide coupled products in a selective fashion. 
We have extrapolated from these results to accomplish the difluoromethylation of 4-chloropyridine 
N-oxide, where the N-oxide acts as both redox trigger and heterocyclic coupling partner (Figure 
2.7B).  
2.1.4 Photochemical Cross Coupling of Acid Derivatives and Heterocycles 
An estimated 25% of all reactions performed in the pharmaceutical industry are cross-coupling 
transformations, a large portion of which are Suzuki couplings.113 These reactions constitute the 
backbone of medicinal chemistry methods; however, required pre-functionalization of the starting 
materials—particularly the boronic acid subunit—is a step-intensive process with associated 
synthetic challenges and waste streams.114 Numerous methods exist for the synthesis of boronic 
acid derivatives,115 and many boronic acids are produced as (or converted to) the corresponding 
ester to improve chemical stability and compatibility with chromatography.116 Associated issues 
include widespread difficulties in the separation of cleaved diol byproducts—particularly 
pinacol—from subsequent reaction mixtures.117,118 As a consequence of these factors, a move away 
from the use of prefunctionalized materials is currently underway in the chemical community;119 
within this context, the prospective utility of the N-oxide acylation/reduction process for 
pharmaceutical synthesis is high, as it involves readily available starting materials and results in 
C–H functionalization of a corresponding heterocyclic coupling partner with few byproducts 
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(Figure 2.8).  We have formally conceptualized this goal into two phases of orthogonal selectivity. 
The first, phase, is centered on the coupling of electron-poor radicals with electron-rich 
heterocycles, for which our group has demonstrated significant proof-of-principal through our 
trifluoromethylation methodology. Phase 2 involves the heterocyclic substrate itself acting as the 
coupling partner and transient redox-trigger for activation of the carboxylic acid counterpart. 
Through the use of this strategy, waste production is significantly decreased by minimizing 
synthetic operations,8 and the mutual substrate activation through acylation limits the number of 
required additives for inherent reactivity. Cleaved heterocycles act as endogenous base, the 
reactive radical intermediates can be controlled based upon the electronics of the reagents in the 
system. 
 
Figure 2.8. Direct, selective cross coupling strategy 
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We envisioned the immediate applicability of this reaction paradigm (Figure 2.9A) towards 
the design of a facile Minisci alkylation reaction. The Minisci reaction (Figure 2.9B), which 
involves the direct C─H alkylation of heteroarenes by a carbon-centered radical, has garnered 
much attention and undergone significant development in recent years.120-122 Minisci's original 
protocol for the decarboxylative alkylation of heterocycles relied on the use of stoichiometric silver 
salts, persulfate oxidants, and elevated temperatures.33a Since this initial publication, methods for 
achieving the Minisci alkylation have evolved to incorporate a diverse range of alkylating agents, 
including trifluoroborate salts,34a,b sulfinates,34c,d and alcohols.35a In particular, the application of  
photoredox catalysis for Minisci alkylations has led to significant improvements in the 
sustainability of this transformation, with the development of conditions that require lower reagent 
loadings and non-oxidative routes for alkyl radical generation.35   
 
Figure 2.9. Decarboxylative alkylation reaction design principles 
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While a multitude of protocols have been developed for the oxidative generation of 
alkyl/fluoroalkyl radicals for Minisci-type transformations, methods that promote the reductive 
radical alkylation of N-heteroarenes are comparatively less established (Figure 2.9C).35b,g In the 
context of photoredox catalysis, the formation of alkyl radicals through a reductive pathway would 
enable a net redox-neutral catalytic cycle, thereby eliminating the need for a stoichiometric 
terminal oxidant. Notably, in 2014, DiRocco and co-workers reported the photocatalytic alkylation 
of N-heterocycles through the reductive generation of alkyl radicals using perester reagents.35b 
Recently, the groups of Sherwood and Proctor have independently demonstrated the usage of N-
(acyloxy)phthalimides for the reductive decarboxylation of alkyl carboxylic acids in Minisci-type 
transformations.35g,h In comparison with previously reported Minisci alkylation methods, the 
decarboxylative alkylation strategy disclosed herein precludes the use of strongly acidic conditions 
and a sacrificial redox auxiliary. In using a fragment coupling approach, waste production can be 
inevitably decreased, as the mutual substrate activation through acylation avoids the use of 
stoichiometric additives for inherent reactivity. Reduced heterocyclic N-oxides can additionally 
act as endogenous bases, and reactive radical intermediates can be controlled based upon the 
electronics of reagents in the system.  
2.2 Results and Discussion 
Pivaloyl chloride and 4-phenylpyridine N-oxide were chosen as model substrates for initial 
pyridine alkylation evaluation.  Upon screening several solvents and photocatalysts, we discovered 
that a combination of acetonitrile and 1 mol% [Ir(ppy)2(dtbbpy)]PF6 furnished the desired 2-tert-
butyl-4-phenylpyridine product in 75% yield, as well as the 2,4-di-tert-butylated product in 5% 
yield (Figure 2.10). Under the optimized conditions, the scope of decarboxylative alkylations was 
examined with a number of alkyl carboxylic acid derivatives. Successful methylation (2.8) of 4-
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phenylpyridine N-oxide was achieved, albeit at a lower yield (15%), due to decreased radical 
stability and nucleophilicity.123  The importance of the methyl group to drug discovery is vast, as 
it is a feature which can improve solubility, binding, potency, and a host of other properties.124 As 
a consequence, late-stage introduction of the methyl group to un-functionalized positions on a drug 
scaffold holds significant potential utility.  Traditional methods for the Minisci decarboxylation of 
acetic acid require high temperatures, as well as silver and persulfate as oxidants.125 Furthermore, 
the formation of unstable intermediates such as the CH3 radical is energetically challenging.  
 
Figure 2.10. Alkyl carboxylic acid scope 
Scientists at Merck recently reported the generation of such intermediates using photocatalysis via 
the reduction of tert-butylperacetate,126 but to our knowledge this is the only synthetically useful 
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instance of CH3 radical generation to date. Our result represents the first photochemical 
decarboxylation of acetyl chloride at room temperature.  Difluoromethylation (2.9) was also 
achieved with the use of difluoromethylacetic anhydride as a source of the CF2H radical.  
Moreover, propionic acid could be used for the ethylation (2.10) of 4-phenylpyridine in modest 
yield (50%).  This protocol proved amenable to the coupling of 4-phenylpyridine with a wide range 
of secondary and tertiary cyclic alkanes (2.11-2.19), including the cyclohexyl (2.15) motif, which 
has been demonstrated to be a bioisostere of the phenyl functionality.127  Linear alkyl chains (2.20) 
could also be successfully accessed in modest yields, along with bridged cyclic alkane motifs such 
as the medicinally relevant norbornene bicycle (2.12).128 In contrast, the benzylation (2.21) of 4-
phenylpyridine N-oxide proceeded with significantly diminished yields. A predominant side 
reaction that was observed involved the formal decarbonylation of phenylacetyl chloride, yielding 
73% formation of benzyl chloride.  Furthermore, these conditions enabled the successful 
appendage of medicinally-relevant fluorinated isosteres129 onto heteroarenes, including the first 
example of incorporating the 1-fluorocyclopropane motif (2.23) onto a heterocyclic scaffold in 
one step from its carboxylic acid precursor. A variety of heterocyclic motifs (2.25-2.30) 
successfully underwent cross coupling with 4-phenylpyridine N-oxide, including the 
tetrahydropyranyl (2.22) and piperidinyl (2.28-2.30) ring systems, which have been used as H-
bond donor/acceptor probes in SAR studies.130  Most notably, we have demonstrated the unique 
coupling of a tertiary azetidine-derived radical (2.26) with an unactivated heteroarene, a 
transformation otherwise inaccessible to traditional transition metal-mediated cross-coupling 
methods. Overall, a variety of alkyl substrates, differing in size and electronic properties, have 
been demonstrated to be successful coupling partners in this transformation. An added benefit to 
this methodology entails the direct in situ formation of non-commercially available acid chloride 
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reagents from the corresponding carboxylic acid (via oxalyl chloride and catalytic DMF), followed 
by addition of the heterocyclic N-oxide, without the need for any additional purification or 
isolation steps.  
 
Figure 2.11. Heteroarene substrate scope 
In the next phase of this study, we evaluated a variety of diverse and pharmaceutically relevant 
heterocyclic motifs (Figure 2.11). The tert-butylation of mildly electron-deficient pyridine N-
oxide derivatives, such as ethyl isonicotinate N-oxide (2.31), as well as 4-acetylpyridine N-oxide 
(2.32) proceeded in good yields (75% and 52% respectively). Additionally, our studies showed 
that electron-rich pyridine N-oxides, such as alkylated N-oxides and protected alcohols (2.33-
2.35), could undergo tert-butylation in good to modest yields. 7-Azaindole, which can be 
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considered as a bioisostere of the indole and purine motifs and constitutes an essential subunit of 
many pharmacophores,131 could also be functionalized regioselectivity (2.36) using this protocol. 
Quinoline N-oxide was successully tert-butylated in 76% yield, leading to a 4:3 mixture of 
regioisomers (2.39). Several quinoline N-oxide derivatives containing methyl, methoxy, bromo, 
and chloro substituents, in addition to benzoquinoline, were alkylated in modest yields (2.37, 2.40-
2.42). The lower yields observed in the tert-butylation of lepidine N-oxide (2.40) can be attributed 
to competing deprotonation of the methyl substituent upon generation of the acylated complex, 
which results in displacement of pivalic acid and precludes reductive alkyl radical generation. 
Furthermore, difluoromethylation of 6-methoxyquinoline (2.43) exclusively resulted in 
functionalization at the 4-position. While a variety of pyridine and quinoline-based heterocyclic 
scaffolds could be accessed as coupling partners, functionalization of other five- and six-
membered heterocyclic N-oxides including benzylimidazole, quinoxaline, pyrimidine, and 
pyridazine N-oxide derivatives could not be achieved using this fragment coupling approach. As 
is evidenced by the significant recovery of N-oxide starting material, the observed lack of reactivity 
is suspected to be due to the diminished nucleophilicity of the N-oxide motif rather than inefficient 
radical addition. 132   tert-Butylation of quinoxaline did proceed successfully, however, in the 
presence of pyridine N-oxide as a redox auxiliary. Furthermore, transitioning from simple 
heterocyclic substrates to more complicated, biologically relevant molecular scaffolds presents 
further challenges as both the selective formation of the N-oxide functionality and the ability to 
predict the nucleophilicity of the N-oxide increase in complexity. We envisioned that the use of 
pyridine N-oxide as a sacrificial redox auxiliary would be an ideal platform for the alkylation of 
complex pharmacophore molecules. This concept came to fruition as subjection of brimonidine, a 
drug molecule used for the treatment of rosacea and open-angle glaucoma, with decarboxylative 
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alkylation conditions furnished the tert-butylated derivative in 11% yield (2.45). Additionally, we 
were able to tert-butylate (44% yield) the imidazopyridazine core structure (2.47).133 Further 
diversification of the scaffold gave rise to the methylated (2.48) (16% yield) and 
difluoromethylated (2.49) (13% yield) analogs.  
Quantum yield studies indicate that radical chain processes are operative in our system, as 
evidenced by a  of 1.7. Finally, we have demonstrated the capability to run this decarboxylative 
alkylation reaction on gram scale both in batch and in flow, suggesting that this methodology may 
translate beyond discovery scale.  Using a 900 μL flow reactor, 1 gram of quinoline N-oxide was 
tert-butylated in an overall 71% yield (relative to 68 % yield on a 1 gram scale in batch), with a 
residence time of 2.25 min. 
2.3 Conclusion 
In conclusion, we have reported an operationally simple and visible light-mediated method for 
the decarboxylative alkylation of heterocyclic N-oxides.  Most significantly, this protocol offers a 
platform for the reductive generation of alkyl radicals without the reliance on stoichiometric 
additives, harsh reagents, and sacrificial redox auxiliaries. We envision this methodology to be of 
significant utility and practicality for the diversification of heterocyclic scaffolds in a multitude of 
medicinal applications.  
2.4 Experimental Methods and Characterization of Compounds 
2.4.1 General Information and Experimental Procedures 
Chemicals were either used as received or purified according to the procedures outlined in 
Purification of Common Laboratory Chemicals. Hygroscopic N-oxide substrates were dried on a 
high vaccuum line for 6 h at ambient temperature prior to use.  Pyridine N-oxide was dried on a 
high vacuum line at 60 °C for 12 hours.  Thin-layer chromatography (TLC) analysis of reaction 
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mixtures was performed using Merck silica gel 60 F254 TLC plates and visualized by a dual short 
wave/long wave UV lamp. Column flash chromatography was performed using 230–400 mesh 
silica gel or via automated column chromatography.    
Nuclear magnetic resonance (NMR) spectra were recorded using an internal deuterium lock 
on Varian MR400, Varian Inova 500 and Varian Vnmrs 700 spectrometers.   Chemical shifts for 
1HNMR were reported as δ, parts per million, relative to the signal of CHCl3 at 7.26 ppm. Chemical 
shifts for 13CNMR were reported as δ, parts per million, relative to the center line signal of the 
CDCl3 triplet at 77.36 ppm. Multiplicities are reported using the following abbreviations: s = 
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = broad resonance, 
dd = doublet of doublet, dt = doublet of triplet, etc. High-resolution mass spectra (ESI) were 
recorded at the Mass Spectrometry Facility at the Department of Chemistry of the University of 
Michigan in Ann Arbor, MI, on a Micromass AutoSpec Ultima Magnetic Sector mass spectrometer 
using electrospray ionization (ESI), positive ion mode.  IR spectra were recorded on a Perkin-
Elmer Spectrum BX FT-IR spectrometer fitted with an ATR accessory.   Actinometry and quantum 
yield measurements were performed with a Fluoromax-2 fluorimeter equipped with a 150W Xe 
arc lamp.  UV-VIS measurements were obtained on a Shimadzu UV-1601 UV-VIS Spectrometer. 
LED lights and the requisite power box and cables were purchased from Creative Lighting 
Solutions (http://www.creativelightings.com) with the following item codes: CL-FRS5050-12WP-
12V (4.4 W blue LED light strip), CL-FRS5050WPDD-5M- 12V-BL (72 W LED strip), CL-
PS94670-25W (25 W power supply), CL-PS16020-150W (150 W power supply), CL-PC6FT-
PCW (power cord), CL-TERMBL-5P (terminal block). A reaction performed with a 24 W CFL 
placed 5 cm from the vial provided identical results. Unless stated otherwise, all reactions were 
run on a 0.8 mmol scale in a 2 dram vial equipped with stir bar and septum. The light apparatuses 
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used to irradiate the reactions were constructed from test tube racks and wrapped with three 4.4 W 
blue LED strips. Reactions were run only in slots marked by an X in the picture below so as to 
keep a moderate distance from the light source (~2.5 cm). At this distance the temperature of the 
reactions did not exceed 35 ˚C (Figure 2.12). 
Figure 2.12. Experimental light setup 
General Experimental Procedures 
 
Procedure A. To a 2 dram vial equipped with a stir bar was added heterocyclic N-oxide (0.80 
mmol, 1.0 equiv) and [Ir(ppy)2(dtbbpy)]PF6 (1.0 mol%). The combined materials were dissolved 
in MeCN (0.5 M, 1.6 mL) and stirred.  Upon subsequent addition of the acid chloride or anhydride 
(0.88 mmol, 1.1 equiv), the resulting solution was stirred for 5 min. The vial was equipped with a 
screw-on cap with septum, and a 20 gauge needle was placed through the septum for the duration 
of the reaction. Three 4.4 W LED light strips (positioned 2.5 cm away) were turned on and the 
reaction was allowed to run for 12-15 hours before the light source was removed.  Workup was 
performed by diluting the reaction with CH2Cl2 and washing with saturated NaHCO3 (x1) and then 
brine (x1). The organic layer was dried over sodium sulfate before filtering and concentrating at 
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40 ˚C under reduced pressure.  The crude residue can then be purified by column chromatography 
to afford the desired alkylation product(s). 
Reaction Optimization: Trimethoxybenzene (0.80 mmol) was added as a stoichiometric internal 
standard upon completion of the reaction. A sample of the reaction was removed and diluted with 
CDCl3 for NMR analysis.  
 
Procedure B. To a 2 dram vial equipped with a stir bar was added the heterocyclic substrate (0.8 
mmol), pyridine N-oxide (1.6 mmol, 5.0 equiv), and [Ir(ppy)2(dtbbpy)]PF6 (1.0 mol%). The 
combined materials were dissolved in MeCN (0.5 M, 1.6 mL) and stirred.  Upon subsequent 
addition of pivaloyl chloride (1.76 mmol, 5.5 equiv), the resulting solution was stirred for 5 min. 
The vial was equipped with a screw-on cap with septum, and a 25 gauge needle was placed through 
the septum for the duration of the reaction. Three 4.4 W LED light strips (positioned 2.5 cm away) 
were turned on and the reaction was allowed to run for 12-15 hours before the light source was 
removed.  Workup was performed by diluting the reaction with CH2Cl2 and washing with saturated 
NaHCO3 (x1) and then brine (x1). The organic layer was dried over sodium sulfate before filtering 
and concentrating at 40 ˚C under reduced pressure.  The crude residue can then be purified by 
column chromatography to afford the desired alkylation product(s). 
 
General procedure for acid chloride synthesis.  To an oven-dried round bottom flask was added 
the carboxylic acid substrate  (0.96 mmol, 1.0 equiv) and dichloromethane (0.2 M) under a 
nitrogen atmosphere.  To the resulting stirred solution was added oxalyl chloride (1.15 mmol, 1.2 
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equiv) and 2 drops of DMF.  The mixture was stirred at room temperature until all gas evolution 
ceased (generally 1-5 hours), and reaction progress was monitored by 1H NMR 
spectroscopy.  Product decomposition may be observed if the solution is stirred for over 5 
hours.  Upon reaching >99% conversion, the mixture was concentrated in vacuo to remove excess 
oxalyl chloride, and the crude acid chloride residue was used in the subsequent decarboxylation 
alkylation step without further purification.   
 
General heterocyclic N-oxide synthesis.  This procedure was adapted from the work of Herzon 
and co-workers.134  3-Chloroperbenzoic acid (1.0 equiv, 60% w/w) was added in one portion to a 
solution of the heterocyclic substrate (1.0 equiv) in dichloromethane (0.2 M) at 24 °C. The reaction 
mixture was stirred for 12 h at 24 °C.  PPh3 (0.5 equiv) was added and the solution was stirred for 
another 4 h.  The product mixture was concentrated to dryness and the residue obtained was 
purified by flash-column chromatography (eluting with ethyl acetate initially, grading to 10% 
methanol–ethyl acetate, linear gradient).    
Equipment and Procedure for Batch and Flow Processing 
A.  Equipment and Setup 
Figures 2.13-2.15 represent the specific equipment and setup used while performing the 
decarboxylative tert-butylation of quinoline N-oxide in continuous flow.  This setup was used for 
both small (200 μmol) and large (6.9 mmol) scale reactions.   
The LED assembly was obtained from Luxeon StarLEDs (Model No.: SP-02-V4, consisting 
of a series of seven LXML-PR02-A900 Royal Blue Luxeon Rebel ES LEDs mounted to a SinkPad-
II base; http://www.luxeonstar.com/royal-blue-447.5nm-sinkpad-ii-40mm-7-led-round-led-
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1030mw) and was adhered to a heat sink to dissipate heat from the LED (Luxeon, 60 mm round x 
45 mm high alpha heat sink; http://www.luxeonstar.com/60mm-round-3.9-degree-cw-alpha-heat-
sink). This was powered with a Costway DC power supply (Model No.: EP20570-110V), with 
both constant current (0-5 A) and constant voltage (0-30 V) capabilities. The light source was 
operated at 700 mA (unless otherwise noted); the manufacturer lists this as the optimal operating 
current.  Material was pumped through the system with an IPC-04 Ismatec peristaltic pump (Model 
No.: ISM930C, 4 channel pump) with a range of 32.2 μL/min up to 3.2 mL/min. Material was 
flowed through Teflon PFA tubing (0.030” inner diameter, 1/16” outer diameter) which was 
obtained from IDEX Health & Science (Part No.: 1514L; https://www.idex-hs.com/fluidic-
connections/dupontr-pfa-tubing-natural-1-16-od-x-030-id-x-50ft.html). 
 
Figure 2.13. Continuous flow processing equipment (Left: Luxeon SP-02-V4 Royal Blue LED 
mounted to heat sink; Middle: Ismatec peristaltic pump; Right: Costway DC controller) 
 
Figure 2.14 depicts the setup for the gram-scale continuous flow reaction.  Beyond the 
peristaltic pump, the tubing was wrapped around two 18x150 mm borosilicate test tubes and 
secured in place with tape, generating a 900 μL internal volume reactor.  Aluminum foil was taped 
around the tubing at the points outside of the intended irradiation window as this would define the 
“reaction vessel”. The reaction vessel itself was suspended 1 cm above and below the two light 
pucks.  A back pressure regulator of 20 psi (obtained from IDEX Health & Science; Part No. P-
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791) was fitted in between the reactor and the collection flask to control the release of carbon 
dioxide after the mixture has left the reactor.  Finally, the end of the tubing was threaded through 
a rubber septum which was fitted onto a collection flask with a 20 gauge needle for the dissipation 
of any pressure build-up from the generation of gaseous byproducts.  During each run, a cardboard 
box lined with aluminum foil (not depicted) was placed over the light source and reaction vessel 
to minimize irradiation of the starting material vessel or the collection vessel.  To get an estimate 
of the reaction mixture temperature, a thermometer was placed inside one of the borosilicate test 
tubes. As the light source tends to generate heat even when attached to the heat sink, a stream of 
compressed air was blown between the LEDs and the tubing to keep the temperature near room 
temperature. The light source was turned on at least a few minutes before each run to ensure the 
reaction vessel equilibrated to the steady state temperature (generally 32-35 °C). 
 
 
Figure 2.14. Full flow apparatus (direction of flow is from left to right) 





Figure 2.15. Continuous flow and batch reaction vessels (Left: Side view of continuous flow reaction 
vessel; Right: Gram-scale batch reaction vessel with light sources 1 cm apart on either side of vial) 
 
 For the large-scale batch reactions (ca. 1 g, 6.9 mmol of quinoline N-oxide), the reaction setup 
mimicked the flow apparatus. Thus, the reaction vessel was placed in between two light pucks (1 
cm distance on each side) and cooled with a stream of compressed air (see Figure 2.15).   A 20 
gauge needle was inserted into the septum cap to allow for release of carbon dioxide.   
B. Optimization of Flow Conditions on Small Scale (200 μmol) 
 
Figure 2.16. Optimization of continuous flow conditions on small scale 
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General Optimization Procedure. To a 2 dram vial equipped with a stir bar was added anhydrous 
quinoline N-oxide (0.20 mmol, 1.0 equiv), which had been pre-dried on a high vacuum line for 6 
h at ambient temperature.  Upon addition of [Ir(ppy)2(dtbbpy)]PF6 (1.0 mol%), the combined 
materials were dissolved in MeCN (0.5 M) and stirred.  Upon subsequent addition of pivaloyl 
chloride (0.22 mmol, 1.1 equiv), the resulting solution was stirred for 5 min. The vial was equipped 
with a septum, through which the reactor tubing had been threaded.  The reaction mixture was then 
flowed through the flow apparatus (see Section A) at various flow rates (see Figure 2.16).  
Trimethoxybenzene (0.20 mmol) was added as a stoichiometric internal standard upon completion 
of the reaction. A sample of the reaction was removed and diluted with CDCl3 for 
1H NMR 
analysis. 
C. Gram-scale Flow and Batch Reactions  
 
 
General Gram-Scale Flow Procedure. To a 2 dram vial equipped with a stir bar was added 
anhydrous quinoline N-oxide (6.9 mmol, 1.0 g), which had been pre-dried on a high vacuum line 
for 6 h at ambient temperature.  Upon addition of [Ir(ppy)2(dtbbpy)]PF6 (0.1 mol%), the combined 
materials were dissolved in MeCN (0.5 M) and stirred.  Pivaloyl chloride (7.59 mmol, 1.1 equiv) 
was added and the resulting solution was stirred for 5 min. The vial was equipped with a septum, 
through which the reactor tubing had been threaded.  The reaction mixture was then flowed through 
the flow apparatus (see Section A) at a flow rate of 400 μL/min, providing a residence time of 2.3 
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min.  Workup was performed by diluting the reaction with CH2Cl2 and washing with saturated 
NaHCO3 (x1) and then brine (x1). The organic layer was dried over sodium sulfate before filtering 
and concentrating at 40 ̊ C under reduced pressure.  The crude residue was then purified by column 
chromatography (gradient of 10% ethyl acetate/hexanes to 20% ethyl acetate/hexanes) to afford a 
3:4 mixture of 2-tert-butyl quinoline and 4-tert-butyl quinoline (overall yield: 0.91 g, 71%).   
General Gram-Scale Batch Procedure. To a 20 mL microwave vial equipped with a stir bar was 
added anhydrous quinoline N-oxide (6.9 mmol, 1.0 g), which had been pre-dried on a high vacuum 
line for 6 h at ambient temperature.  Upon addition of [Ir(ppy)2(dtbbpy)]PF6 (0.1 mol%), the 
combined materials were dissolved in MeCN (0.5 M) and stirred.  Pivaloyl chloride (7.59 mmol, 
1.1 equiv) was added and the resulting solution was stirred for 5 min. The vial was sealed with a 
septum cap, through which was inserted a 20 gauge needle.  The reaction mixture was stirred and 
irradiated for 35 min.  Upon completion of the reaction, workup was performed by diluting the 
reaction with CH2Cl2 and washing with saturated NaHCO3 (x1) and then brine (x1). The organic 
layer was dried over sodium sulfate before filtering and concentrating at 40 ˚C under reduced 
pressure.  The crude residue was then purified by column chromatography (gradient of 10% ethyl 
acetate/hexanes to 20% ethyl acetate/hexanes) to afford a 3:4 mixture of 2-tert-butyl quinoline and 







2.4.2 Reaction Optimization Data 























2.4.3 Electrochemical Measurements 
As discussed in a previous report135 by our group, the measurement of reduction potentials for 
the acylonium salts reported in this manuscript cannot be accurately performed through cyclic 
voltammetry analysis. The observed signal using cyclic voltammetry is found to have variations 
in shape and peak potential from run to run, and the peak shape is dependent upon sweep rate. 
Therefore, differential pulse voltammetry (DPV) was performed to obtain the reduction potentials 
of the various pyridine N-oxide/acid chloride combinations, and reproducible potentials were 
obtained through these methods. Measurements were performed with a model CHI660C multi-
potentiostat from CH Instruments. DPV pulse parameters were selected based on previous reported 
methods from our group in measuring reduction potentials for acylated pyridine N-oxides.135 
Measurements were performed with a glassy carbon working electrode, Pt auxiliary electrode, 
Ag/AgCl reference electrode, Bu4NPF6 electrolyte (0.1 M in MeCN), and analyte (pyridine-N-
oxide/pivaloyl chloride, 1:1, 0.01 M) with the following settings: Incr E (V) = 0.001, Amplitude 
(V) = 0.005, Pulse Width (sec) = 0.05, Sampling Width (sec) = 0.01, Pulse Period (sec) = 0.5, 
Quiet Time (sec) = 2, Sensitivity (A/V) = 1 e-5.  All voltammograms are reported/displayed after 
conversion to voltage vs. SCE, where: 
 
 Onset potentials are estimated based on the intersection of the baseline and onset slope (shown): 
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Figure 2.17. DPV of the pivaloyl chloride/pyridine N-oxide adduct.  Onset reduction potential is 
observed at  –0.51 V vs. SCE.  Peak reduction potential is observed at –0.63 V vs. SCE. 
 
 
Figure 2.18. DPV of the pivaloyl chloride/4-phenylpyridine N-oxide adduct.  Onset reduction 























































Potential (V vs. SCE)
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2.4.4 Quantum Yield Measurements 
 This experiment closely followed the procedure reported by Cismesia and Yoon.22 The only 
modification was the use of a 0.1 cm path length cuvette for the UV/Vis data during the calculation 
of the photon flux, a modification made during recent investigations into our photochemical radical 
trifluoromethylation chemistry.48 
 The light source employed was a 150 W Xenon Arc lamp within a Fluoromax-2 Fluorimeter. 
UV/Vis data was collected on a Shimadzu UV-1601 UV-Vis Spectrometer. The photon flux of 
this specific fluorimeter had previously been determined within the group to be 5.46x10-9 einstein/s 
at 436 nm (1 einstein = 1 mol photons). The experiment was repeated as is detailed in the 
Supplementary Information of our recent report48 to obtain a photon flux of 5.55x10-9 einstein/s at 
436 nm; this value was used in the following calculations. Specific details for the experimental 
determination of the quantum yield for the tert-butylation of quinoline N-oxide are provided 
below:  
 
Procedure for Quantum Yield Calculation.  In a dark room, anhydrous quinoline N-oxide (0.8 
mmol) was added to a dry quartz cuvette (1 cm path length) equipped with a stir bar.  Upon addition 
of [Ir(ppy)2(dtbbpy)]PF6 (1 mol%), the combined materials were dissolved in MeCN (2 mL) and 
stirred.  Pivaloyl chloride (0.88 mmol) was added and the resulting solution was capped, sealed, 
and stirred for 5 min.   Light exclusion was achieved by wrapping the cuvette in aluminum foil 
until the reaction was placed in the fluorimeter.  The sample holder was pre-equilibrated to 35 °C, 
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and the reaction sample was allowed to equilibrate to this temperature over 10 minutes.  The 
sample was stirred and irradiated at 436 nm with a 10 nm slit width for 21600 (6 h).  After 
irradiation, workup was performed by diluting the reaction with CH2Cl2 and washing with 
saturated NaHCO3 (x1) and then brine (x1). The organic layer was dried over sodium sulfate before 
filtering and concentrating at 40 ˚C under reduced pressure.  The crude residue was then purified 
by column chromatography (gradient of 10% ethyl acetate/hexanes to 20% ethyl acetate/hexanes) 
to afford a 3:4 mixture of 2-tert-butylquinoline and 4-tert-butylquinoline, with an overall yield of 
26% (0.204 mmol).   
 The quantum yield was calculated as follows (Equations 1 and 2), where flux = photon flux; 
t = time of irradiation (s); f = fraction of light absorbed = 1 ─ 10─A, where A = absorbance.  As 
seen in the aforementioned reports, the absorbance of the system is substantial (>3), leading to an 
f value of approximately 1.  For the purposes of this calculation, f is assumed to be equal to 1, 








2.4.5 Preparation and Characterization of Substrates and Products 
 
 
2-tert-butyl-4-phenylpyridine (2.7a) and 2,6-di-tert-butyl-4-phenylpyridine (2.7b) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford 2-tert-butyl-4-phenylpyridine (118 
mg, 71%) and 2,6-di-tert-butyl-4-phenylpyridine (6 mg, 3%) as colorless oils.  In addition, 4-
phenylpyridine (19 mg, 15%) was recovered. The acquired 1H and 13 CNMR spectra were identical 
to those reported in the literature.136 
2-tert-butyl-4-phenylpyridine (2.7a): Rf = 0.75 (ethyl acetate/hexanes 1:4; UV). 
1HNMR (CDCl3, 
700 MHz): δ 8.61 (d, J = 5.1 Hz, 1H), 7.63 (d, J = 7.3 Hz, 2H), 7.54 (s, 1H), 7.48 (t, J = 7.6 Hz, 
2H), 7.43 (t, J = 7.3 Hz, 1H), 7.30 (dd, J = 5.0, 1.5 Hz, 1H), 1.43 (s, 9H). 13C NMR (176 MHz, 
CDCl3): δ 170.13, 149.33, 148.95, 139.42, 129.31, 129.03, 127.41, 119.19, 117.52, 37.82, 30.58.  
HRMS (ESI) m/z [M + H]+ calcd for: C15H17N: 212.1434; found: 212.1435.   
2,6-di-tert-butyl-4-phenylpyridine (2.7b): Rf = 0.88 (ethyl acetate/hexanes 1:4; UV).  
1HNMR 
(CDCl3, 700 MHz): δ 7.64 – 7.59 (m, 2H), 7.47 (t, J = 7.7 Hz, 2H), 7.41 (d, J = 7.2 Hz, 1H), 7.29 
(s, 2H), 1.40 (s, 18H).  13C NMR (176 MHz, CDCl3): δ 168.46, 149.01, 140.74, 129.19, 128.60, 
127.61, 114.17, 38.10, 30.58.  HRMS (ESI) m/z [M + H]+ calcd for: C19H25N: 268.2060; found: 
268.2061.  IR (neat): v = 2953, 2901, 2864, 1594, 1552, 1498, 1477, 1458, 1400, 1359, 1254, 1167, 






The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (27 mg, 20 %) 
in a mixture with 4-phenylpyridine (76 mg, 61%).  Rf = 0.25 (ethyl acetate/hexanes 1:4; UV).  1H 
NMR (700 MHz, CDCl3) δ 8.66 (d, J = 5.3 Hz, 2H), 8.54 (d, J = 5.1 Hz, 1H), 7.66 – 7.59 (m, J = 
12.2, 7.8 Hz, 4H), 7.53 – 7.39 (m, 9H), 7.37 (s, 1H), 7.31 (d, J = 5.1 Hz, 1H), 2.62 (s, 3H). 13C 
NMR (176 MHz, CDCl3) δ 158.82, 150.23, 149.54, 148.69, 148.32, 138.42, 138.12, 129.10, 
129.04, 129.02, 128.88, 126.99, 126.98, 121.63, 121.20, 118.86, 24.57.  HRMS (ESI) m/z [M + 
H]+ calcd for: C12H11N: 170.0964; found: 170.0963.  The acquired 
1H and 13 CNMR spectral data 
corresponding to the mono-methylated product were identical to those reported in the literature.137 
 
Note: 2-methyl-4-phenylpyridine and 4-phenylpyridine were inseparable by column 
chromatography and recrystallization.  Attempts to selectivity oxidize 4-phenylpyridine using 
mCBPA at low temperatures of 0°C and facilitate the isolation of the methylated product were alos  








The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (34 mg, 21%) 
as a pale yellow oil and 4-phenylpyridine (78 mg, 63%).  Rf = 0.69 (ethyl acetate/hexanes 1:4; 
UV).  1H NMR (700 MHz, CDCl3) δ 8.70 (d, J = 5.1 Hz, 1H), 7.86 (s, 1H), 7.71 – 7.59 (m, 3H), 
7.57 – 7.46 (m, 3H), 6.70 (t, J = 55.5 Hz, 1H).  13C NMR (176 MHz, CDCl3) δ 153.76 (t, J = 25.5 
Hz), 150.34, 150.31, 137.73, 129.93, 129.62, 127.43, 123.62, 118.41, 114.37 (t, J = 240.5 Hz).  19F 
NMR (377 MHz, CDCl3) δ -115.86 (d, J = 55.5 Hz). HRMS (ESI) m/z [M + H]
+ calcd for: 
C12H9F2N: 206.0776; found: 206.0778.  IR (neat): v = 3034, 1603, 1551, 1450, 1412, 1373, 1206, 





















2-ethyl-4-phenylpyridine and 2,6-diethyl-4-phenylpyridine (2.10) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford 2-ethyl-4-phenylpyridine (65 mg, 
44%) and 2,6-diethyl-4-phenylpyridine (10 mg, 6%) as colorless oils and 4-phenylpyridine (41 mg, 
33%).  
2-ethyl-4-phenylpyridine: Rf = 0.38 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, 
CDCl3) δ 8.57 (d, J = 5.1 Hz, 1H), 7.63 (d, J = 8.0 Hz, 2H), 7.48 (t, J = 7.5 Hz, 2H), 7.43 (t, J = 
7.3 Hz, 1H), 7.38 (s, 1H), 7.32 (d, J = 5.1 Hz, 1H), 2.89 (q, J = 7.6 Hz, 2H), 1.36 (t, J = 7.6 Hz, 
3H).  13C NMR (176 MHz, CDCl3) δ 164.36, 149.96, 149.16, 138.96, 129.37, 129.20, 127.39, 
120.38, 119.42, 31.87, 14.35.  HRMS (ESI) m/z [M + H]+ calcd for: C13H13N: 184.1121; found: 
184.1121.  The acquired 1H and 13 CNMR spectra were identical to those reported in the 
literature.138 
2,6-diethyl-4-phenylpyridine: Rf = 0.57 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, 
CDCl3) δ 7.63 (d, J = 7.3 Hz, 2H), 7.49 – 7.41 (m, 3H), 7.19 (s, 2H), 2.87 (q, J = 7.6 Hz, 4H), 1.34 
(t, J = 7.6 Hz, 6H).  13C NMR (126 MHz, CDCl3) δ 163.82, 149.59, 139.49, 129.28, 128.98, 127.43, 
117.58, 31.98, 14.66.  HRMS (ESI) m/z [M + H]+ calcd for: C15H17N: 211.1361; found: 211.1353.  








The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (47 mg, 30%) 
as a pale yellow oil and 4-phenylpyridine (50 mg, 40%).  Rf = 0.68 (ethyl acetate/hexanes 1:4; 
UV).  1HNMR (CDCl3, 700 MHz): δ 8.48 (d, J = 5.1 Hz, 1H), 7.62 (d, J = 7.4 Hz, 2H), 7.47 (t, J 
= 7.6 Hz, 2H), 7.42 (t, J = 7.3 Hz, 1H), 7.34 (s, 1H), 7.24 (dd, J = 5.1, 1.6 Hz, 1H), 2.13 – 2.06 (m, 
1H), 1.11 – 1.06 (m, 2H), 1.02 (ddd, J = 10.9, 6.6, 4.0 Hz, 2H).  13C NMR (176 MHz, CDCl3): δ 
163.63, 149.98, 148.60, 138.95, 129.31, 129.12, 127.33, 119.65, 118.93, 17.63, 10.15.  HRMS 
(ESI) m/z [M + H]+ calcd for: C14H13N: 196.1121; found: 196.1121.  The acquired 
1H and 13 
















The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (70 mg, 42%) 
as a pale yellow oil and 4-phenylpyridine (43 mg, 35%).  Rf = 0.62 (ethyl acetate/hexanes 1:4; 
UV).  1H NMR (700 MHz, CDCl3): δ 8.61 (d, J = 5.1 Hz, 1H), 7.63 (d, J = 7.5 Hz, 2H), 7.48 (t, J 
= 7.5 Hz, 2H), 7.43 (dd, J = 8.0, 6.5 Hz, 1H), 7.36 (s, 1H), 7.31 (d, J = 5.1 Hz, 1H), 3.74 (p, J = 
8.8 Hz, 1H), 2.44 – 2.35 (m, 4H), 2.14 – 2.03 (m, 1H), 1.98 – 1.87 (m, 1H).  13C NMR (176 MHz, 
CDCl3) δ 165.52, 149.96, 148.92, 139.00, 129.32, 129.13, 127.35, 119.39, 119.26, 42.47, 28.78, 
18.59.  HRMS (ESI) m/z [M + H]+ calcd for: C15H15N: 210.1277; found: 210.1279.  IR (neat): v 

















The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (70 mg, 39%) 
as a colorless oil and 4-phenylpyridine (50 mg, 40%).  Rf = 0.68 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, CDCl3): δ 8.58 (d, J = 5.1 Hz, 1H), 7.63 (d, J = 7.5 Hz, 2H), 7.48 (t, J = 7.5 
Hz, 2H), 7.43 (t, J = 7.3 Hz, 1H), 7.39 (s, 1H), 7.30 (d, J = 5.0 Hz, 1H), 3.30 – 3.18 (m, 1H), 2.17 
– 2.08 (m, 2H), 1.90 – 1.80 (m, 4H), 1.73 – 1.70 (m, 2H).  13C NMR (176 MHz, CDCl3): δ 166.50, 
149.91, 148.91, 139.07, 129.32, 129.10, 127.36, 120.04, 119.42, 48.43, 33.91, 26.19.  HRMS (ESI) 
m/z [M + H]+ calcd for: C16H17N: 224.1434; found: 224.1436.  IR (neat): v = 2947, 2865, 1594, 














The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (81 mg, 40%) 
as a pale yellow oil and 4-phenylpyridine (59 mg, 47%).  Rf = 0.71 (ethyl acetate/hexanes 1:4; 
UV).  1HNMR (CDCl3, 700 MHz): δ 8.64 (d, J = 5.0 Hz, 1H), 7.65 – 7.61 (m, 2H), 7.53 (s, 1H), 
7.49 (dd, J = 10.5, 4.7 Hz, 2H), 7.43 (t, J = 7.4 Hz, 1H), 7.29 (dd, J = 5.1, 1.6 Hz, 1H), 2.25 (d, J 
= 9.9 Hz, 2H), 1.64 – 1.59 (m, 4H), 1.48 – 1.42 (m, 4H), 1.28 (s, 3H). 13C NMR (176 MHz, CDCl3): 
δ 169.39, 149.59, 148.89, 139.52, 129.32, 129.01, 127.44, 119.02, 118.57, 41.24, 37.62, 37.54, 
26.65, 23.15.  HRMS (ESI) m/z [M + H]+ calcd for: C17H19N: 252.1751; found: 252.1752.  IR 












2-cyclohexyl-4-phenylpyridine and 2,6-dicyclohexyl-4-phenylpyridine (2.15) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford 2-cyclohexyl-4-phenylpyridine 
(94 mg, 50%) and 2,6-dicyclohexyl-4-phenylpyridine (10 mg, 5%) as colorless oils.  In addition, 
4-phenylpyridine (13 mg, 10%) was recovered. The acquired 1H and 13 CNMR spectra were 
identical to those reported in the literature.140 
2-cyclohexyl-4-phenylpyridine: Rf = 0.38 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, 
CDCl3): δ 8.57 (d, J = 5.1 Hz, 1H), 7.63 (dd, J = 5.2, 3.3 Hz, 2H), 7.48 (dd, J = 10.3, 4.7 Hz, 2H), 
7.45 – 7.40 (m, 1H), 7.36 (s, 1H), 7.31 (dd, J = 5.1, 1.7 Hz, 1H), 2.77 (tt, J = 12.0, 3.4 Hz, 1H), 
2.00 (dd, J = 13.5, 1.6 Hz, 2H), 1.91 – 1.84 (m, 2H), 1.80 – 1.73 (m, 1H), 1.59 (qd, J = 12.7, 3.3 
Hz, 2H), 1.44 (qt, J = 13.0, 3.4 Hz, 2H), 1.36 – 1.27 (m, 1H).  13C NMR (176 MHz, CDCl3): δ 
167.31, 149.77, 149.07, 139.07, 129.28, 129.08, 127.33, 119.47, 119.35, 47.01, 33.30, 26.93, 26.40.  
HRMS (ESI) m/z [M + H]+ calcd for: C17H19N: 238.1590; found: 238.1592. 
2,6-dicyclohexyl-4-phenylpyridine: Rf = 0.75 (ethyl acetate/hexanes 1:4; UV). 
1HNMR (CDCl3, 
700 MHz): δ 7.64 – 7.59 (m, 2H), 7.46 (t, J = 7.6 Hz, 2H), 7.40 (t, J = 7.4 Hz, 1H), 7.16 (s, 2H), 
2.75 (tt, J = 11.9, 3.4 Hz, 2H), 2.02 – 2.01 (m, 4H), 1.88 – 1.83 (m, 4H), 1.78 – 1.74 (m, 2H), 1.54 
(ddd, J = 24.8, 12.7, 3.1 Hz, 4H), 1.48 – 1.41 (m, 4H), 1.33 – 1.27 (m, 2H).  13C NMR (176 MHz, 
CDCl3): δ 166.60, 149.34, 139.98, 129.22, 128.81, 127.48, 116.33, 47.12, 33.56, 27.00, 26.56.  
HRMS (ESI) m/z [M + H]+ calcd for: C23H29N: 320.2373; found: 320.2377.  IR (neat): v = 3059, 





The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (67 mg, 31%) 
as a yellow oil and 4-phenylpyridine (51 mg, 41%).  Rf = 0.50 (ethyl acetate/hexanes 1:4; UV).  
1HNMR (CDCl3, 700 MHz): δ 8.54 (d, J = 5.1 Hz, 1H), 7.65 – 7.60 (m, 2H), 7.47 (t, J = 7.5 Hz, 
2H), 7.45 – 7.39 (m, 2H), 7.32 – 7.27 (m, 3H), 7.21 – 7.17 (m, 3H), 2.62 – 2.55 (m, 1H), 2.38 – 
2.33 (m, 1H), 1.86 – 1.81 (m, 1H), 1.51 (ddd, J = 8.6, 6.0, 4.8 Hz, 1H).  13C NMR (176 MHz, 
CDCl3):
 δ 161.95, 150.17, 148.69, 142.62, 138.80, 129.37, 129.22, 128.73, 127.35, 126.23, 126.17, 
120.40, 119.20, 29.99, 28.52, 19.27.  HRMS (ESI) m/z [M + H]+ calcd for: C20H17N: 272.1438; 
found: 272.1437.  IR (neat): v = 3025, 1949, 1594, 1545, 1496, 1473, 1457, 1415, 1371, 1191, 















The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (93 mg, 43%) 
as a pale yellow solid and 4-phenylpyridine (44 mg, 35%).  Rf = 0.50 (ethyl acetate/hexanes 1:4; 
UV).  1HNMR (CDCl3, 500 MHz): δ 8.62 (d, J = 5.1 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.50 – 7.45 
(m, 3H), 7.43 (t, J = 7.3 Hz, 1H), 7.36 (dd, J = 5.1, 1.5 Hz, 1H), 7.28 – 7.26 (m, 2H), 7.21 – 7.17 
(m, 2H), 3.95 (p, J = 8.8 Hz, 1H), 3.43 (dd, J = 15.7, 8.5 Hz, 2H), 3.35 (dd, J = 15.7, 9.1 Hz, 2H).  
13C NMR (176 MHz, CDCl3): δ 165.14, 149.96, 149.16, 143.03, 138.84, 129.36, 129.23, 127.35, 
126.78, 124.66, 119.96, 119.83, 47.85, 40.06.  HRMS (ESI) m/z [M + H]+ calcd for: C20H17N: 












2-(bicyclo[2.2.1]hept-5-en-2-yl)-4-phenylpyridine (2.18)  
The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (55 mg, 28%) 
as a colorless oil and 4-phenylpyridine (59 mg, 48%).  Rf = 0.53 (ethyl acetate/hexanes 1:4; UV).  
1HNMR (CDCl3, 700 MHz): δ 8.58 (d, J = 5.1 Hz, 1H), 7.63 (d, J = 7.8 Hz, 2H), 7.48 (t, J = 7.5 
Hz, 2H), 7.45 – 7.42 (m, 2H), 7.32 – 7.29 (m, 1H), 6.28 (dd, J = 5.4, 3.0 Hz, 1H), 6.22 (dd, J = 
5.3, 2.8 Hz, 1H), 3.03 (d, J = 10.9 Hz, 2H), 2.90 (dd, J = 8.7, 4.5 Hz, 1H), 2.14 (dt, J = 11.7, 4.0 
Hz, 1H), 1.81 (d, J = 8.3 Hz, 1H), 1.65 – 1.61 (m, 1H), 1.42 (d, J = 8.2 Hz, 1H). 13C NMR (176 
MHz, CDCl3): δ 165.98, 149.71, 148.88, 139.11, 138.38, 137.33, 129.37, 129.16, 127.41, 120.92, 
119.36, 49.03, 46.70, 46.00, 42.66, 32.59.  HRMS (ESI) m/z [M + H]+ calcd for: C18H17N: 
248.1437; found: 248.1436.  IR (neat): v = 3057, 2937, 2864, 1787, 1594, 1544, 1497, 1470, 1397, 
1342, 1303, 1254, 1173.  
2D NMR Data 
- COSY, HSQC, HMBC, and NOESY experiments were employed to assign various resonances 





2-adamantyl-4-phenylpyridine and 2,6-diadamantyl-4-phenylpyridine (2.19) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford 2-adamantyl-4-phenylpyridine (97 
mg, 42%) and 2,6-diadamantyl-4-phenylpyridine (41 mg, 12%) as white solids.  In addition, 4-
phenylpyridine (43 mg, 10%) was recovered.  
2-adamantyl-4-phenylpyridine: Rf = 0.50 (ethyl acetate/hexanes 1:4; UV). 
1HNMR (CDCl3, 700 
MHz): δ 8.63 (d, J = 5.0 Hz, 1H), 7.63 (d, J = 7.3 Hz, 2H), 7.48 (dd, J = 9.2, 5.8 Hz, 3H), 7.42 (t, 
J = 7.3 Hz, 1H), 7.30 (dd, J = 5.0, 1.5 Hz, 1H), 2.14 (s, 3H), 2.07 (d, J = 2.2 Hz, 6H), 1.82 (d, J = 
12.8 Hz, 6H).  13C NMR (176 MHz, CDCl3): δ 169.91, 149.50, 148.98, 139.50, 129.30, 129.01, 
127.42, 119.25, 117.38, 42.32, 39.40, 37.15, 29.15.  HRMS (ESI) m/z [M + H]+ calcd for: C21H23N: 
290.1903; found: 290.1905.  IR (neat): v = 3056, 2899, 2846, 1591, 1547, 1467, 1450, 1392, 1320, 
1101.  
2,6-diadamantyl-4-phenylpyridine: Rf = 0.78 (ethyl acetate/hexanes 1:4; UV).  
1HNMR (CDCl3, 
700 MHz): δ 7.61 (d, J = 7.9 Hz, 2H), 7.45 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.3 Hz, 1H), 7.21 (s, 
2H), 2.13 (d, J = 19.2 Hz, 6H), 2.06 (d, J = 1.8 Hz, 12H), 1.79 (d, J = 12.1 Hz, 12H).  13C NMR 
(176 MHz, CDCl3): δ 168.29, 148.94, 140.84, 129.14, 128.51, 127.59, 114.09, 42.41, 39.70, 37.39, 
29.31.  HRMS (ESI) m/z [M + H]+ calcd for: C31H37N: 424.2999; found: 424.2999.  IR (neat): v 








The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (64 mg, 28%) 
as a pale yellow oil and 4-phenylpyridine (51 mg, 41%).  Rf = 0.39 (ethyl acetate/hexanes 1:4; 
UV).  1HNMR (CDCl3, 500 MHz): δ 8.57 (d, J = 5.1 Hz, 1H), 7.62 (d, J = 7.3 Hz, 2H), 7.51 – 7.39 
(m, 3H), 7.36 – 7.29 (m, 2H), 7.34 – 7.26 (m, 2H), 7.20 – 7.14 (m, 3H), 2.88 (t, J = 7.7 Hz, 2H), 
2.67 (t, J = 7.6 Hz, 2H), 1.88 – 1.78 (m, 2H), 1.76 – 1.70 (m, 2H). 13C NMR (126 MHz, CDCl3): 
δ 162.94, 149.89, 149.12, 142.81, 138.80, 129.35, 129.22, 128.74, 128.59, 127.36, 125.98, 121.02, 
119.46, 38.63, 36.14, 31.54, 29.91.  HRMS (ESI) m/z [M + H]+ calcd for: C21H21N: 288.1747; 





















The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (29 mg, 15%) 
as a pale yellow oil and 4-phenylpyridine (91 mg, 73%).  Rf = 0.42 (ethyl acetate/hexanes 1:4; 
UV).  1HNMR (CDCl3, 500 MHz): δ 8.60 (d, J = 5.5 Hz, 1H), 7.57 (d, J = 7.1 Hz, 2H), 7.44 (dt, J 
= 14.0, 7.0 Hz, 3H), 7.34 - 7.31 (m, 6H), 7.23 (dd, J = 8.5, 4.3 Hz, 1H), 4.22 (s, 2H).  13C NMR 
(126 MHz, CDCl3): δ 161.80, 150.11, 149.37, 139.81, 138.72, 129.45, 129.36, 129.27, 128.96, 
127.37, 126.76, 121.44, 119.76, 45.14.  HRMS (ESI) m/z [M + H]+ calcd for: C18H15N: 246.1277; 
















The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (71 mg, 37%) 
as a colorless oil and 4-phenylpyridine (55 mg, 44%).  Rf = 0.64 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, Chloroform-d) δ 8.59 (d, J = 5.1 Hz, 1H), 7.63 (dd, J = 7.4, 1.7 Hz, 2H), 7.52 
– 7.41 (m, 3H), 7.38 (s, 1H), 7.35 (dd, J = 5.1, 1.7 Hz, 1H), 4.12 (dt, J = 11.3, 3.0 Hz, 2H), 3.58 
(td, J = 11.4, 3.0 Hz, 2H), 3.02 (td, J = 11.1, 5.5 Hz, 1H), 2.02 – 1.92 (m, 4H).  13C NMR (126 
MHz, CDCl3) δ 164.89, 149.65, 149.04, 138.55, 129.05, 128.93, 127.02, 119.61, 118.83, 68.14, 
43.57, 32.53. HRMS (ESI) m/z [M + H]+ calcd for: C16H17NO: 240.1383; found: 240.1384.  IR 












The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (56 mg, 33%) 
as a colorless oil and 4-phenylpyridine (66 mg, 52%).  Rf = 0.63 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, CDCl3) δ 8.51 (d, J = 5.1 Hz, 1H), 7.85 (s, 1H), 7.71 – 7.66 (m, 2H), 7.52 – 
7.42 (m, 3H), 7.35 (dd, J = 5.2, 1.7 Hz, 1H), 1.54 – 1.47 (m, 4H).  13C NMR (126 MHz, CDCl3) δ 
160.03, 159.83, 149.56, 148.77, 138.33, 129.05, 127.09, 119.56, 116.76, 80.29 (d, J = 214.1 Hz), 
15.50, 15.41.  19F NMR (470 MHz, CDCl3) δ -193.55 (s). HRMS (ESI) m/z [M + H]
+ calcd for: 
C14H12FN: 214.1027; found: 214.1025.  IR (neat): v = 3086, 3011, 2925, 1594, 1552, 1501, 1473, 














The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford the title compound (105 mg, 48%) 
as a colorless oil and 4-phenylpyridine (38 mg, 31%).  Rf = 0.69 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, Chloroform-d) δ 8.58 (d, J = 5.1 Hz, 1H), 7.62 (d, J = 7.5 Hz, 2H), 7.46 (dt, 
J = 24.1, 7.3 Hz, 3H), 7.40 – 7.32 (m, 2H), 2.90 – 2.85 (m, 1H), 2.31 – 2.18 (m, 2H), 2.14 – 2.04 
(m, 2H), 2.04 – 1.92 (m, 3H), 1.90 – 1.84 (m, 1H).  13C NMR (126 MHz, CDCl3) δ 164.40, 149.60, 
149.12, 138.42, 129.70, 128.99, 127.02, 123.13 (dd, J = 242.3, 239.7 Hz), 119.75, 118.88, 44.35, 
33.77 (dd, J = 25.6, 22.8 Hz), 28.86 (d, J = 9.8 Hz).   19F NMR (470 MHz, CDCl3) δ -91.79 (d, J 
= 235.9 Hz), -101.70 (d, J = 236.5 Hz). HRMS (ESI) m/z [M + H]+ calcd for: C17H17F2N: 274.1402; 













2,2,2-trichloroethyl 3-(4-phenylpyridin-2-yl)azetidine-1-carboxylate (2.25) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (20% to 50% ethyl acetate in hexanes) to afford the title compound (83 mg, 27%) 
as a colorless oil and 4-phenylpyridine (60 mg, 48%).  Rf = 0.53 (ethyl acetate/hexanes 1:1; UV).  
1H NMR (500 MHz, Chloroform-d) δ 8.67 (d, J = 5.0 Hz, 1H), 7.62 (d, J = 7.0 Hz, 2H), 7.52 – 
7.43 (m, 3H), 7.43 – 7.39 (m, 2H), 4.84 – 4.63 (m, 2H), 4.56 – 4.34 (m, 4H), 4.05 (tt, J = 8.8, 6.3 
Hz, 1H).  13C NMR (126 MHz, CDCl3) δ 160.52, 154.35, 150.31, 149.23, 138.00, 129.19, 129.14, 
127.00, 120.31, 119.89, 95.67, 74.55, 55.56, 54.91, 35.66. HRMS (ESI) m/z [M + H]+ calcd for: 
C17H15Cl3N2O2: 385.0272; found: 385.0274.  IR (neat): v = 2951, 2884, 1718, 1596, 1547, 1401, 














1-((2,2,2-trichloroethoxy)carbonyl)azetidine-3-carboxylic acid  
Azetidine-3-carboxylic acid (1 g, 10 mmol) was placed in a round bottom flask equipped with a 
magnetic stir bar, dissolved in 15 mL of 2.0 N aqueous NaOH solution, and cooled to -10 ⁰C.  
2,2,2-Trichloroethyl chloroformate (1.4 mL, 11 mmol) was then added dropwise to the stirred 
solution at 0 ⁰C.  The mixture was stirred for 1 h at 0 ⁰C and an additional 2 h at r.t.  After the 
reaction, the mixture was extracted with diethyl ether (3 x 10 mL) and the aqueous phase was 
acidified to pH 2 with 2 N HCl.  The aqueous phase was extracted with ethyl acetate (4 x 20 mL), 
and the combined ethyl acetate extracts were washed with brine, dried with Na2SO4, and 
concentrated to yield the desired product (2.4 g, 87%) as a white solid.   1H NMR (700 MHz, 
Chloroform-d) δ 10.63 (s, 1H), 4.71 (d, J = 11.4 Hz, 2H), 4.31 (d, J = 34.4 Hz, 4H), 3.51 (p, J = 
7.5 Hz, 1H). 13C NMR (176 MHz, CDCl3) δ 176.67, 153.46, 94.73, 73.96, 51.15 (d, J = 111.6 Hz), 
31.79. HRMS (ESI) m/z [M + H]+ calcd for: C7H8Cl3NO4: 275.9592; found: 275.9597.  IR (neat): 










2,2,2-trichloroethyl 3-methyl-3-(4-phenylpyridin-2-yl)azetidine-1-carboxylate (2.26) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (20% to 50% ethyl acetate in hexanes) to afford the title compound (138 mg, 43%) 
as a colorless oil and 4-phenylpyridine (50 mg, 40%).  Rf = 0.57 (ethyl acetate/hexanes 1:1; UV).  
1H NMR (500 MHz, Chloroform-d) δ 8.63 (d, J = 4.9, 1.1 Hz, 1H), 7.64 – 7.59 (m, 2H), 7.52 – 
7.43 (m, 3H), 7.41 – 7.37 (m, 2H), 4.79 – 4.66 (m, 2H), 4.64 – 4.53 (m, 2H), 4.17 – 4.04 (m, 2H), 
1.76 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 164.68, 154.58, 149.73, 149.76, 149.34, 138.23, 
129.17, 127.05, 119.87, 117.63, 95.71, 74.59 – 74.46 (m), 61.25, 60.50, 40.57, 27.31.  HRMS (ESI) 
m/z [M + H]+ calcd for: C18H17Cl3N2O2: 399.0428; found: 399.0436.  IR (neat): v = 2965, 2876, 












3-methyl-1-((2,2,2-trichloroethoxy)carbonyl)azetidine-3-carboxylic acid  
3-Methylazetidine-3-carboxylic acid (0.5 g, 4.34 mmol) was placed in a round bottom flask 
equipped with a magnetic stir bar, dissolved in 6.5 mL of 2.0 N aqueous NaOH solution, and 
cooled to -9 ⁰C.  2,2,2-Trichloroethyl chloroformate (0.6 mL, 4.77 mmol) was then added dropwise 
to the stirred solution at 0 ⁰C.  The mixture was stirred for 1 h at 0 ⁰C and an additional 2 h at r.t.  
After the reaction, the mixture was extracted with diethyl ether (3 x 10 mL) and the aqueous phase 
was acidified to pH 2 with 2 N HCl.  The aqueous phase was extracted with ethyl acetate (4 x 20 
mL), and the combined ethyl acetate extracts were washed with brine, dried with Na2SO4, and 
concentrated to yield the desired product (1.1 g, 84%) as a white solid.   1H NMR (700 MHz, 
Chloroform-d) δ 10.31 (s, 1H), 4.71 (d, J = 13.7 Hz, 2H), 4.43 (d, J = 42.7 Hz, 2H), 3.88 (d, J = 
33.7 Hz, 2H), 1.62 (s, 3H).  13C NMR (176 MHz, CDCl3) δ 178.96, 153.68, 94.80,  73.95, 57.76 
(d, J = 119.2 Hz), 38.61, 21.62.  HRMS (ESI) m/z [M + H]+ calcd for: C8H10Cl3NO4: 289.9752; 
found: 289.9748.  IR (neat): v = 2968, 2895, 2582, 1723, 1964, 1466, 1434, 1414, 1358, 1317, 









2,2,2-trichloroethyl 1-(4-phenylpyridin-2-yl)pyrrolidine-3-carboxylate (2.27) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (10% acetone in dichloromethane) to afford the title compound (42 mg, 13%) as 
a colorless oil and 4-phenylpyridine (77 mg, 62%).  Rf = 0.65 (10% acetone/dichloromethane; UV).  
1H NMR (500 MHz, Chloroform-d) (50:50 mixture of rotamers) δ 8.63 – 8.58 (m, 1H), 7.62 (d, J 
= 7.5 Hz, 2H), 7.57 – 7.42 (m, 3H), 7.42 – 7.36 (m, 2H), 4.85 – 4.70 (m, 2H), 4.00 (ddd, J = 18.3, 
10.9, 7.8 Hz, 1H), 3.86 – 3.70 (m, 2H), 3.70 – 3.52 (m, 2H), 2.43 – 2.27 (m, 2H).  13C NMR (126 
MHz, CDCl3) (50:50 mixture of rotamers) δ 160.79, 160.61, 152.89, 152.86, 150.00, 149.97, 
149.94, 149.22, 149.17, 138.13, 129.13, 127.02, 120.22, 120.16, 120.10, 120.01, 119.95, 95.86, 
95.78, 74.86, 74.83, 51.62, 51.23, 46.48, 46.19, 45.99, 45.35, 32.14, 31.48. HRMS (ESI) m/z [M 
+ H]+ calcd for: C18H17Cl3N2O2: 289.9748; found: 289.9748.  IR (neat): v = 2949, 2881, 1713, 














1-((2,2,2-trichloroethoxy)carbonyl)pyrrolidine-3-carboxylic acid  
Pyrrolidine-3-carboxylic acid (1 g, 8.7 mmol) was placed in a round bottom flask equipped with a 
magnetic stir bar, dissolved in 13 mL of 2.0 N aqueous NaOH solution, and cooled to -9 ⁰C.  2,2,2-
Trichloroethyl chloroformate (1.2 mL, 9.57 mmol) was then added dropwise to the stirred solution 
at 0 ⁰C.  The mixture was stirred for 1 h at 0 ⁰C and an additional 2 h at r.t.  After the reaction, the 
mixture was extracted with diethyl ether (3 x 10 mL) and the aqueous phase was acidified to pH 2 
with 2 N HCl.  The aqueous phase was extracted with ethyl acetate (4 x 20 mL), and the combined 
ethyl acetate extracts were washed with brine, dried with Na2SO4, and concentrated to yield the 
desired product (2.3 g, 90%) as a white solid.   1H NMR (700 MHz, Chloroform-d) δ 10.37 (s, 1H), 
4.80 – 4.69 (m, 2H), 3.76 (dd, J = 21.7, 6.9 Hz, 2H), 3.69 – 3.48 (m, 2H), 3.17 (dp, J = 22.1, 7.5 
Hz, 1H), 2.25 (tt, J = 14.2, 7.2 Hz, 2H). 13C NMR (176 MHz, CDCl3) δ 177.58, 177.48, 152.15, 
152.09, 94.95, 94.92, 74.31, 47.73, 47.16, 45.10, 44.62, 42.26, 41.46, 28.08, 27.40.  HRMS (ESI) 
m/z [M + H]+ calcd for: C8H10Cl3NO4: 275.9592; found: 275.9597.  IR (neat): v = 3184, 2899, 









2,2,2-trichloroethyl 4-(4-phenylpyridin-2-yl)piperidine-1-carboxylate (2.28) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (20% to 50% ethyl acetate in hexanes) to afford the title compound (331 mg, 36%) 
as a colorless oil and 4-phenylpyridine (52 mg, 42%).  Rf = 0.55 (ethyl acetate/hexanes 1:1; UV).  
1H NMR (500 MHz, Chloroform-d) δ 8.58 (d, J = 5.3 Hz, 1H), 7.64 – 7.59 (m, 2H), 7.46 (dt, J = 
23.5, 7.4 Hz, 4H), 7.36 (d, J = 3.8 Hz, 2H), 4.77 (s, 2H), 4.45 – 4.35 (m, 3H), 3.07 (t, J = 13.2 Hz, 
1H), 2.99 (td, J = 12.0, 6.1 Hz, 2H), 2.08 – 2.01 (m, 3H), 1.87 (qd, J = 12.7, 4.3 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 164.33, 153.39, 149.72 (d, J = 6.0 Hz), 149.16, 138.39, 129.09, 129.03, 
127.01, 119.79 (d, J = 10.4 Hz), 119.01 (d, J = 10.3 Hz), 95.75, 75.21 – 75.01 (m), 44.62 (d, J = 
15.6 Hz), 44.36, 31.59 (d, J = 26.1 Hz). HRMS (ESI) m/z [M + H]+ calcd for: C19H19Cl3N2O2: 













1-((2,2,2-trichloroethoxy)carbonyl)piperidine-4-carboxylic acid  
Piperidine-4-carboxylic acid (1 g, 7.0 mmol) was placed in a round bottom flask equipped with a 
magnetic stir bar, dissolved in 10 mL of 2.0 N aqueous NaOH solution, and cooled to -9 ⁰C.  2,2,2-
Trichloroethyl chloroformate (1 mL, 7.7 mmol) was then added dropwise to the stirred solution at 
0 ⁰C.  The mixture was stirred for 1 h at 0 ⁰C and an additional 2 h at r.t.  After the reaction, the 
mixture was extracted with diethyl ether (3 x 10 mL) and the aqueous phase was acidified to pH 2 
with 2 N HCl.  The aqueous phase was extracted with ethyl acetate (4 x 20 mL), and the combined 
ethyl acetate extracts were washed with brine, dried with Na2SO4, and concentrated to yield the 
desired product (2.0 g, 93%) as a white solid.   1H NMR (700 MHz, Chloroform-d) δ 10.61 (s, 
1H), 4.75 (d, J = 12.2 Hz, 2H), 4.21 – 4.05 (m, 2H), 3.18 – 2.92 (m, 2H), 2.58 (tt, J = 10.6, 4.0 Hz, 
1H), 1.97 (d, J = 10.3 Hz, 2H), 1.73 (qd, J = 11.1, 4.2 Hz, 2H). 13C NMR (176 MHz, CDCl3) δ 
180.43, 153.72, 95.98, 75.46, 43.79 (d, J = 18.9 Hz), 40.80, 27.91 (d, J = 41.1 Hz).  HRMS (ESI) 
m/z [M + H]+ calcd for: C9H12Cl3NO4: 303.9905; found: 303.9909.  IR (neat): v = 3209, 2861, 













The reaction was run according to General Procedure A and was purified by column 
chromatography (20% to 50% ethyl acetate in hexanes) to afford the title compound (314 mg, 31%) 
as a colorless oil and 4-phenylpyridine (60 mg, 48%).  Rf = 0.51 (ethyl acetate/hexanes 1:1; UV).  
1H NMR (500 MHz, Chloroform-d) δ 8.55 (d, J = 5.1 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.61 – 
7.58 (m, 2H), 7.51 – 7.41 (m, 3H), 7.37 – 7.33 (m, 3H), 7.31 (s, 1H), 4.00 – 3.90 (m, 2H), 2.69 (tt, 
J = 12.0, 3.9 Hz, 1H), 2.48 – 2.37 (m, 5H), 2.11 – 1.91 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 
164.07, 149.65 (d, J = 4.9 Hz), 149.13, 143.45, 138.34, 133.34, 129.63 (d, J = 8.3 Hz), 129.08, 
127.73 (d, J = 7.2 Hz), 126.99, 119.83 (d, J = 9.3 Hz), 118.76 (d, J = 9.3 Hz), 46.52, 46.49, 43.65, 
31.17, 21.53 (d, J = 7.2 Hz).  HRMS (ESI) m/z [M + H]+ calcd for: C23H24N2O2S: 393.1631; found: 










(9H-fluoren-9-yl)methyl 4-(4-phenylpyridin-2-yl)piperidine-1-carboxylate (2.30) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (20% to 50% ethyl acetate in hexanes) to afford the title compound (85 mg, 23%) 
as a colorless oil and 4-phenylpyridine (73 mg, 59%).  Rf = 0.54 (ethyl acetate/hexanes 1:1; UV).  
1H NMR (500 MHz, Chloroform-d) δ 8.59 (d, J = 5.1 Hz, 1H), 7.76 (d, J = 7.5 Hz, 2H), 7.67 – 
7.54 (m, 4H), 7.55 – 7.42 (m, 3H), 7.42 – 7.35 (m, 4H), 7.32 (t, J = 7.4 Hz, 2H), 4.44 (t, J = 4.5 
Hz, 3H), 4.27 (t, J = 6.9 Hz, 2H), 2.96 (ddt, J = 12.2, 7.5, 3.7 Hz, 3H), 2.00 (d, J = 13.1 Hz, 2H), 
1.79 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 164.61, 155.21, 149.71, 149.69, 149.13, 144.13, 
141.33, 138.46, 129.09, 129.01, 127.63, 127.03, 125.03, 119.95, 119.76, 119.01, 67.27, 47.42, 
44.54, 44.37, 31.66.  HRMS (ESI) m/z [M + H]+ calcd for: C31H28N2O2: 461.2331; found: 

















Ethyl 2-(tert-butyl)isonicotinate (2.31) 
The reaction was run according to General Procedure A and the N-oxide substrate was prepared 
according to a reported procedure.141 The crude product was purified by column chromatography 
(0% to 15% ethyl acetate in hexanes) to afford the title compound (124 mg, 75%) as a colorless 
oil.  Rf = 0.71 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 5.0 Hz, 
1H), 7.89 (d, J = 1.5 Hz, 1H), 7.63 (dd, J = 4.9, 1.5 Hz, 1H), 4.41 (q, J = 7.2 Hz, 2H), 1.44 – 1.38 
(m, 12H).  13C NMR (126 MHz, CDCl3) δ 170.52, 165.70, 149.29, 137.83, 119.80, 118.38, 61.61, 
37.65, 30.09, 14.22.  HRMS (ESI) m/z [M + H]+ calcd for: C12H17NO2: 208.1332; found: 208.1332.  























The reaction was run according to General Procedure A and the N-oxide substrate was prepared 
according to a reported procedure.143  The crude product was purified by column chromatography 
(0% to 15% ethyl acetate in hexanes) to afford the title compound (74 mg, 52%) as a colorless oil.  
Rf = 0.5 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, CDCl3) δ 8.74 (d, J = 5.0 Hz, 1H), 
7.77 (s, 1H), 7.55 – 7.48 (m, 1H), 2.62 (s, 3H), 1.39 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 198.35, 
171.30, 150.06, 143.55, 118.81, 116.79, 38.07, 30.45, 27.09.  HRMS (ESI) m/z [M + H]+ calcd 
for: C11H15NO: 178.1226; found: 178.1225.  IR (neat): v = 2959, 2867, 1694, 1594, 1557, 1480, 














The reaction was run according to General Procedure A and the N-oxide substrate was prepared 
according to a reported procedure.144  The crude product was purified by column chromatography 
(0% to 15% ethyl acetate in hexanes) to afford the title compound (147  mg, 76%) as a colorless 
oil.  Rf = 0.45 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, CDCl3) δ 8.41 (d, J = 5.6 Hz, 
1H), 7.47 – 7.31 (m, 5H), 6.93 (s, 1H), 6.72 – 6.67 (m, 1H), 5.09 (s, 2H), 1.34 (s, 9H).  13C NMR 
(176 MHz, CDCl3) δ 171.44, 165.44, 150.32, 136.22, 129.03, 128.65, 127.93, 107.20, 106.89, 
70.01, 37.66, 30.41.  HRMS (ESI) m/z [M + H]+ calcd for: C16H19NO: 242.1539; found: 242.1541.  






















The reaction was run according to General Procedure A on a 0.5 mmol scale and the N-oxide 
substrate was prepared according to a reported procedure.55  The crude product was purified by 
column chromatography (0% to 30% ethyl acetate in hexanes) to afford the title compound (53 
mg, 55%) as a colorless oil.  Rf = 0.56 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, 
CDCl3) δ 8.47 (d, J = 5.6 Hz, 1H), 7.32 (d, J = 1.4 Hz, 1H), 7.08 (dd, J = 5.6, 1,4 Hz, 1H), 1.37 
(s, 9H) 1.31 (s, 9H). 13C NMR (176 MHz, CDCl3) δ 168.98, 159.86, 148.32, 117.75, 115.68, 37.39, 
34.74, 30.61, 30.28. HRMS (ESI) m/z [M + H]+ calcd for: C13H21N: 192.1747; found: 192.1747.  
IR (neat): v = 2960, 2869, 1810, 1767, 1743, 1597, 1551, 1481, 1461, 1396, 1364, 1296, 1255, 














The reaction was run according to General Procedure A on a 0.5 mmol scale and the N-oxide 
substrate was purchased from ArkPharm and distilled under vacuum prior to use.   Following the 
reaction, triethylamine (69 uL, 50.6 mg, 0.5 mmol) was added to the crude reaction mixture, and 
the crude reaction mixture was filtered through Celite. The mixture was then purified by column 
chromatography (0% to 60% ethyl acetate in hexanes) to afford the title compound (40 mg, 54%) 
as a colorless oil.  Rf = 0.61 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, CDCl3) δ 8.40 
(d, J = 2.3 Hz, 1H), 7.41 (dd, J = 8.2, 2.2 Hz, 1H), 7.23 (d, J = 8.1 Hz, 1H), 2.29 (s, 3H), 1.35 (s, 
9H). 13C NMR (176 MHz, CDCl3) δ166.68, 149.25, 137.13, 130.10, 118.90, 30.59, 27.53, 18.30. 
HRMS (ESI) m/z [M + H]+ calcd for: C10H16N: 150.1277; found: 150.1278.  IR (neat): v = 2956, 














The reaction was run according to General Procedure A and the N-oxide substrate was prepared 
according to a reported procedure.145 The crude product was purified by column chromatography 
(0% to 15% ethyl acetate in hexanes) to afford the title compound (41 mg, 27%) as a colorless oil.  
Rf = 0.56 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 5.0 Hz, 1H), 
7.15 (d, J = 3.5 Hz, 1H), 6.97 (d, J = 5.1 Hz, 1H), 6.64 (d, J = 3.5 Hz, 1H), 3.89 (s, 3H), 1.49 (s, 
9H). 13C NMR (126 MHz, CDCl3) δ 152.65, 148.31, 143.04, 127.25, 118.15, 112.03, 100.37, 35.81, 
31.45, 30.28.  HRMS (ESI) m/z [M + H]+ calcd for: C12H16N2: 189.1386; found: 189.1382.  IR 













The reaction was run according to General Procedure A on a 0.5 mmol scale and the N-oxide 
substrate was prepared according to a reported procedure.55  The crude product was purified by 
column chromatography (0% to 20% ethyl acetate in hexanes) to afford the title compound (49 
mg, 49%) as a colorless oil.  Rf = 0.64 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, 
CDCl3) δ 8.03 (d, J = 8.61 Hz, 1H), 7.60 (d, J = 9.2 Hz, 1H), 7.53- 7.49 (m, 2H), 7.36 (dd, J = 
8.0 Hz, 1H), 2.81 (s, 3H), 1.47 (s, 9H). 13C NMR (176 MHz, CDCl3) δ167.76, 146.11, 137.37, 
135.93, 128.96, 126.16, 125.28, 125.07, 117.71, 38.40, 30.20, 17.71.HRMS (ESI) m/z [M + H]+ 
calcd for: C14H17N: 200.1434; found: 200.1435.  IR (neat): v = 2954, 2923, 2864, 1616, 1599, 












2-tert-butylbenzoquinoline (2.38a) and 4-tert-butylbenzoquinoline (2.38b) 
The reaction was run according to General Procedure A and the N-oxide substrate was prepared 
according to a reported procedure.55  The crude product was purified by column chromatography 
(0% to 15% ethyl acetate in hexanes) to afford 2-tert-butylbenzoquinoline (68 mg, 36%) and 4-
tert-butylbenzoquinoline (19 mg, 10%) as colorless oils.   
2-tert-butylbenzoquinoline (2.38a): Rf = 0.88 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 
MHz, CDCl3) δ 9.40 (d, J = 8.1 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.75 
(d, J = 8.7 Hz, 1H), 7.73 – 7.68 (m, 1H), 7.69 – 7.64 (m, J = 10.5, 5.0 Hz, 2H), 7.62 (d, J = 8.3 Hz, 
1H), 1.55 (s, 9H).  13C NMR (176 MHz, CDCl3) δ 168.35, 145.42, 136.07, 134.00, 132.25, 128.07, 
127.95, 126.97, 126.97, 125.43, 124.94, 124.32, 118.56, 38.72, 30.77.  HRMS (ESI) m/z [M + H]+ 
calcd for: C17H17N: 236.1434; found: 236.1435.  IR (neat): v = 2960, 1594, 1561, 1496, 1476, 
1389, 1359, 1144, 1129. 
4-tert-butylbenzoquinoline (2.38b): Rf = 0.67 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 
MHz, CDCl3) δ 9.35 (d, J = 8.1 Hz, 1H), 8.90 (d, J = 4.8 Hz, 1H), 8.34 (d, J = 9.4 Hz, 1H), 7.89 
(d, J = 7.5 Hz, 1H), 7.80 (d, J = 9.4 Hz, 1H), 7.74 – 7.65 (m, 2H), 7.51 (d, J = 4.8 Hz, 1H), 1.66 
(s, 9H).  13C NMR (126 MHz, CDCl3) δ 155.97, 148.81, 147.87, 132.86, 132.79, 128.31, 127.58, 
127.14, 126.23, 125.47, 125.37, 124.27, 119.24, 36.42, 31.76.  HRMS (ESI) m/z [M + H]+ calcd 
for: C17H17N: 236.1434; found: 236.1435.  IR (neat): v = 2956, 2873, 1755, 1621, 1564, 1514, 




2-(tert-butyl)quinoline (2.39a) and 4-(tert-butyl)quinoline (2.39b) 
The reaction was run according to General Procedure A and was purified by column 
chromatography (0% to 15% ethyl acetate in hexanes) to afford 2-(tert-butyl)quinoline (64 mg, 
43%) and 4-(tert-butyl)quinoline (49 mg, 33%) as colorless oils.  The acquired 1H and 13 CNMR 
spectra were identical to those reported in the literature.146 
2-(tert-butyl)quinoline (2.39a): Rf = 0.71 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, 
CDCl3): δ 8.09 – 8.04 (m, 2H), 7.76 (dd, J = 8.1, 1.4 Hz, 1H), 7.66 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 
7.52 (d, J = 8.7 Hz, 1H), 7.47 (ddd, J = 8.0, 6.9, 1.2 Hz, 1H), 1.47 (s, 9H).  13C NMR (176 MHz, 
CDCl3): δ 169.22, 147.42, 135.80, 129.41, 128.93, 127.18, 126.42, 125.58, 118.19, 38.11, 30.17, 
30.13.  HRMS (ESI) m/z [M + H]+ calcd for: C13H15N: 186.1277; found: 186.1274. 
4-(tert-butyl)quinoline (2.39b): Rf = 0.56 (ethyl acetate/hexanes 1:4; UV). 
1HNMR (CDCl3, 700 
MHz): δ  8.81 (d, J = 4.7 Hz, 1H), 8.41 (dd, J = 8.7, 1.3 Hz, 1H), 8.14 (dd, J = 8.4, 1.4 Hz, 1H), 
7.67 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.56 – 7.50 (m, 1H), 7.35 (d, J = 4.7 Hz, 1H), 1.62 (s, 9H).  
13C NMR (176 MHz, CDCl3): δ 155.68, 150.21, 149.44, 131.14, 128.06, 127.08, 126.45, 125.10, 







The reaction was run according to General Procedure A on a 0.5 mmol scale and the N-oxide 
substrate was prepared according to a reported procedure.55  The crude product was purified by 
column chromatography (0% to 20% ethyl acetate in hexanes) to afford the title compound (21 
mg, 21%) as a colorless oil. The reaction of lepidine N-oxide immediately discolors to a dark 
purple upon the addition of acyl chloride, this is believed to be due to a competing decomposition 
pathway.   Rf = 0.68 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, CDCl3) δ 8.06 (d, J = 
7.8 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.66 (t, J = 6.9 Hz, 1H), 7.49 (t, J = 6.9 Hz, 1H), 7.35 (s, 
1H), 2.69 (s, 3H), 1.46 (s, 9H). 13C NMR (176 MHz, CDCl3) δ 169.07, 147.43, 143.72, 130.09, 
128.81, 126.67, 125.51, 123.52, 119.04, 38.06, 30.27, 19.12. HRMS (ESI) m/z [M + H]+ calcd for: 
C14H17N: 200.1434; found: 200.1436.  IR (neat): v = 3061, 2955, 2863, 1601, 1558, 1506, 1480, 












2-(tert-butyl)-6-bromoquinoline (2.41a) and 3-(tert-butyl)-6-bromoquinoline (2.41b) 
The reaction was run according to General Procedure A on a 0.5 mmol scale and the N-oxide 
substrate was prepared according to a reported procedure.55  The crude product was purified by 
column chromatography (0% to 30% ethyl acetate in hexanes) to afford 2-(tert-butyl)-6-
bromoquinoline (43 mg, 33%) as a yellow oil and 3-(tert-butyl)-6-bromoquinoline (14 mg, 11%) 
as a colorless oil.   
2-(tert-butyl)-6-bromoquinoline (2.41a) 
Rf = 0.64 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, CDCl3) 7.98 (d, J = 8.8 Hz, 1H), 
7.92 (d, J = 8.9 Hz, 1H), 7.92 (d, J = 2.1 Hz, 1H) 7.72 (dd, J = 9.0, 2.0 Hz, 1H), 7.54 (d, J = 8.7 
Hz, 1H), 1.45 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 170.11, 146.36, 135.19, 132.68, 131.56, 
129.58, 127.92, 119.61, 119.43, 38.58, 30.38.  HRMS (ESI) m/z [M + H]+ calcd for: C13H14BrN: 
264.0382; found: 264.0385.  IR (neat): v = 2958, 2865, 1594, 1550, 1487, 1458, 1363, 1301, 11889, 
1104, 1059. 
3-(tert-butyl)-6-bromoquinoline (2.41b) 
Rf = 0.24 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, CDCl3) δ 8.81 (d, J = 4.7 Hz, 1H), 
8.56 (s, 1H), 8.00 (d, J = 8.9 Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.37 (d, J = 4.8 Hz, 1H), 1.61 (s, 
9H) ppm.  13C NMR (176 MHz, CDCl3) δ 155.15, 150.72, 148.21, 132.94, 131.74, 128.97, 128.40, 
119.49, 119.02, 36.26, 31.40 ppm. HRMS (ESI) m/z [M + H]+ calcd for: C13H14BrN: 264.0382; 






The reaction was run according to General Procedure A on a 0.5 mmol scale and the N-oxide 
substrate was prepared according to a reported procedure.55  The crude product was purified by 
column chromatography (0% to 30% ethyl acetate in hexanes) to afford the title compound (27 
mg, 20%) as a colorless oil.  Rf = 0.75 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, 
CDCl3) δ 8.35 (s,1H), 8.02 (d, J = 8.4 Hz, 1H), 7.70 - 7.65 (m, 2H), 7.50 (t, J = 7.0 Hz, 1H) 1.64 
(s, 9H). 13C NMR (176 MHz, CDCl3) δ 163.96, 145.29, 141.54, 129.59, 129.53, 127.80, 126.96, 
126.13, 116.57, 40.38, 29.16. HRMS (ESI) m/z [M + H]+ calcd for: C13H14BrN: 264.0382; found: 
264.0370.  IR (neat): v = 2954, 2927, 2868, 1587, 1480, 1459, 1397, 1363, 1321, 1300, 1200, 













The reaction was run according to General Procedure A and the N-oxide substrate was prepared 
according to a reported procedure.55  The crude product was purified by column chromatography 
(0% to 15% ethyl acetate in hexanes) to afford the title compound (54 mg, 32%) as a colorless oil.  
Rf = 0.63 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (500 MHz, CDCl3) δ 8.86 (d, J = 4.4 Hz, 1H), 
8.09 (d, J = 9.2 Hz, 1H), 7.54 (d, J = 4.4 Hz, 1H), 7.44 (dd, J = 9.3, 2.7 Hz, 1H), 7.31 (dt, J = 2.6, 
1.4 Hz, 1H), 7.09 (t, J = 54.6 Hz, 1H), 3.97 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 158.54, 147.23, 
144.88, 136.22 (t, J = 3.2 Hz), 131.77, 125.29 (t, J = 3.0 Hz), 122.64, 118.38 (t, J = 7.8 Hz), 113.74 
(t, J = 240.1 Hz), 101.21, 55.61.  19F NMR (471 MHz, CDCl3) δ -115.32 (d, J = 54.7 Hz). HRMS 
(ESI) m/z [M + H]+ calcd for: C11H9F2NO: 210.0725; found: 210.0725.  IR (neat): v = 2937, 1921, 











The reaction was run according to General Procedure B on a 0.5 mmol scale and was purified by 
column chromatography (5% to 80% ethyl acetate in hexanes) to afford the title compound (68 
mg, 73%) as a light yellow oil.  Rf = 0.56 (ethyl acetate/hexanes 1:4; UV).  1H NMR (700 MHz, 
CDCl3) δ 8.99 (s, 1H), 8.06 (d, J = 5.7 Hz, 1H), 8.05 (d, J = 5.6 Hz, 1H), 7.73 (t, J = 7.0 Hz, 1H), 
7.70 (t, J = 7.0 Hz, 1H) 1.52 (s, 9H). 13C NMR (176 MHz, CDCl3) δ 163.65, 143.40, 141.56, 
140.72, 129.60, 129.24, 128.86, 128.84, 37.21, 29.71 ppm. HRMS (ESI) m/z [M]+ calcd for: 
C12H15N2: 186.1157; found: 186.1162. IR (neat): v = 3025, 2963, 2669, 1596, 1546, 1495, 1464, 























The reaction was run according to General Procedure B using 1:1 dichloromethane/MeCN (0.5 M) 
as the reaction solvent.  The crude material was purified by column chromatography (10% to 30% 
ethyl acetate in hexanes) to afford the title compound (48 mg, 11%) as a yellow solid.  Rf = 0.58 
(ethyl acetate/hexanes 1:4; UV).  1H NMR (500 MHz, CDCl3) δ 8.97 (s, 1H), 7.87 – 7.79 (m, 1H), 
7.49 – 7.41 (m, 1H), 3.90 – 3.85 (m, 4H), 1.48 (s, 9H), 1.30 (s, 18H). 13C NMR (126 MHz, CDCl3) 
δ 161.46, 149.92, 143.04, 139.61, 138.93, 127.97, 127.21, 126.60, 126.32, 83.10, 42.71, 29.75, 
27.88, 27.85. HRMS (ESI) m/z [M + H]+ calcd for: C25H34BrN5O4: 548.1867; found: 548.1874.  




















The reaction was run according to General Procedure B on a 0.5 mmol scale using 1:1 
dichloromethane/MeCN (0.5 M) as the reaction solvent.  The crude material was purified by 
column chromatography (0% to 30% ethyl acetate in hexanes) to afford the title compound (84 
mg, 44%) as a white solid.  Rf = 0.59 (ethyl acetate/hexanes 1:4; UV).  
1H NMR (700 MHz, CDCl3) 
δ 7.60 (t, J = 7.8 Hz, 1H), 7.29 (d, J = 6.5 Hz, 1H), 7.12 (d, J = 10.1 Hz, 1H), 6.98 (s, 1H), 2.66 
(s, 3H), 1.58 (s, 9H). 13C NMR (176 MHz, CDCl3) δ 180.57, 161.37, 159.92, 151.55, 150.69, 
147.13, 139.08, 139.02, 138.79, 131.54, 131.51, 127.25, 127.17, 125.40, 125.38, 125.09, 117.43, 
116.73, 116.58, 36.44, 29.13, 16.81. 19F NMR (377 MHz, CDCl3) δ -112.42 (dd, J = 10.1, 7.5 Hz). 
HRMS (ESI) m/z [M + H]+ calcd for: C18H17Cl2FN3O: 380.0727; found: 380.0731.  IR (neat): v 
= 3091, 2959, 1636, 1604, 1573, 1539, 1506, 1480, 1410, 1376, 1345, 1316, 1290, 1257, 1242, 









The reaction was run according to General Procedure B using 1:1 dichloromethane/MeCN (0.5 M) 
as the reaction solvent.  The crude material was purified by column chromatography (0% to 30% 
ethyl acetate in hexanes) to afford the title compound (43 mg, 16%) as a white solid.  Rf = 0.56 
(ethyl acetate/hexanes 1:4; UV).  1H NMR (500 MHz, CDCl3) δ 7.62 (t, J = 7.9 Hz, 1H), 7.30 (dd, 
J = 8.4, 1.8 Hz, 1H), 7.12 (dd, J = 10.0, 1.9 Hz, 1H), 7.02 (d, J = 1.5 Hz, 1H), 2.69 (s, 3H), 2.67 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 180.15, 160.37 (d, J = 255.1 Hz), 152.00, 146.58, 139.55, 
138.99 (d, J = 10.6 Hz), 138.47, 131.26 (d, J = 3.7 Hz), 126.59 (d, J = 13.9 Hz), 125.66, 125.13 
(d, J = 3.4 Hz), 120.75, 116.35 (d, J = 25.7 Hz), 16.65, 16.25. 19F NMR (377 MHz, CDCl3) δ -
112.41 (dd, J = 10.2, 7.5 Hz).  HRMS (ESI) m/z [M + H]+ calcd for: C15H10Cl2FN3O: 338.0258; 
found: 338.0263.  IR (neat): v = 2051, 2922, 1636, 1606, 1553, 1503, 1480, 1400, 1379, 1347, 












yl)methanone (2.48)  
The reaction was run according to General Procedure B using 1:1 dichloromethane/MeCN (0.5 M) 
as the reaction solvent.  The crude material was purified by column chromatography (0% to 30% 
ethyl acetate in hexanes) to afford the title compound (39 mg, 13%) as a white solid.  Rf = 0.61 
(ethyl acetate/hexanes 1:4; UV).  1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.69 – 7.62 (m, 1H), 
7.32 (d, J = 8.3 Hz, 1H), 7.14 (d, J = 10.0 Hz, 1H), 6.84 (t, J = 54.1 Hz, 1H), 2.73 (s, 3H).  19F 
NMR (471 MHz, CDCl3) δ -112.50 (t, J = 8.7 Hz), -117.65 (d, J = 54.3 Hz). 
 13C NMR (126 MHz, 
CDCl3) δ 179.82, 161.18, 159.73, 153.40, 146.64, 139.62 (d, J = 10.6 Hz), 135.33, 131.95 – 130.86 
(m, 2C), 126.38 – 125.53 (m), 125.35 (d, J = 3.4 Hz), 117.58 (t, J = 6.2 Hz), 116.47 (d, J = 25.5 
Hz), 109.15 (t, J = 242.0 Hz). 16.23. HRMS (ESI) m/z [M + H]+ calcd for: C11H15NO: 374.0069; 
found: 374.0071.  IR (neat): v = 3432, 3100, 2921, 1634, 1609, 1572, 1503, 1480, 1417, 1316, 










































































































































































































































Chapter 3: High-Throughput Optimization of Photoredox Catalysis Reactions Using 
Segmented Flow Nanoelectrospray Ionization-Mass Spectrometry 
This work was performed with equal contribution from Daniel Steyer. Contributions of A. Sun 
include the development of an HTE photoreactor setup, preparation of reaction screens, as well as 
characterization and isolation of products. Contributions of D. Steyer to this work include the 
development and implementation of droplet generation methods, MS assays, and statistical 
analyses.  
3.1 Introduction 
3.1.1 High-Throughput Experimentation in Organic Synthesis 
In the search for breakthrough medicines, materials, and agrichemicals, the accelerated 
preparation of complex small molecules in a miniaturized fashion can have a profound impact on 
reducing chemical footprint while expanding upon reaction space. 147 - 150  High-throughput 
experimentation (HTE) technology offers avenues for rapid data collection and process 
automation, and its implementation in organic synthesis has enabled the expedited discovery and 
optimization of various reaction manifolds. From a pharmaceutical standpoint, the rapid 
development and application of novel synthetic methodology plays a central role in accelerating 
access to highly functionalized drug leads.151-155 Given the short supply of substrate libraries at the 
start of a drug discovery program, it is often necessary to decrease the scale of experimentation to 
access broader chemical space. The use of HTE techniques represents a streamlined approach for 
enabling the exploration of a myriad of catalysts and reaction conditions in a time and resource-
efficient manner. Recent advances in miniaturized HTE have supported the diversification of 
expansive pharmaceutical libraries via palladium-catalyzed C–C, C–O, and C–N bond forming 
reactions at nanomole scale, using both continuous flow and plate-based approaches.156 Most 
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notably, seminal work reported by Dreher, Cernak, and co-workers at Merck in 2015 provided an 
elegant solution to enable chemistry an nanomole scale using equipment and technology from 
biological assay screening.7  Iterative screening in 1000 nL volumes allowed for the successful 
optimization of a Pd-catalyzed Buchwald-Hartwig cross coupling to yield an extensive library of 
drug compound fragements.  Impressively, 1536 reactions were evaluated in 2.5 hours with little 
as 0.02 mg per reaction. These innovative HTE methods promise to empower chemists to run 
orders of magnitude more experiments while utilizing "big data" informatic approaches for 
reaction design and troubleshooting.  Furthermore, platforms that integrate high throughput 
reaction optimization with subsequent biological evaluation provide additional opportunities for 
streamlining bioactive molecular discovery.1,8  
3.1.2 Mass Spectrometry-Based Methods for High-Throughput Experimentation 
The combined objectives of rapid reaction screening and product analysis are contingent upon 
integration of high throughput analytical instrumentation to provide near real-time data collection. 
Conventional screening methodologies rely on optical detection techniques to rapidly assess 
reaction progress. While these methods provide high throughput levels, reactions can be difficult 
to directly monitor if they lack a change in optical response upon product formation or there are 
high optical backgrounds associated with reaction matrices. This often necessitates the application 
of time intensive chemical separations, optical labelling of substrates, or the addition of a 
secondary reaction. Mass spectrometry (MS) detection has been demonstrated as an enabling 
technology in HTE, due to the high degree of chemical information and specificity imparted in 
these measurements.7,9 The application of rapid liquid chromatography and solid phase extraction 
techniques have led to the MS-based analysis of reactions at upwards of 5 s/sample.7,9, 157 
Alternatively, direct analysis of samples by MS has enabled even higher throughput levels. 
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Commercially available flow injection electrospray ionization (ESI)-MS systems provide a 
throughput as high as 2.5 s/sample.11,158 Ionization methods based on plating samples, such as 
matrix-assisted laser desorption (MALDI) and desorption electrospray ionization (DESI) have 
both been utilized for the analysis of organic synthesis reactions at throughput levels exceeding 1 
sample/s.159-161 Acoustic mist systems can also be used for the generation of nL volume droplets, 
and they have found applications in pre-MS analysis sample transfer, as well as in the direct 
formation of gaseous ions for MS analysis at a rate of 3 samples/s.162-165   
While the aforementioned approaches present impressive capabilities in MS-based HTE, 
interfacing MS with droplet microfluidics can unlock further avenues in HTE. Droplet 
microfluidics is a powerful approach for sample handling, as discrete fL-µL volume “droplet” 
samples can be isolated by an immiscible carrier phase and manipulated in a high throughput 
manner. Since multiple microsample units can be formed rapidly, parallel processing and analysis 
can be easily achieved, enabling the efficient acquisition of large data sets.  As a result, droplet 
microfluidics has found utility across a variety of chemical and biological applications.166-168 
Pairing droplet microfluidics with MS, typically through ESI or MALDI, has produced powerful 
systems for HTE work.169-175 NanoESI (nESI) is a nL/min flow variant on conventional ESI and 
presents significant advantages in sensitivity and matrix tolerance, compatibility with low volume 
samples, as well as observation of structurally unstable molecules through gentle ionization. 
Application of nESI-MS has led to the development of systems for monitoring the molecular 
content of pL-nL volume droplets with high analytical stability at throughputs as high as 10 
droplets/s.176-179 
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3.1.3 Development of a Droplet Microfluidics/nESI-MS Platform for Screening 
Photochemical Reactions 
As it stands, analytical platforms that combine droplet microfluidics and MS for organic 
synthesis applications have been very limited in scope.29 The development of novel droplet 
microfluidic MS approaches and application to chemical transformations of rising interest is 
therefore necessary to drive further innovations in HTE. Over the past decade, photoredox catalysis 
has risen to the forefront of organic synthesis by enabling rapid access to nontraditional bond 
constructions and aiding in sustainability efforts through the use of visible light. 180 - 183   In 
particular, photoredox catalysis has gained meaningful traction in medicinal chemistry 
applications by providing versatile access to scaffolds and building blocks that previously required 
a significant number of operations. 184 -186  Nonetheless, one key challenge faced in achieving 
widespread implementation of photoredox catalysis within medicinal chemistry stems from the 
scalability and generality of existing reactor platforms. In order to use these visible light-driven 
methods to their full potential, development of a user-friendly benchtop photoreactor featuring 
reaction screening and facile scale-up capabilities is needed.  With the goal of facilitating the rapid 
exploration and optimization of photoredox reactions, we have implemented a combined droplet 
microfluidics/MS-based high throughput screening platform to expand upon the robust capabilities 
and impact of photoredox catalysis in drug discovery and development. By interfacing droplet 
microfluidics with nanoESI-MS, we report the design of a system that allows for the rapid 
manipulation of nanoliter volume samples to enable the efficient screening of pharmaceutical 
libraries for visible light-mediated late-stage C–H functionalization reactions (Figure 3.1).   
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Figure 3.1. Development of a droplet microfluidics nESI-MS screening platform 
Screening of photoredox catalysis fluoroalkylation reactions was performed with the concerted 
objectives of enabling reaction discovery and high throughput optimization of 'hit' reaction 
conditions. ESI-MS analysis throughput as high as 3 samples/s and methods for accounting for 
ionization in variable sample matrices were demonstrated, providing a robust system for the high-
throughput MS analysis of photoredox droplet reaction samples. Successful translation of 
nanomole-scale conditions to millimole-scale reactions was further demonstrated, highlighting the 
ability to concertedly perform rapid reaction discovery as well as subsequent scale-up. 
With the goal of enabling high throughput photochemical reaction discovery and optimization 
for the synthesis of novel therapeutics, we aimed to leverage droplet microfluidics in the 
development of a nESI-MS-based screening platform. To achieve this objective, our preliminary 
studies have centered on the design of a system that allows for the rapid manipulation of nanoliter 
volume samples to enable the efficient screening of pharmaceutical libraries for visible light-
mediated late-stage C–H functionalization reactions. Upon establishing a segmented flow nESI-
MS method to screen photochemical reactions in multiwell plates, we have also demonstrated the 
rapid screening of reaction parameters for the radical perfluoroalkylation of pharmaceutical 
compound libraries. Through a collaboration with Pfizer, we have gained access to an extensive 
library of complex drug scaffolds to validate the application and immediate benefit of our 
technology towards accelerating drug discovery.  Specifically, we intend to utilize the wealth of 
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HTE data collected by our system to facilitate downstream structure-activity relationship (SAR) 
studies and biological assays in a medicinal chemistry setting. Translation of nanomole-scale 
conditions to millimole-scale reactions have also been investigated, in order to highlight the ability 
to concertedly perform rapid reaction discovery as well as subsequent scale-up. Ultimately, our 
objective is to develop a fully continuous platform that enables the integration of automated droplet 
generation from a standard multiwell plate with in-line nESI-MS analysis of droplet reaction 
samples.   
3.2 Results and Discussion 
3.2.1 Multiwell Plate Photoreactor and Droplet nESI-MS Platform Development 
Our studies into leveraging droplet microfluidics technology for reaction discovery have been 
centered on the development of a nESI-MS platform, which can be utilized for characterizing 
visible light-driven late-stage functionalization reactions.  We chose to employ a radical 
perfluoroalkylation strategy developed by the Stephenson group187-190 as a model reactive system 
for the diversification of pharmaceutical compound libraries.  As such, we have developed a 
droplet microfluidics-based HTE platform that interfaces nESI-MS analysis with a custom plate-
based photoreactor to accommodate the rapid screening of complex drug molecule libraries. We 
envisioned that this setup would be amenable to applications including the late-stage 
functionalization of drug scaffolds and rapid optimization of substrate-specific reaction conditions.   
Notably, our system includes an upstream setup for the high-throughput handling of 
pharmaceutical libraries and reagent stock solutions in 96, 384, or 1536 multiwell plates. With the 
objective of maximizing photon flux while enhancing reproducibility, we aimed to design a 
modular bench-top photoreactor for the irradiation of multiwell plate reactions using high-powered 
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Cree Royal Blue XTE LEDs (2 W per LED). We constructed a 25 LED array (approx. 50 W total 
output) to accommodate the dimensions of a standard 96, 384, or 1536 well plate (Figure 3.2A). 
 
Figure 3.2. Optimized workflow for droplet nESI-MS analysis 
The LEDs were mounted onto a heat sink, with two fans placed below and adjacent to the heat 
sink, in order to provide sufficient cooling to maintain reactions at ambient temperatures.  An 
acrylic shield positioned 5 cm above the LED array provided a mounting stage for the well plate, 
as well as an additional layer of protection for the LEDs.  A custom-built plastic amber light shield 
was placed around the setup for user eye protection. Following irradiation and subsequent dilution, 
our platform enables the automated generation of nanoliter-volume reaction droplets. Furthermore, 
downstream nESI-MS analysis of individual droplets provides real time data analysis on product 
formation and reaction kinetics.  
The optimized workflow (Figure 3.2) for droplet generation involved loading a pre-mixed 
stock solution onto a microwell plate, followed by blue light irradiation. A small fraction of each 
reaction was then withdrawn and diluted. The dilution served to both quench the reaction and 
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facilitate MS analysis, as the analysis of high concentration (> 1 mM) analytes can lead to 
saturation of MS signal and contamination of the MS source. 8 L of each diluted reaction mixture 
was deposited into a separate well plate and covered with perfluorodecalin (PFD) for subsequent 
droplet formation in perfluoroalkoxy (PFA) tubing (150 x 360 m internal diameter x outer 
diameter). Droplet samples (5-10 nL) were generated from microwell plates using equipment and 
methods previously reported by the Kennedy group.25,26  








Figure 3.3. Validation of droplet microfluidics nESI-MS method. (A) Photoredox trifluoromethylation 
of caffeine and 5-Br-7-(N-Boc)azaindole substrates (B) Droplet nESI-MS analysis of photoredox 
trifluoromethylation reactions. Droplet trains of repeating 3x3 format were flowed at to nESI-MS analysis 
at a rate of 0.67 droplets/s. The two traces represent the extracted m/z for 3.1 (m/z=367, top) and 3.2 




To demonstrate the general capabilities of our system, samples were prepared from the 
photoredox trifluoromethylation of N-Boc-5-bromo-7-azaindole and caffeine substrates (Figure 
3.3). Sample droplets (8 nL) were formed in a repeating 3x3 fashion. Droplet analysis was 
performed at a rate of 0.67 droplets/s, allowing for triplicate analysis to be performed in under 5 
s. Analysis throughput was limited only by the rate at which our mass spectrometer could scan the 
desired region, which required 170 ms to scan the range of 75-750 m/z.  By extracting out the m/z 
values associated with expected products (m/z for 3.1, m/z 263 for 3.2), we were able to 
successfully monitor product formation for both reactions. As shown in Figure 3.3, two separate 
droplet populations can be observed in the anticipated 3x3 fashion. Droplets that show high 
response for product formation in one trace show low response in the other, yielding an offset 
product signal pattern across the two traces. These results not only validate the capability of our 
system to detect product formation, but also demonstrate the ability to perform rapid analysis while 
maintaining the identity of the individual samples, with minimal material carryover between 
droplets. In this manner, we were able to establish proof-of-concept for the rapid analysis of 
photoredox reaction droplets to yield hit/no-hit responses by means of nESI-MS detection. 
3.2.2 Accelerated Late-Stage Functionalization of Drug Compound Libraries 
With the developed system, we aimed to achieve two goals: (1) accomplish late-stage 
functionalization using diverse radical coupling partners and (2) perform the high throughput 
optimization of reaction conditions for individual drug scaffolds. To achieve our first objective of 
performing the late-stage functionalization of complex drug molecules, we carried out the 
fluoroalkylation (CF3, CF2H, CF2Cl) of 17 drug and drug-like compounds provided to us through 
Pfizer's Sigma Aldrich compound library (Figure 3.4).  Reactions were irradiated with blue light 
for 1 hour in a 384 polypropylene well plate prior to dilution and subsequent droplet generation  
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Figure 3.4. Library of Pfizer compounds investigated in screen 
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for nESI-MS analysis. In order to enhance substrate solubility and maintain homogeneity of 
reactions, substrate stock solutions were prepared using a 10% DMF/MeCN solvent system. 
Excess amounts of trifluoroacetic anhydride (16 equiv) were added to accommodate acylation by 
nucleophilic functionalities (e.g. free amines and alcohols) on substrates within our targeted 
library. 
Upon generating reaction droplets in triplicate to ensure reproducibility, nESI-MS analysis was 
performed at a throughput of under 5s/sample. As a control experiment, "control background" 
samples containing no added substrate were run for each type of fluoroalkylation reaction. This 
enabled us to differentiate between MS signals that derived from the reaction of interest and signals 
that were simply artifacts of our sample matrices.  Shown in Figure 3.5A is the extracted mass 
trace (523 m/z) for the trifluoromethylated product of compound PF1, Verapamil HCl. Upon 
analysis of the droplets containing compound PF1, a significant spike in signal is observed in 
comparison to the control background samples, suggesting successful product formation. This 
same approach was applied to each of the tested substrates in our library.  
 
Figure 3.5. Screen for late-stage fluoroalkylation of pharmaceutical compounds by droplet nESI-MS. 
(A) General scheme for fluoroalkylation of 17-compound library. (B) Mass trace for predicted verapamil 
HCl (compound 1) product. Displayed is the m/z = 523, which is the predicted MH+ ion of mono-
trifluoromethylated verapamil HCl. (C) Coloration on heat map describes increased response for desired 
product MH+ ion over control, while blue asterisks denote statistical significance in response increase. 
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We were able to identify several "hit" reactions for each perfluoroalkylation condition 
(indicated by blue asterisks), in which desired product m/z signals were observed. Product m/z 
signals were further confirmed using isotopic modeling and tandem MS analysis. In order to 
qualitatively assign "hit"/"no hit" responses to each reaction, we conducted statistical analyses to 
assess the statistical relevance of our product m/z signals over background noise.  A two-sample 
t-test was performed, in which each reaction of interest was compared against the control 
background samples to confirm the presence of newly generated product m/z signals (Figure 
3.5B). Reactions were deemed a hit if they achieved a P<0.01. Across 5 distinct substrates that 
yielded "hit" responses, significant product m/z signal increases were observed for all three 
fluoroalkylation conditions, demonstrating the capability of our method to successfully detect 
product formation across a diversity of complex small molecules. MS counts were also utilized to 
show the strength of "hit" responses. A log10(product response-control response) test was used to 
gauge the magnitude of the signal increase and in turn, highlight promising reaction conditions.   
Three "hit" reactions were scaled up on 0.1 mmol scale for subsequent purification and product 
isolation to further validate our nESI-MS results. Successful isolation of monotrifluoromethylated 
(40% yield) and bis-trifluoromethylated (45% yield) varenicline tartrate was achieved, validating 
our corresponding nESI-MS screen data.  Isolation of trifluoromethylated Verapamil HCl and 
PF15 products was attempted to elucidate regioisomer formation; however, desired products could 
not be successfully isolated as a result of low yields and product decomposition upon column 
chromatography.  The HTE data obtained from our screen provided insight into several reactivity 
trends that arose from varying substrates and perfluoroalkyl radical reagents. Our screen revealed 
"hit" responses across 11 substrates (65% of 17 compound library), as well as successful product 
formation across all three perfluoroalkylation conditions for 5 substrates (compounds PF 1, 11, 13, 
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14, and 15). Among our "hit" compounds, a variety of heteroarene scaffolds, including 
quinoxalines, furo[2,3]pyridines, quinazolinones, pyrrolopyrimidines, and pyrrolopyridinones 
could be accessed.  We were gratified to see that several of these "hit" response scaffolds expanded 
upon the scope of structures formerly reported by the Stephenson group.  These results highlight 
the successful application of this methodology for substrates of increased complexity and diverse 
functionality. Upon isolation of trifluoromethylated and difluoromethylated varenicline tartrate 
products, we were intrigued to find that the regiochemical outcome varied across these two 
conditions, most likely due to differences in substrate and radical electronics.  While 
trifluoromethylation occurred exclusively at the electron-rich 6-position of the quinoxaline 
scaffold, the more nucleophilic difluoromethyl radical gave rise to functionalization at the 
electron-deficient 2-position.  These results suggest a preference for the formation of electronically 
matched radical functionalization products.  Among substrates that did not yield any product 
formation (PF 2, 3, 6, 12, 16, 17), we noted that the presence of electron rich alkyl amine motifs 
(PF 2, 12, 16) could be problematic, as these functionalities can be prone to single electron 
oxidation and subsequent decomposition. Additionally, the presence of sterically hindered 
aromatic groups (PF 12) could further hinder radical functionalization. 
3.2.3 High-Throughput Reaction Optimization 
In addition to enabling the accelerated late-stage functionalization of diverse pharmaceuticals, 
our droplet microfluidics platform can also be utilized for the high throughput optimization of 
photoredox reaction conditions. To demonstrate this feature, we set out to optimize reaction 
parameters for three of our "hit" compounds and one "potential hit" compound from our original 
compound library screen. Reaction variables including photocatalyst (8 photocatalysts screened) 
and pyridine N-oxide reagent (3 N-oxides screened) were evaluated across the four selected 
 173 
substrates, yielding a total of 96 individual reactions (Figure 3.6). Upon irradiating reaction 
mixtures (60 nanomole scale) with blue light for 1 hour and performing subsequent droplet 
generation and MS analysis, we were able to identify distinct optimal conditions for each drug 
molecule.  Most importantly, the high throughput capabilities of our system were effectively 
captured by the expedient generation and ESI-MS analysis of 228 droplet reactions within 20 
minutes.  Our results suggest that subtle changes in photocatalyst and N-oxide identity give rise to 
significant variations in product conversion, as exemplified by a 60% increase in MS product 
signal intensity upon substituting the Ru(bpy)3Cl2 photocatalyst for Ir(ppy)2(dtbbpy)PF6 in the 
trifluoromethylation of Verapamil HCl (Figure 3.7).  
 
Figure 3.6. Parameters screened for optimization of photoredox trifluoromethylation reaction 
With the broader aim of obtaining quantitative insight into product conversion and reaction 
kinetics, as well as expanding upon screen parameters to include various solvent systems, we have 
developed both quantitative and semi-quantitative ESI-MS methods for measuring product 
formation.  To expand upon our platform's high-throughput reaction optimization capabilities, we 
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aimed to test a broad set of parameters for the radical trifluoromethylation of caffeine, including 
solvents, photocatalysts, and heterocyclic N-oxide reagents.  Specifically, we set out to establish a 
robust analytical method to enable quantitative measurement of product conversion while 
accommodating sample-to-sample variability in product response due to matrix effects. Our efforts 
focused on minimizing background signals and accounting for variations in ionization efficiency.  
 
Figure 3.7. Optimization of Verapamil HCl trifluoromethylation reaction 
To lower background signals, MS-MS analysis was performed to target a specific 
fragmentation pattern arising from the trifluoromethylated caffeine analyte (m/z = 263→206). 
Development of an MS-MS assay can help to reduce, and possibly remove, background noise by 
increasing assay specificity towards the product of interest. In order to accommodate different 
solvent systems, we also needed to address challenges associated with ion suppression, as changes 
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(e.g. solvent environment) in the sample matrix can drastically affect analyte ionization and 
observed MS response. While this effect is typically resolved through sample cleanup methods 
(e.g. liquid chromatography and chemical extractions), we aimed to implement a methodology that 
would allow for the direct analysis of droplet samples to maximize throughput. 
By using the radical trifluoromethylation of caffeine as our model reaction system, we have 
demonstrated successful screening of co-solvent systems including 10% co-solvent/MeCN (co-
solvents: DMF, DMA, CH2Cl2, MeNO2, DMSO). In the presence of these co-solvents, analyte 
response was found to observe nearly a 4-fold drop, despite constant analyte concentrations, which 
would have major ramifications in a condition screen.   
 
Figure 3.8. Condition screen for photoredox caffeine trifluoromethylation reaction. (A) Internal 
standard trace (m/z = 277→192, top) and product MS-MS trace (m/z = 263→206, bottom) across 72-
reaction screen. Insets are enlarged regions for 125-150s (left) and molecular structures (right). (B) Heat 
map results based on the analyte to internal standard ratios. Each cell represents the average of 3 droplets. 
Darker shading represents a higher observed ratio, indicating greater observed product turnover. 
To overcome matrix effects, we explored three methods: the use of standard addition, internal 
standard, and higher dilution factor.  Moving forward, we chose to use ethyltheophylline as an 
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internal standard, as it provided excellent results with regards to signal normalization and 
minimizing variability in measurement. 
Additionally, the generation of an ESI-MS calibration curve enabled us to extract quantitative 
yield data from our reaction optimization screens, in order to benchmark and compare results 
obtained from different conditions. A 72-reaction screen was then performed to optimize the 
caffeine trifluoromethylation reaction by screening parameters including photocatalyst, N-oxide 
reagent, and co-solvent (Figure 3.8).  The triplicate analysis of all 72 reactions was performed in 
380 s (1.7 s/droplet). Successful product formation was observed over a wide range of conditions.  
Solvent choice was found to have the largest influence on product formation. The use of 10% 
DMSO (6) yielded very poor turnover, while 10% DMF and DMA (4 and 5 respectively) gave the 
highest turnover across multiple conditions. These results highlight the importance of addressing 
matrix effects. DMF and DMA were both observed to suppress product signal, and as such, would 
not likely have been viable co-solvents prior to adjusting for variable ionization efficiencies.   
 
Figure 3.9. Demonstration of reliability in scaling up reactions. Droplet nESI-MS comparison (n=10 
droplets) of samples run at screen scale (3 µmol) and 100x scale (300 µmol) showed similar response for 
all 5 different reaction conditions. Normalization of results was performed within each pairing.  The top 5 
reaction conditions are listed in order as conditions 1-5. 
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Five of our top performing reactions were selected for subsequent scale-up on 300 umol scale 
and irradiated in a 96 well plate (Figure 3.9).  Gratifyingly, ESI-MS results suggested that the 
yields obtained from the scale-up reaction show strong correlation with that of our small-scale 
screens, which further validates the scalability of our screening method and the opportunity to 
quantitatively benchmark reaction performance in a high-throughput manner. 
3.2.4 Increasing Analysis Throughput and Analysis of Reaction Droplets 
With the aim of enhancing the throughput of our nESI-MS screening platform beyond a duty cycle 
of 40 ms, we focused on the optimization of two system components: the internal diameter (i.d.) 
of the fused silica nESI emitter and the size of the droplets (Figure 3.10). Our original caffeine 
trifluoromethylation nESI-MS analysis conditions involved the use of a 75 µm i.d. emitter  
 
Figure 3.10. Efforts toward increasing analytical throughput. Traces are for the MS-MS detection of 
trifluormethylated caffeine (m/z = 263→191). Samples were formatted into repeat 10x10 units of samples 
(50 µm product) and blanks (Top) The use of 75 µm i.d. capillary emitter, 8 nL droplets, and 12 nL PFD 
spacing was capable of stable analysis at 800 nL/min flow and 0.67 droplet/s throughput (Middle). The use 
of 100 µm i.d. capillary emitter, 8 nL droplets, and 12 nL PFD spacing was capable of stable analysis at 
1500 nL/min flow and 1.3 droplet/s throughput (Bottom). The use of 100 µm i.d. capillary emitter, 4 nL 
droplets, and 3 nL PFD spacing was capable of stable analysis at 1500 nL/min flow and 2.9 droplet/s 
throughput. 
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capillary to form 8 nL droplets with 12 nL PFD segmentation, flowed at 800 nL/min to give a 
throughput of 0.67 droplets/s. While increasing analysis flow rate caused breakage of droplets 
inside of the emitter, we discovered that increasing the capillary i.d. to 100 µm allowed for stable 
flow of droplets at higher flow rates. Stable droplet transfer through the capillary at 1500 nL/min 
flow was now possible, yielding an analysis throughput of 1.3 droplets/s. To further increase 
throughput, the volumes of the droplets and PFD spacing were decreased to 3 nL and 4 nL, 
respectively. By combining reduced sample volumes with higher flow rates, analysis throughput 
was successfully increased to 2.9 droplets/s. 
3.3 Conclusion 
 
In summary, an HTE platform for the screening of visible light-driven reactions was developed 
and successfully applied to photoredox catalysis reactions. Simultaneous irradiation of samples in 
micro well plates, followed by translation into segmented droplets post-reaction facilitated rapid 
reaction screening and delivery to downstream analysis. The use of nESI-MS provided detection 
of a diverse population of reaction products with minimal assay development, as well as highly 
gentle ionization for the observation of labile species. The implementation of methods to address 
variable ionization efficiency in droplet nESI-MS analysis enabled the screening across a variety 
of photoredox reaction conditions. The systems and methodologies presented show great promise 
for future work in visible light-driven reaction design and rapid diversification of pharmaceutical 




3.4 Experimental Methods 
3.4.1 General Information 
Chemical Reagents and Analytical Instrumentation 
All chemicals were used as received. Perfluorodecalin (PFD) was purchased from Oakwood 
Products (Estill, SC).  All other reagents were purchased from Fisher Scientific or Millipore Sigma.  
Compounds PF1-17 were generously provided by Pfizer.  Reactions were monitored by TLC and 
visualized with a dual short wave/long wave UV lamp.  Column flash chromatography was 
performed using 230-400 mesh silica gel or via automated column chromatography. NMR spectra 
were recorded on Varian MR400, Varian Inova 500, Varian Vnmrs 500, or Varian Vnmrs 700 
spectrometers. Chemical shifts for 1HNMR were reported as δ, parts per million, relative to the 
signal of CHCl3 at 7.27 ppm. Chemical shifts for 13CNMR were reported as δ, parts per million, 
relative to the center line signal of the CDCl3 triplet at 77.16 ppm. Chemical shifts for 19FNMR 
were reported as δ, parts per million, relative to the signal of a trifluorotoluene internal standard at 
–63.72 ppm. The abbreviations s, br. s, d, dd, br. d, ddd, t, q, br. q, qi, m, and br. m stand for the 
resonance multiplicity singlet, broad singlet, doublet, doublet of doublets, broad doublet, doublet 
of doublet of doublets, triplet, quartet, broad quartet, quintet, multiplet and broad multiplet, 
respectively. IR spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR spectrometer fitted 
with an ATR accessory. Mass Spectra were recorded at the Mass Spectrometry Facility at the 
Department of Chemistry of the University of Michigan in Ann Arbor, MI on an Agilent Q-TOF 
HPCL-MS with ESI high resolution mass spectrometer. LED lights and the requisite heat sink, 
fan, and power supplies were purchased from LED Supply (https://ledsupply.com) with the 
following item codes: CREEXTE-ROY-X (XLamp XT-E Royal Blue LEDs), MAKERSLED 
(MakersLED Heat Sink), PDA060B-XXXB (60W Phihong IP67 Constant Current AC Drivers).  
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A Westpointe Electrical Co Wp 4’’ Hi Velocity Fan 1002 Personal Fan was purchased from 
http://amazon.com.   
Irradiation Chamber Setup 
A 25 LED array of Cree Royal Blue XTE LEDs (2 W per LED, 50 W total output) was 
assembled to accommodate the dimensions of a standard 96, 384, or 1536 microwell plates (Figure 
3.11). The LEDs were mounted onto a heat sink, with two fans placed below and adjacent to the 
heat sink, in order to provide sufficient cooling to maintain reactions at ambient temperatures. An 
acrylic shield positioned 5 cm above the LED array provided a mounting stage for the well plate, 
as well as an additional layer of protection for the LEDs.  A custom-built plastic amber light shield 
was placed around the setup for user eye protection.  
 
Figure 3.11. (Left) Setup for irradiation of multiwell plate with blue LED lights (Middle) Close-
up view of irradiation device in operation (Right) Entire setup for irradiation of multiwell plates. 
 
Reagent Preparation for Fluoroalkylation Reactions 
 1 mol% photocatalyst and 4 equivalents of N-oxide reagent were dissolved in acetonitrile. The 
reagent solutions were sparged with a stream of nitrogen gas for 5 min. 4.4 equivalents of acetic 
anhydride reagent were subsequently added, and the mixtures were stirred for 10 min to facilitate 
complete conversion to the acylated species. Separate solutions of substrate in acetonitrile (0.1 M), 
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with co-solvent when applicable, were also prepared. 10 µL of each solution were mixed together 
in a 384 multiwell plate to form the final reaction solution. 
Droplet Generation 
Before generation, all samples were diluted down 500:1 by a 50:50 methanol:water solution 
w/0.5% formic acid, with the exception of the trifluoromethylation condition screen, in which 
samples were diluted down to an additional 4:1 with acetonitrile. Droplet plugs were generated 
from microwell plates using equipment and methods described in our previous work.25 Briefly, 
samples were drawn into either 100 or 150 µm inner diameter (i.d) x 360 µm outer diameter (o.d) 
perfluoroalkoxyalkane (PFA) tubing (IDEX Health and Science, Oak Harbor, WA) by a PHD 2000 
Programmable syringe pump (Harvard Apparatus, Holliston, TX). Samples of 8 µL in volume 
were deposited into 384-microwell PCR plates (Corning, Corning, NY) with PFD placed on top. 
To form the droplet samples, an XYZ-position manipulator moved the tubing between sample 
wells and fluorous phase while the syringe was continuously withdrawing. When diluted only with 
methanol:water diluent, 8 nL droplets with 12 nL perfluorodecalin spacing were generated at 800 
nL/min, except when otherwise stated. When additional acetonitrile dilution was performed, 
droplets were found to be less stable, so 6 nL droplets with 10 nL spacing were generated at a flow 
rate of 600 nL/min . 
nESI-MS and ESI-MS Analysis 
Connections from PFA tubing to nanoelectrospray emitters were formed using zero dead-
volume PicoclearTM unions (New Objective, Woburn, MA). nESI emitters were pulled from 75 or 
100 µm i.d. x 360 µm o.d. fused silica capillary to an i.d. of 30 µm (FS360-50-30-CE, New 
Objective, Woburn, MA). Electrospray potential of 1.75 kV was applied to the exterior of the 
platinum coated emitters, with 35 V applied to the sample cone. Mass spectrometry analysis was 
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performed on a Micromass Quattro Ultima triple-quadrupole mass spectrometer (Waters, Milford, 
MA). Nitrogen cone gas emerging from sampling inlet was set to 125 L/h to help stabilize the 
electrospray. For data analysis in MS-only scanning, droplet response was reported as the average 
of three data points in the center of each droplet. For MS-MS analysis, 5 data points were used. 
Flow rates to nESI-MS analysis matched droplet generation flow rates, except in experiments 
testing higher throughputs, which were flowed at 1500 nL/min. For work using a standard 
electrospray source, ESI voltage was 3.0 kV, the source was heated to 100 ºC, the cone gas was 
set at 225 L/h, the desolvation gas was 300 L/h and 200 ºC. The nebulizing gas flow was not 
measured, but it was adjusted to one half turn of the dial. 
3.4.2 ESI vs. nESI-MS Signal Detection Studies 
We found that nESI could promote the formation of molecular ions even when ESI could not 
(Figure 3.12), further highlighting the potential utility of a nESI-MS in screening applications. 
Samples composed of 50 mM trifluoromethyl azaindole before dilution were examined by both 
nESI-MS and ESI-MS analysis.  nESI-MS analysis of sample containing analyte at a flow rate of 
800 nL/min yielded spectra that showed the intact MH+ molecular ion at m/z=365 and 367, along 
with prominent fragments at 309 and 311.  MS-MS analysis of the 365 m/z ion showed the 
formation of the m/z=309 ion with very little energy applied, validating it as a fragment of the 
original molecular ion. When using the standard ESI source with sample flow at 100 µL/min, the 
molecular ion was not visible as nearly complete fragmentation was observed. While some 
fragmentations can be easily predicted (e.g. Boc protection), predicting fragmentation patterns and 
performing more in-depth structural assignments would not be amenable to HT work, making an 




Figure 3.12. Comparison of ESI and nESI analysis.  Predicted structures for intact molecule (Right) and 
loss of t-butyl group (Left) are shown. Arrows point to m/z peaks associated with each structure. (Top) 
nESI-MS analysis affording observation of the labile MH+ molecular ion. While the 309/311 m/z fragments 
are the most prominent, the 365/367 m/z molecular ions were readily apparent. (Middle) nESI-MS-MS 
analysis of 365 m/z ion at 10 eV collision energy. Fragmentation of the 365 m/z ion showed almost 
complete conversion to 309 m/z ion, validating that molecular ions can fragment to form the 309/311 m/z 
ions observed in MS spectra. (Bottom) ESI-MS analysis of same sample. In this spectrum, molecular ions 
are no longer observed. 
3.4.3 MS Strategies for Overcoming Matrix Effects 
In addition to enabling the accelerated late-stage functionalization of diverse pharmaceuticals, 
our screening platform can also be utilized for the high throughput optimization of photoredox 
reaction conditions. To explore capability in such applications, we aimed to test a broad set of 
conditions for the trifluoromethylation of caffeine and discover new conditions for 
enhancingproduct formation. To make this type of work possible, an analytical method needed to 
be established to measure product conversion while tolerating sample-to-sample variability in 
product response due to matrix effects. Our efforts focused on minimizing background signals and 
accounting for variations in ionization efficiency. To lower backgrounds, MS-MS analysis was 
performed to target a specific fragmentation pattern demonstrated by the trifluoromethylated 
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caffeine analyte (m/z = 263→206). The development of an MS-MS assay will reduce or even 
remove backgrounds by increasing the assay specificity towards the product of interest. The 
second point is a general concern in the direct analysis of samples by MS. Changes in the sample 
matrix can drastically affect analyte ionization and observed MS response. This effect is typically 
resolved through sample cleanup methods such as liquid chromatography and chemical 
extractions. Because the use of such methods is time-intensive, we aimed to implement 
methodologies that would allow for the direct analysis of droplet samples. 
Shown in Figure 3.13 are the MS traces associated with the detection of trifluoromethylated  
caffeine in the presence of suppressing solvents.  
 
Figure 3.13. Analysis of trifluoromethylated caffeine in the presence of suppressing cosolvents. (Top) 
MS trace for TFM caffeine (m/z = 263). Droplet samples over the first 13 seconds of analysis were dissolved 
in 100% acetonitrile. The following droplets had one of the cosolvents present and saw massively decreased 
response for the trifluoromethylated caffeine. (2nd, 3rd and 4th traces) In descending order, the MS traces for 
NMP (m/ z= 100), DMA (m/z = 88) and DMF (m/z = 74). 
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Trifluoromethylated caffeine analyte was dissolved in either acetonitrile (50 mM), or in 
acetonitrile with 4% of either N-methyl-2-pyrollidone (NMP), dimethylformamide (DMF), or 
dimethylacetamide (DMA) present. These represent commonly used cosolvents in photoredox 
reactions, and even after diluting samples 500:1, were found to have a major effect on analyte 
ionization. In the presence of cosolvent, analyte response was found to observe nearly a 4-fold 
drop, even though analyte concentration remained constant, which would have major ramifications 
in a condition screen. 
To overcome matrix effects, we explored three methods: the use of standard addition, internal 
standard, and higher dilution factor. (Figures 3.14, 3.15, 3.16).   
 
Figure 3.14. Trifluoromethylated caffeine MS-MS trace (m/z = 263→206) for standard addition 
method. Droplets with “A” designation were diluted normally, while “B” designation denotes droplets that 
were diluted with additional solution. 0% DMF (blue bar), 4% DMF (grey bar), and 10% DMF (green bar) 
showed variable ionization, but these changes could be accounted for upon normalization of Samples A 
against Samples B (A/B). 
For these experiments, sample solutions consisted of 30 mM trifluoromethylated caffeine in 
reaction mixture, which was then diluted 1:1 with 0%, 8% or 20% DMF, respectively, in 
acetonitrile. The first method involved the use of standard addition, a commonly employed tactic 
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for addressing samples that have unknown matrix effects (Figure 3.14).  For this approach, each 
sample of interest was further split into two samples to analyze. The first was made by the 
previously described 500:1 dilution. The second used the same dilution solvent with 15 µM 
trifluoromethylated caffeine standard present. Because both samples contain the same matrices 
and therefore similar analyte ionization efficiencies, taking the ratio of the two responses gives a 
measure of analyte concentration that accounts for matrix effects.  
 
Figure 3.15. Internal standard method.  Trifluoromethylated caffeine MS-MS trace (m/z = 263→206, 
top) and trifluoromethylated ethyl theophylline (m/z = 277→192, bottom) for internal standard method. 0% 
DMF (blue bar), 4% DMF (grey bar), and 10% DMF (green bar) showed variable ionization, but upon 
normalizing each droplet’s analyte response against its internal standard response (A/IS), these effects can 
be accounted for. 
The second method entailed the addition of an internal standard (Figure 3.15). For our caffeine 
trifluoromethylation reaction, we chose to use trifluoromethylated ethyltheophylline as the internal 
standard, as it only varies in structure by a single methylene group.  This change is easily 
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discernable by MS but should not significantly affect ionization. Trifluoromethyl ethyl 
theophylline was present in the dilution phase at a concentration of 30 µM. For each droplet 
sample, the response for analyte could be normalized against internal standard, which should show 
similar changes in ionization from variable matrices. Finally, the use of a higher dilution factor 
(10,000x vs. 500x) was examined (Figure 3.16). By increasing the dilution and therefore further 
reducing the concentration of matrix components, we sought to reduce matrix effects to a 
negligible level. 
 
Figure 3.16. Comparison of performance across high dilution, standard addition (Std. Add.) and 
internal standard (I.S.) methods. Each bar represents the results from 15 separate samples analyzed in 
triplicate. Control samples were prepared from trifluoromethylated caffeine responses from base conditions 
with no extra measures employed. Responses are normalized within each method. 
Each of the examined methods have associated strengths and weaknesses. The standard 
addition method directly accounts for matrix effects but halves throughput by doubling the number 
of samples. Use of internal standard performed gave the best performance both in precision of 
measurements (RSDs for all samples were less than 4%) and ability to normalize for matrix effects 
(normalized responses ranged from 0.94-1.00). The major drawback is that internal standards 
function best for structurally similar molecules, potentially requiring a need for new molecular 
standards when switching between substrates. The increased dilution method would be desirable 
for its simplicity in implementation but would not account for any remaining variability in matrix 
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effects. This method also gave the worst performance with regards to measured precision (RSDs 
ranged from 6-9%), possibly due to the lower analyte concentration associated with a higher 
dilution factor. 
In our droplet microfluidics reaction optimization screen, we opted to use an internal standard, 
as it provided excellent results in terms of enabling signal normalization and minimizing variability 
in measurement. Namely, a 72-reaction screen was then performed to optimize the caffeine 
trifluoromethylation reaction by screening parameters including photocatalyst, N-oxide reagent, 
and co-solvent (Table 3.1).  
 
Table 3.1. Parameters examined for optimization of caffeine trifluoromethylation reaction 
The triplicate analysis of all 72 reactions was performed in 380 s (1.7 s/droplet) by ESI-MS 
(see section 3.2 for results). 19F-NMR was applied as an orthogonal detection technique to 
validate our MS results (Figure 3.17). Analysis of our 5 scaled-up reactions showed yields ranging 
from 22-57%. The relative rankings of the reactions did not match between the original screen and 
scale-up, i.e. the best response from the screen did not give the highest product formation by 19F-
NMR. This can be accounted for by day-to-day or sample-to-sample variability in the reaction 
performance, as formation of the acylated N-oxide species required for trifluoromethyl radical 
formation is moisture sensitive. Heterogeneity in the screen samples also presents a potential 
source of error. 
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Figure 3.17. Validation of optimization screen MS results. The top 5 reaction conditions are listed in 
order as conditions 1-5 (A) Demonstration of reliability in scaling up reactions. Droplet nESI-MS 
comparison (n=10 droplets) of samples run at screen scale (3 µmol) and 100x scale (300 µmol) showed 
similar response for all 5 different reaction conditions. Normalization of results was performed within each 





























Chapter 4: Development of a Droplet Microfluidic Platform for the High-Throughput 
Screening of Photoredox Catalysis Reactions 
This work was performed with equal contribution from Daniel Steyer. Contributions of A. Sun 
include performance of in-droplet reaction screens and continuous flow reaction scale-up, as well 
as characterization and isolation of products. Contributions of D. Steyer to this work include the 
development and implementation of droplet incubation and reagent addition methods, as well as 
performance of MS assays and statistical analyses.  
 
*Portions of this chapter have been published in Telmesani, R. Sun, A. C., Beeler, A. B.; 
Stephenson, C. R. J., Flow Photochemistry in Organic Synthesis. Science of Synthesis: Flow 
Chemistry in Organic Synthesis, 2018, 103, Stuttgart, Germany: Thieme. 
4.1 Introduction 
4.1.1 Continuous Flow Photochemistry 
Over the past decade, visible light-mediated photoredox catalysis has emerged as a robust 
strategy to activate small molecules, forge challenging chemical bonds, and construct complex 
molecular scaffolds.191-194  In particular, visible light (400-700 nm) irradiation offers a more 
chemoselective means of initiating radical-based transformations, as the lack of visible light 
absorbance by most organic molecules eliminates side reactions that may be triggered by UV light.  
With the burgeoning development and application of photoredox catalysis methodology across the 
synthetic community, efforts to address the scalability of these highly pathlength-dependent 
processes have spurred the adaptation of photoredox catalysis reactions in continuous flow 
systems.195-198 
 
Equation 1. The Beer-Lambert-Bouger Law 
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The efficiency of photochemical reactions is necessarily dependent on the availability of 
photons in a reaction mixture.  The challenges associated with this availability are readily 
illustrated by the Beer-Lambert-Bouger law (Equation 1), which relates absorbance to the molar 
absorption coefficient () of light absorbing molecules, their concentrations (c), and the path length 
of light propagation (l).  As it relates to photoredox catalysis, the high molar absorptivity  (Table 
4.1) of traditional photocatalysts (e.g. tris(bipyridine)ruthenium(II)chloride) puts severe 
limitations on the scalability of batch processing, as the intensity of incident radiation decreases 
rapidly beyond the reactor surface, with minimal productive radiation at the center of the reactor 
(Figure 4.1).199,200 
Photocatalyst Molar Absorption 
Coefficient (M-1cm-1) 
Measured 
 Wavelength (nm) 
Ref 
Ru(bpy)3
2+ 13000 452 11 
fac-Ir(ppy)3 1100 462 12 
Ir(ppy)2(dtbbpy)
+ 900 465 13 
Ir(dF(CF3)ppy)2(dtbbpy)
+ 180 452 14 
 








In particular, the extent of photocatalyst light absorbance may have a significant impact on 
reactions that do not exhibit high levels of radical chain propagation and are characterized by 
quantum yield values ≤ 1.  Quantum yield () measurements can be used to determine the 
efficiency of product formation relative to the total number of photons absorbed by the reaction 
medium (Equation 2).  Quantum yield values above 1 indicate the presence of radical chain 
pathways, in which absorption of a photon leads to the propagative generation of radical 
intermediates.205,206  On the other hand, values between 0 and 1 may be suggestive of non-chain 
reactions that show a greater dependence on photon flux density.207  
 
Equation 2. Quantum Yield Measurement 
The use of continuous flow reactors for photoredox catalysis is especially appealing, as the 
greater surface area-to-volume ratio results in increased photon flux density, which can lead to 
reaction acceleration.7,9  Using actinometry measurements, Loubière and co-workers observed a 
150-fold increase in photon flux absorbance when transitioning from a batch to microreactor 
setup. 208  In addition to providing more productive irradiation and enabling the scale-up of 
photochemical reactions, continuous flow reactor technology also imparts other advantages, 
including better mass and heat transfer, increased operational safety, and opportunities for 
performing automated multi-step syntheses7,18-211 The continued development and implementation 
of photochemical flow processes is critical for the efficient production of high-value chemical 
compounds across a multitude of synthetic applications and industrial sectors.  It is anticipated that 
future advancements in this field will support the design of systems that offer enhanced operational 
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flexibility, place an emphasis on sustainability, and provide additional platforms for reaction 
discovery and optimization.    
4.1.2 Continuous Flow-Based Screening Platforms in Organic Synthesis 
High-throughput experimentation (HTE) techniques hold the potential to revolutionize modern 
catalysis and reaction discovery by enabling the exploration of myriad reaction conditions in a 
time and resource-efficient manner.212-217  In recent years, efforts have been directed towards the 
development of mass spectrometry-based (MS) HTE systems for the automated processing of Pd-
based cross coupling reactions on nanomole scale, in both batch and continuous flow 
settings.218219220221   In order to overcome challenges associated with solvent evaporation and 
heating in nanomole plate-based screening, there has been a significant drive to develop next-
generation continuous flow-based HTE platforms for organic synthesis.  These innovative HTE 
methods promise to empower chemists to run orders of magnitude more experiments while 
utilizing "big data" informatic approaches for reaction design and troubleshooting.   
In 2017, the Jensen group reported the elegant design of an automated flow chemistry platform 
that allows for the optimization of single, microliter-sized droplet reactions.222 More recently, 
researchers at Pfizer have developed a modular, automated system to enable nanomole scale 
screening and micromole scale synthesis in continuous flow.  This platform was successfully 
employed to expedite reaction discovery in flow while providing an analysis throughput of over 
1500 samples/day (1 sample/45 s).30  While the above screening technology have been successfully 
applied to non-photochemical reactions, we are interested in developing a novel HTE platform for 
screening visible light-driven photochemical reactions in continuous flow by leveraging droplet 
microfluidics. 
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4.1.3 Leveraging Droplet Microfluidics Technology for Photoredox Catalysis 
Among the repertoire of modern catalysis methods, photoredox catalysis has exerted a 
significant influence on industrial chemistry by enabling otherwise infeasible bond disconnections 
and aiding sustainability efforts. 223   The widespread implementation of photoredox catalysis 
renders the development and dissemination of flow technology for reaction scale-up to be broadly 
impactful.7,224  The use of continuous flow reactors for photochemical reactions is especially 
appealing, as the greater surface area-to-volume ratio accessible results in increased photon flux, 
which can lead to reaction acceleration.7  
 
Figure 4.2. Development of a droplet microfluidics screening platform for photoredox reactions 
However, conditions developed for an efficient discovery-scale (i.e. milligram-scale) batch 
process often do not translate effectively to a pilot-scale (i.e. kilogram-scale) flow system, and 
significant resources can be wasted during re-optimization. For example, 0.5 kg of starting material 
was wasted on optimizing the residence time for a trifluoromethylation reaction in a large scale 
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photoflow reactor built by our group in collaboration with Eli Lilly.225 Given the time and resource 
constraints of translating discovery scale (i.e. microgram scale) batch reactions to large scale (i.e. 
kilogram scale) continuous flow conditions, we envision employing droplet microfluidics as a 
unique platform for continuous flow-based reaction discovery and optimization (Figure 4.2).  To 
increase throughput in conventional flow reaction screening, multiple reaction plugs, spaced by 
reaction solvent, need to be present in the reactor simultaneously. Taylor diffusion of these plugs 
into surrounding carrier solvent makes the determination of exact reaction conditions impossible 
and leads to cross contamination over longer incubation times.  It is in this context that we aim to 
develop novel droplet microfluidics HTE technology, with the goal of expanding upon the robust 
capabilities and impact of photoredox catalysis in drug discovery and development. 
We have identified droplet microfluidics as an excellent platform for continuous flow-based 
reaction discovery. Over the past decade, droplet microfluidics has been used to enable further 
miniaturization and higher throughput in biological and chemical experiments.  Segmentation of 
samples with an immiscible phase can enable the simultaneous handling of numerous samples over 
extended periods of time.32  From a material consumption standpoint, droplet microfluidics screens 
are typically performed at nanoliter to femtoliter scale, which can translate to a reduction in starting 
material usage by six to eight orders of magnitude relative to a traditional multiwell plate-based 
screen. Droplet microfluidics is also well suited for photocatalytic reactions, as the micrometer 
dimension of the reaction vessel allows for high photon flux through the reaction channel in an 
analogous manner to the narrow tubing employed in flow reactors.9,226-229    Manipulating droplet 
samples in closed systems also provides the benefit of avoiding solvent evaporation, allowing for 
the use of volatile solvents over extended incubation times.  In addition to providing reduced 
reagent consumption, droplet microfluidics systems can improve screening efficiency through 
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process automation and online analysis.  The disruptive impact and utility of droplet microfluidics 
has been demonstrated across several biological applications, including single-cell analysis, 
droplet-based polymerase chain reactions, and directed enzyme evolution.36,230 ,231 ,232 -238   The 
ability to manipulate discrete droplets through immiscible multi-phase fluids in microchannels 
shows potential for chemical synthesis by allowing for cost reduction through small reagent 
volumes, rapid reactions on the order of milliseconds, and greater control over local conditions to 
enhance product selectivity.  In recent years, droplet microfluidic reactors have been developed to 
rapidly merge two libraries of reagents in creating a combinatorial product library.239  
 
Figure 4.3. Highlights of droplet microfluidcs screening platform 
As such, we envisioned employing droplet microfluidics as a new platform for high-throughput 
reaction discovery and optimization, to further reduce material consumption while increasing 
chemical space coverage in early-stage pharmaceutical discovery (Figure 4.3).  We aimed to 
develop a droplet microfluidic reactor that would enable prepare nanoliter-sized reaction droplets, 
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perform photochemical reactions on picomole scale, as well as conduct subsequent ESI-MS 
analysis, all in a continuous and automated manner (Figure 4.4).  We have designed a microfluidic 
reactor that features the integration of a reagent addition chip, oscillatory photoreactor, as well as 
in-line dilution and nESI-MS analysis capabilities in one continuous flow system. Namely, the use 
of a reagent addition microfluidic chip would provide the benefit of performing direct, in-droplet 
reagent addition to streamline and expedite droplet preparation.  This helps increase material 
efficiency, as stock solutions can be conserved for further use, without the need for pre-mixed 
solutions.  
 
Figure 4.4. Photoredox droplet microfluidic reactor design features 
Additionally, we aimed to design an oscillatory flow setup, which would give us the opportunity 
to optimize reaction residence time at a constant volume and flow rate.  We anticipate that the use 
of droplet microfluidics will propel forward in-flow screening efforts to where throughputs can 
approach or even match the throughput of batch-scale screens, while more accurately reflecting 
optimal continuous flow conditions to facilitate subsequent photochemical reaction scale-up (i.e. 
gram to kilogram scale).  Here, we report the advances towards a droplet microfluidic/MS platform 
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to enable picomole-scale discovery of visible light-driven reactions and provide robust 
translatability to millimole flow scale-up processes. We foresee the synergistic combination of 
droplet microfluidics, MS, and photoredox catalysis as an enabling platform for accelerating 
pharmaceutical discovery and development, with a concerted emphasis on time and material 
efficiency.   
4.2 Results and Discussion 
Our studies into leveraging droplet microfluidics technology for reaction discovery have been 
centered on the development of an ESI-MS platform, which can be utilized for characterizing 
product formation in visible light-driven reactions.  Previous applications of ESI-MS have led to 
the development of systems for monitoring the molecular content of pL-nL volume droplets with 
high analytical stability at throughput levels as high as 10 droplets/s.240-247  In this work, we aimed 
to develop a droplet microfluidic reactor that would enable us to perform on-chip reagent addition, 
droplet reaction irradiation, in-line dilution, and subsequent ESI-MS analysis in one continuous 
system (Figure 4.4). Additionally, we aimed to design an oscillatory flow setup, which would give 
us the opportunity to optimize reaction residence times at a constant volume and flow rate.  
Our optimized workflow for droplet generation begins with the upstream formation of reaction 
droplets (5-10 nL) from a standard 384 or 1536 microwell plate using equipment and methods 
previously reported by the Kennedy group.50-53  In our preliminary studies, we constructed an 
easily assembled, low-footprint photoreactor that could enable us to flow irradiated reaction 
droplets directly into our triple quadrupole mass spectrometer for analysis. We assembled our 
photoreactor by wrapping a single strip of 4.4 W blue LEDs around the inner diameter of an 
aluminum foil-lined petri dish, at the center of which was fitted with a coil of perfluoroalkoxy 
(PFA) tubing (100 µm inner diameter; 360 µm outer diameter).  Upon flowing reaction droplets 
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through our photoreactor chamber, simultaneous dilution and ESI-MS analysis were performed 
using a sheath sprayer.50  In-line dilution of droplets served to both quench the reaction and 
facilitate MS analysis, as the analysis of high concentration (> 1 mM) analytes can lead to 
saturation of MS signal and contamination of the MS source.   
In our preliminary studies, we chose to employ a radical perfluoroalkylation strategy developed 
by the Stephenson group248,249  as a model reactive system for the late-stage functionalization of 
complex pharmaceutical intermediates.  To demonstrate the general operation of our system, we 
performed the in-droplet trifluoromethylation of four distinct substrates, three of which were either 
approved therapeutics or drug candidates provided from Pfizer’s Millipore Sigma Library. 
Reaction droplets (4 nL), segmented by a perfluorodecalin (PFD) carrier phase (8 nL), were formed 
in a 100 µm internal diameter (i.d.) PFA tubing.  Droplet reactions containing different substrates 
were generated in a consecutive manner (Figure 4.5).  
 
Figure 4.5. ESI-MS analysis of in-droplet trifluoromethylation reactions. Extracted m/z ratios for 
trifluoromethylated products. MH+ molecular ions were monitored for all trifluoromethylated products 
except for 4.3, which was prominently observed as a m/z=309 fragment. 
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After a 10 min irradiation, droplets were flowed at 500 nL/min into the sheath sprayer and merged 
with a dilution stream of 50:50 methanol:water w/ 0.5% formic acid (1:500 dilution, 100 µL/min 
flow rate). ESI-MS analysis of droplet samples was performed at 17 droplets/min (0.3 samples/s). 
Product formation was monitored by extracting out the expected m/z values for each 
trifluoromethylated product. As anticipated, prominent product m/z signals were observed 
iteratively throughout the four traces in the expected ABCD pattern. These results not only validate 
the capability of our system to detect product formation, but also demonstrate the ability to perform 
rapid in-line analysis while maintaining the identity of individual samples, with minimal material 
carryover between droplets.  Notably, the analytes were not subject to Taylor diffusion as in a 
conventional plug flow reactor. In this manner, we established proof-of-concept for the successful 
performance and ESI-MS analysis of in-droplet organic synthesis reactions.    
 
Figure 4.6. Design of an oscillatory flow reactor for in-droplet alkene aminoarylation reactions.  (A) 
Scheme for oscillatory flow reactor. While being irradiated, droplet flow was cycled between moving 
towards (withdraw) or away from (infuse) the syringe to allow for continuous flow in a linear, volume 
limited reactor. (B) Extracted traces for 4 CN (m/z = 309) and 3,4 F (m/z = 320) substrate reaction products, 
showing the formation of the two products in alternating droplets.  
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Upon demonstrating the success of our in-droplet reactions, we set out to explore droplet-based 
flow reactions.  In order to perform residence time optimization at a constant flow rate (between 
0.2 - 0.5 µL/min) and reactor volume, we designed an oscillatory flow system for the irradiation 
of continuous flow droplet reactions (Figure 4.6).  We implemented the Stephenson group’s 
visible light-driven alkene aminoarylation reaction250 as our reactive system of choice (Figure 4.6) 
to provide us with a manifold for performing high-throughput reaction discovery in continuous 
flow.  Initial validation of our oscillatory system was conducted using 3,4-F and 4-CN-substituted 
sulfonamides, with reaction droplets formed in an alternating fashion between the two substrates. 
Upon irradiation, the droplet reactions were run at a flow rate of 200 nL/min in an oscillatory 
manner by programming a syringe pump to alternate between refill and infusion modes at 10 min 
intervals, yielding a total residence time of 1 h. Successful product formation for both reactions 
was observed upon ESI-MS analysis. Notably, while current state-of-the-art oscillatory flow 
systems have been limited to a single reaction plug during each incubation period, this setup can 
accommodate a throughput of >100x more samples per incubation period.251-253 
With our optimized system on hand, our next goal was to perform HTE reaction discovery of 
the alkene aminoarylation methodology.  Given the demonstrated throughput and material 
efficiency of our droplet microfluidic HTE platform, we aimed to screen an extensive library of 
sulfonamides on picomole scale to furnish a wealth of reactivity data generated from each substrate 
combination.  Following our in-droplet reaction screen, incremental scale-up of select droplet flow 
reactions (0.01 mmol and 0.1 mmol, respectively) would serve to both validate product formation 
and demonstrate the translatability of droplet reaction parameters to millimole scale flow 
conditions. 10 sulfonamides and 10 alkenes were selected for our screen (500 pmol scale), 
resulting in the potential generation of 100 distinct product combinations (Figure 4.7).  For these 
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studies, droplet reactions were irradiated using a custom-built Cree LED array photoreactor, in 
order to maximize photon flux. Our optimized oscillatory flow setup was employed to maintain a 
residence time of 30 min at a flow rate of 200 nL/min during reaction irradiation. ESI-MS analysis 
was performed at a throughput of 0.3 samples/sec (435 total samples over 24 min). ESI-MS results 
suggested the identification of 37 hit conditions, for which significant product m/z signals were 
observed.   
 
Figure 4.7. Droplet microfluidics-enabled HTE reaction discovery on picomole scale. (A) Heatmap 
of coupling 10 sulfonamides with a matrix of 10 alkene substrates.  Gray boxes denote potential hit/hit 
responses.  Boxes containing red and blue circles indicate reactions that were performed on 0.01 mmol 
and 0.1 mol scale. (B) Product yields for millimole scale-up flow reactions. 
 
In line with previously reported batch reaction results, the employment of trans-anethole yielded 
product formation across the entire scope of sulfonamide substrates.  Furthermore, this data 
suggests that electron deficient sulfonamides generally gave rise to enhanced reactivity and 
broader alkene compatibility. Notably, pharmaceutically relevant sulfonamides containing 
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heteroarenes (4.6, 4.10) also yielded several hit responses in our droplet screen.  Our in-droplet 
reaction discovery screen has significantly expanded upon the scope of our reported alkene 
aminoarylation methodology to incorporate substrates of increased structural complexity, as well 
as enabled the elucidation of reactivity trends to inform ongoing mechanistic studies. 
In order to validate our ESI-MS screen results, we selected 9 of our droplet reactions to perform 
0.01 mmol scale-up in flow to provide sufficient material for product isolation (Figure 4.7). These 
reactions were carried out in the same PFA tubing (100 um i.d., 360 o.d.) and run in a continuous 
stream (non-droplet format) at a flow rate of 400 nL/min, providing a residence time of 15 min.  
Upon irradiation, purification was performed using mass-directed HPLC methods.  Of the 9 
reactions selected, 7 of the hit reactions were successfully validated through product isolation.  In 
the case of the reactions 4.12 and 4.13, product isolation was unsuccessful despite ESI-MS 
detection of product m/z signals in both the 500 pmol and 0.01 mmol scale reactions. Control 
experiments suggest the formation of an unidentified byproduct that gives the same m/z signal as 
the desired product.  Finally, we set out to demonstrate the translatability of our droplet screen 
results to a microscale flow reaction, in order to generate milligram scale quantities of material for 
discovery chemistry applications.  As such, a 100 µL plug flow reactor was constructed using 
0.03’’ ID PFA tubing.  Our 0.1 mmol scale reactions were irradiated in the reactor with a residence 
time of 30 min at a flow rate of 3 µL/min.  The same 8 reactions were scaled up to yield isolation 
results that showed strong correlation with that of the 0.01 mmol scale flow reactions.  These 
experiments highlight the utility of our droplet microfluidics platform for enabling reaction 
discovery in a high throughput, material efficient, and data-rich manner.  At the same time, this 
platform shows significant promise in its applicability and translatability to larger flow conditions.  
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Our final goal was to investigate the incorporation of on-chip reagent addition capabilities into 
our system.  Namely, the use of a reagent addition microfluidic chip would provide the benefit of 
performing direct, in-droplet reagent addition to streamline and expedite droplet preparation. Most 
importantly, in-line reagent addition would alleviate the need to prepare individual reaction 
mixture stock solutions in a multiwell plate prior to droplet generation, which leads to increased 
substrate and reagent consumption (0.02 mmol of reagent per 384 reaction screen, per 60 nmol 
scale reaction stock solution).  By adding valuable reagents directly into substrate-containing 
droplets, increased material efficiency can be achieved, as the consumption of valuable reagents 
(e.g. photocatalysts) is at or approaching the amount found in the droplets, thereby alleviating the 
need for excess amounts of stock solutions.  
 
Figure 4.8. Incorporation of a microfluidic chip for reagent addition. (A) Reagent addition device 
design. (B) Device in operation. Each incoming droplet from the left received solution from the upper 
channel and moved right to export. (C) Full setup for in-droplet flow reaction screening. (a) Syringe pump 
driving both droplet flow and reagent flow into reagent addition chip. (b) Syringe pump driving sheath 
flow. (c, in blue box) Reagent addition device. (d) Photoreactor chamber (e) Sheath sprayer for ESI-MS 
analysis.  
 
Polydimethylsiloxane (PDMS) chips were fabricated to enable individual droplets to be imported 
from 100 µm i.d. PFA tubing, flowed through an addition region to receive reagents (photocatalyst 
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solution), and subsequently exported to a 150 µm i.d. PFA tubing for irradiation and ESI-MS 
analysis. Upon achieving consistent addition of reagent amounts to each droplet by optimizing 
flow rate and channel geometry, the reagent addition device was implemented as part of a fully 
continuous flow reactor system (Figure 4.8). Aminoarylation reactions were performed in the final 
system, at a residence time of 7 min. Analysis of droplets post-irradiation at 20 droplets/min (0.3 
samples/s) not only showed that product had formed, but that the formation was highly consistent 
across all of the droplet samples (Figure 4.8). The device demonstrated low carryover between 
droplets.  These experiments have provided initial proof-of-concept for performing successful 
reagent addition using our current droplet and carrier fluid combination.   
4.3 Conclusion 
The droplet microfluidics platform described in this study provides a notable advancement 
in the ability to screen photochemical reactions in a miniaturized (i.e. picomole scale) fashion in 
continuous flow. The use of droplet microfluidics presents several significant advantages for 
performing in-flow reaction discovery.  By designing an oscillatory flow reactor, our reported 
setup allows for the simultaneous irradiation of up to 100 picomole-scale reaction droplets, 
representing a marked improvement from current state-of-the-art systems that typically 
accommodate one droplet/incubation period.  Furthermore, this system enables in-droplet reaction 
discovery to rapidly generate high-volume compound libraries and provide access to greater 
magnitudes of chemical space.  Upon translating our picomole scale droplet reactions to millimole 
scale flow conditions, we have also validated the successful flow scale-up of our droplet reactions 
to enable product isolation.  Notably, the application of in-line ESI-MS provides a highly versatile 
analytical approach for monitoring reaction turnover at an analysis throughput of 0.5 samples/s. 
Future studies will be targeted towards establishing a system to enable continuous droplet 
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generation, as well as further developing reagent addition capabilities to accommodate larger 
screening campaigns. From an early discovery standpoint, this droplet microfluidics HTE platform 
has the potential to facilitate rapid photochemical reaction discovery in flow for the expedited 
generation of compound libraries to enable subsequent biological and pharmacokinetic evaluation.  
We anticipate that this automated HTE platform for droplet generation will continue to expand 
upon and enhance the utility of visible light-mediated transformations from the bench to the drug 
pipeline. 
4.4 Experimental Methods 
4.4.1 General Information  
Chemical Reagents and Analytical Instrumentation 
Chemicals were either used as received or purified according to the procedures outlined in 
Purification of Common Laboratory Chemicals. Perfluorodecalin and trichloro(1H,1H,2H,2H-
perfluorooctyl)silane were purchased from Oakwood Products (Estill, SC).  All other reagents 
were purchased from Fisher Scientific or Sigma Aldrich.  Hygroscopic N-oxide substrates were 
dried on a high vaccuum line for 6 h at ambient temperature prior to use.  Pyridine N-oxide was 
dried on a high vacuum line at 60 °C for 12 hours.  Thin-layer chromatography (TLC) analysis of 
reaction mixtures was performed using Merck silica gel 60 F254 TLC plates and visualized by a 
dual short wave/long wave UV lamp. Column flash chromatography was performed using 230–
400 mesh silica gel or via automated column chromatography.    
Nuclear magnetic resonance (NMR) spectra were recorded using an internal deuterium lock 
on Varian MR400, Varian Inova 500 and Varian Vnmrs 700 spectrometers.   Chemical shifts for 
1HNMR were reported as δ, parts per million, relative to the signal of CHCl3 at 7.26 ppm. Chemical 
shifts for 13CNMR were reported as δ, parts per million, relative to the center line signal of the 
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CDCl3 triplet at 77.36 ppm. Multiplicities are reported using the following abbreviations: s = 
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = broad resonance, 
dd = doublet of doublet, dt = doublet of triplet, etc. High-resolution mass spectra (ESI) were 
recorded at the Mass Spectrometry Facility at the Department of Chemistry of the University of 
Michigan in Ann Arbor, MI, on a Micromass AutoSpec Ultima Magnetic Sector mass spectrometer 
using electrospray ionization (ESI), positive ion mode.  IR spectra were recorded on a Perkin-
Elmer Spectrum BX FT-IR spectrometer fitted with an ATR accessory.    
LED lights and the requisite power box and cables were purchased from Creative Lighting 
Solutions (http://www.creativelightings.com) with the following item codes: CL-FRS5050-12WP-
12V (4.4 W blue LED light strip), CL-FRS5050WPDD-5M- 12V-BL (72 W LED strip), CL-
PS94670-25W (25 W power supply), CL-PS16020-150W (150 W power supply), CL-PC6FT-
PCW (power cord), CL-TERMBL-5P (terminal block).   
Droplet Generation 
Droplet generation from microwell plates was performed using equipment and methods 
described in our previous work. Briefly, samples were drawn into either 100 µm inner diameter 
(i.d) x 360 µm outer diameter (o.d) perfluoroalkoxyalkane tubing (IDEX Health and Science, Oak 
Harbor, WA) by a PHD 2000 Programmable syringe pump (Harvard Apparatus, Holliston, TX). 6 
µL samples were deposited into 384 PCR MWPs (Corning, Corning, NY) with PFD placed on top. 
While solution was being withdrawn through the tubing, an XYZ-position manipulator moved the 
tubing between sample wells and fluorous phase to form alternating droplet/carrier phase trains.  
Photoreactor Chamber Assembly 
All reactions were run in a photoreaction chamber constructed in-house (Figure 4.9). A 150 
mm wide x 15 mm deep polystyrene petri dish was lined with aluminum foil to promote internal 
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reflection of light.  A 4.4 W blue LED strip (Creative Lighting Solutions, Columbia Station, OH) 
was placed around the edge of the interior of the dish.  A small slit was cut from the petri dish wall 
to run wires and tubing through.  During the reaction, tubing was coiled in the middle of the dish, 
only approaching the edge by the inlet. 
 
Figure 4.9. Setup for irradiation and ESI-MS analysis of droplet samples. (A) Setup of sheath sprayer. 
(B) Schematic of sheath sprayer for droplet work. PFA tubing with droplets runs through the middle of the 
sprayer. Sheath liquid flows directly around tubing (Blue arrow). Electrospray is aided by use of nebulizer 
gas (Black arrow) (C) Photoreactor setup. To irradiate droplets in tubing, a petri dish was coated with 
aluminum foil, with an LED array lining the rim. 
Sheath Spray and MS Setup 
Tubing containing droplets was threaded through a sheath sprayer (Agilent Technologies, 
Santa Clara, CA) until approximately 0.5 mm was protruding (Figure 4.9). Sheath and droplet 
flows were driven by Fusion 400 syringe pumps (Chemyx, Stafford, TX). After a 10 min 
irradiation, droplets were flowed at 500 nL/min into the sheath sprayer and merged with a dilution 
stream of 50:50 methanol:water w/ 0.5% formic acid (1:500 dilution, 100 µL/min flow rate). ESI-
MS analysis was performed on an Agilent 6410 triple quadrupole mass spectrometer (Agilent 
Technologies, Santa Clara, CA). ESI potential was set to 2500 V, nebulizer gas to 15 psi, and 
drying gas from MS source was 10 L/min at 325 ºC. Mass spectrometer was set to scan from 75 
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to 750 m/z at 73 ms per scan. Experiment using nESI-MS followed procedures from Chapter 3. 
Briefly droplets were flowed from PFA tubing to a nESI emitter by use of a PicoclearTM union 
(New Objective, Woburn, MA). Applied nESI potential was 1.75 kV. Mass spectrometry analysis 
was performed on a Micromass Quattro Ultima triple-quadrupole mass spectrometer (Waters, 
Milford, MA). Droplet responses for any given m/z value were taken as the average of 3 
consecutive data points from inside of each droplet’s observed peak. 
Chip Fabrication 
Microfluidic chips were fabricated using standard soft lithography procedures.254 SU-8 2050 
photoresist was spun to 100 µm depth on silicon wafers (University Wafer, Boston, MA) then 
developed using photolithography to form negative masters. Uncured PDMS (Curbell Plastics, 
Livonia, MI) was poured on top of clean masters or blank wafers and allowed to cure for 1 h at 65 
°C. Patterned PDMS and blank PDMS were baked for 1 h at 150 °C, followed by 1 min of exposure 
to atmospheric plasma and baking for 2 h at 150 °C to create an irreversible bond. Chip channel 
surfaces were treated with 2% trichloro(1H,1H,2H,2H-perfluorooctyl)silane in PFD by flowing 10 
internal volumes through over 10 minutes, followed by 2 hours baking at 65 ºC. Chips were soaked 
in acetonitrile overnight to prevent solvent loss from droplets. 
Reagent Addition Chip Setup 
PDMS devices were 100 µm depth. Droplets flowed in from a 100 µm wide channel that 
expanded to 200 µm wide at the point of intersection with reagent addition channel, which was 
100 µm wide at this point. The final device was 200 µm wide at all openings to accommodate 




4.4.2 Preliminary Droplet Experiments 
nESI-MS vs. ESI-MS Analysis of Reaction Droplets 
 To analyze the contents of droplets post-irradiation, three separate approaches were 
explored. Since organic synthesis reactions are typically highly concentrated with reagents often 
present at > 10mM, our approaches for ESI-MS analysis aimed to lower this concentration down 
before analysis avoid saturation of MS signal. First, the nESI-MS method from Chapter 3 was used 
for the analysis of a 25 mM trifluoromethylated N-Boc-5-bromo-7-azaindole solution in MeCN. 
Stable detection of analyte from these samples was easily achieved without saturating the observed 
MS signal (Figure 10). This result suggested that droplet formation and nESI-MS analysis can be 
performed without the need for the dilution solvent from Chapter 4 (50:50 methanol:water w/0.5% 
formic acid); however, this approach would only be compatible with reactions that can be run at 
lower (< 1 mM) concentrations. 
 The second method investigated was the in-line dilution of droplet samples into a 
continuous stream. Droplet samples composed of undiluted 25 mM trifluoromethylated azaindole 
were flowed at 200 nL/min into a stainless-steel tee containing 100 µm i.d. channels. A separate 
dilution stream, composed of 50:50 methanol:water w/0.5% formic acid, was flowed at 100 
µL/min, giving a nominal 500x dilution before ESI-MS analysis. Lines leading in and out of the 
tee were comprised of 100 µm i.d. PFA tubing. Each individual droplet was observable in the 
azaindole MS trace at 7 droplets/min, though restrictions on greater throughputs were seen based 
on widening of sample bands in the continuous stream. 
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Figure 4.10. nESI-MS and Tee-dilution ESI-MS systems for in-droplet photoredox reaction analysis. 
(A) Trace for trifluoromethyl azaindole (m/z = 365) using nESI-MS system and acetonitrile-only dilution 
(B) Schematic of in-line dilution of droplets into continuous stream. (C) Trace for trifluoromethyl azaindole 
fragment (m/z = 309) using in-line dilution. 
To remove the restrictions in throughput caused by widening of sample bands after dilution 
while keeping reaction concentrations high, a sheath sprayer was employed (Figure 9). Droplets 
samples emerging from PFA tubing merge into a continuously spraying sheath flow and 
immediately to ESI-MS analysis. Operation of this system has been shown for analyzing 
enzymatic reactions at throughputs exceeding 1 droplet/s.52  For the analysis of droplet photoredox 
reactions, the sheath flow rate was kept high (100 µL/min) and droplet flow low (0.5-1.0 µL/min) 
to dilute the droplets (nominally 100-200x) during the electrospray process. 
Comparison of In-Droplet vs. Small Scale Batch Reactions 
Experiments were conducted to compare reactivity in 4 nL droplets with batch reactions run 
on a standard multiwell plate screen scale of 20 µL (Figure 4.11).  4 nL droplet reactions were 
prepared and run according to the aforementioned procedures and irradiated for 10 min inside of 
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our photoreactor.  20 µL reactions were performed in PCR tubes, with the PCR tubes placed 
directly in the middle of the photoreactor for 10 minutes of irradiation.  Following irradiation, the 
solutions were then formed into 4 nL droplets for direct comparison to the two volume scales. The 
quotient of the product signal over the summed product and substrate signals (
𝑃
𝑃+𝑆
) was used to 
appraise reaction progress. For the two substrates that performed the best in the 20 µL reactions 
(4.3 and 4.4), only slight increases in product formation were observed when run in droplet format; 
however, the increase was drastic for the lower performing substrates (4.1 and 4.2) (Figure 4.11).  
 
Figure 4.11. Comparison of in-droplet reactions vs. non-droplet batch reactions. (A) General schemes 
for running reactions at different scales (Left) Reactions run at 20 µL were irradiated immediately after 
mixing in PCR tubes and then reformatted into 4 nL droplets for analysis (Right) For in-droplet reactions, 
premixed solution was reformatted into 4 nL droplets, which were then irradiated. (B) Evaluation of 
performance across 4 substrates in either 20 µL or 4 nL volume. In every case, P/(P+S) response was found 
to be similar or significantly higher in droplet format. N=20 droplets for each reaction. (C) Example spectra 
from both 20 µL (Top) or 4 nL (Bottom) volume PF15 reactions. The yellow arrow indicates substrate m/z 
value, while the red arrow indicates product m/z value. In the 20 µL reaction, the substrate response was 
over double that of the product; however, the product response was even greater than that of the substrate 
in the 4 nL reaction. 
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The observed changes in reaction performance can be attributed to the narrower sample geometry. 
The 100 µm i.d. tubing presents a drastically narrower pathlength, decreasing the pathlength of 
irradiation and increasing photon flux across the entire sample. Such an effect may be helpful in 
promoting the observation of product in poorly performing reactions, or in reducing reaction time 
requirements for in-droplet reaction screens. 
Oscillatory Flow Reactor 
To allow for extended flow reactions inside of our PFA tubing, an oscillatory flow scheme was 
employed (Figure 6). We implemented the Stephenson group’s visible light-driven alkene 
aminoarylation reaction60 as our reactive system of choice to provide us with a manifold for 
performing high throughput reaction discovery in continuous flow.  Droplets were formed from 
substrate and reaction mixture into a 100 µm i.d. PFA tube, with droplet contents alternating 
between containing the N-((3,4-difluorophenyl)sulfonyl)acetamide substrate and the N-((4-
cyanophenyl)sulfonyl)acetamide substrate, denoted as 3,4 F and 4 CN substrates respectively. A 
PCR tube had a 400 µm hole drilled into the cap and was filled with PFD. The outlet of the tubing 
was threaded through the hole and submerged in PFD to avoid evaporation of samples inside of 
the tubing. Upon irradiation, the droplets were flowed at 200 nL/min, first withdrawing towards 
the syringe pump for 10 min, followed by 10 min of infusing away from syringe. This process was 
performed 3 times, allowing for 1 hour of continuous flow reaction. Upon analysis under the same 
conditions as the previous experiments, both reactions were observable in alternating fashion by 




, with values of 0.919 ± 0.022 for the 4 CN substrate and 0.499 ± 0.044 for the 
3,4 F substrate in the droplet samples shown in Figure 4.6 (substrate traces not shown). There was 
observed variability in the product response for droplets of the same content (RSD in product 
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response was 16% for both populations), which may indicate variable performance of the sheath 
sprayer. Further improvement to setup procedures and ESI parameters could help to lower this 
variability. The current setup allowed for 40 droplets for flow reaction and could conceivably 
increase to >100 droplets with longer tubing lengths and shorter oscillation periods.  
Reagent Addition and Online Screening System 
Reagent addition PDMS chips were fabricated to enable individual droplets to be imported 
from 100 µm i.d. PFA tubing, flowed through an addition region to receive reagents, and then be 
exported to 150 µm i.d. PFA tubing for irradiation and ESI-MS analysis. Larger 150 µm i.d. tubing 
was used for the droplets post-addition as the larger volume droplets were sometimes unstable in 
the 100 µm i.d. tubing. Consistent addition of reagent to 4 nL acetonitrile droplets was achieved 
with the employed geometry (Figure 4.12A-C). By keeping droplet flow consistent (800 nL/min), 
the amount of reagent added to each droplet was controllable by the flow of the reagent stream. 
The reagent solution for the trifluoromethylation reaction was utilized in the demonstration of the 
reagent addition device, as it showed a deep yellow color. At 100 nL/min reagent flow, the final 
droplets were composed of 33 ± 2% added reagent, while a 200 nL/min reagent flow created 
droplets with 45 ± 4% added reagent, showing consistent addition to droplets at both flow rates. 
Also tested was for this geometry was the carry-over between droplets. To test for this, droplets 
were formed in 10x10 units, alternating between blank acetonitrile samples and 
trifluoromethylation reagent solution, with blank acetonitrile used as the addition stream. As the 
reagent addition stream is now colorless, any material carry-over from trifluoromethylation 
reagent droplets into the addition stream would lead to a yellow hue in the proceeding droplets. 
From this approach, pure acetonitrile droplets following trifluoromethylation reagent droplets had 
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no observable yellow coloration, showing that this geometry can be performed with minimal carry-
over between droplets (Figure 4.12D and E). 
 
Figure 4.12. Reagent addition device operation. Samples used were either pure acetonitrile (clear, 
colorless) or trifluoromethylation reagent solution (dark yellow). Droplets were 4 nL initially, with 12 nL 
PFD spacing. (A) Device in operation. Each incoming droplet from the left received solution from the upper 
channel and moved right to export. Additional channels on top and bottom of channel were placed for 
optional saltwater electrodes. This feature was not necessary, as droplets coalesced with reagent stream 
without application of electric field. (B) Final design of reagent addition device, with electrodes removed. 
(C) Droplets post addition in PFA tubing. Droplet flow in was 800 nL/min, while reagent addition flow was 
200 nL/min. Output droplets were found to contain 45 ± 4% added reagent. (D) Carry-over evaluation. 
Droplets were generated from either pure acetonitrile or reagent mixture. Blank acetonitrile was added to 
each droplet. Acetonitrile droplets (highlighted by blue boxes) flowed through addition device after reagent 
droplets show no coloration, indicating that very low carry-over occurs during the operation of the reagent 
addition device. (E) Droplets at 6% reagent, showing significantly more yellow coloration than the blank 
droplets in (D).  
 
The above system was applied to the Smiles-Truce rearrangement described in Section 4.2. 4 
nL acetonitrile droplets containing the 4-CN sulfonylacetamide substrate and trans-anethole with 
12 nL PFD segmentation were flowed through the reagent addition device at 800 nL/min, with 200 
nL/min reagent flow, forming 7 nL reaction droplets for irradiation and analysis. Irradiation time 
was approximately 7 min, calculated from the volume of tubing contained within the reactor and 
the 1000 nL/min volumetric flow rate. Analysis of droplets post-irradiation at 20 droplets/min not 
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only showed that product had formed, but that formation was highly consistent across all the 
droplet samples (Figure 4.13). To confirm that signal was a result of in-droplet chemistry, 
premixed reaction mixture was made into droplets and analyzed in the same manner. Very little 
signal was observed, with the droplet samples barely distinguishable from background noise. 
These results indicate the successful application of our system for performing and analyzing in-
droplet photoredox reactions.  
 
Figure 4.13. Results from online flow reactor and control experiments. Traces represent the m/z values 
of the Smiles-Truce rearrangement product for the 4-CN sulfonamide and trans-anethole (m/z = 309). (A) 
Droplet samples processed with online flow reactor. (B) Control samples for (A), where no irradiation was 





4.4.3 General Experimental Procedures 
General Procedure A: Preparation of Trifluoromethylation Reaction Solutions 
 
Photocatalyst (1 mol%), pyridine N-oxide (4 equiv), and acetonitrile (0.2 M) were added to a vial 
charged with a stir bar. The solution was sparged with a stream of nitrogen gas for 5 min. Acetic 
anhydride (4 equiv) was subsequently added, and the solution was stirred for 10 min to facilitate 
formation of the acylated species. Separate solutions of substrate in acetonitrile (0.2 M) were also 
prepared. 10 µL of each solution were combined in a PCR tube to yield the final reaction mixture. 
General Procedure B: Preparation of Smiles-Truce Rearrangement Reaction Solutions 
 
To a flame dried 1-dram vial was added tetrabutylammonium benzoate (30 mol%), and 
[Ir(dF(CF3)ppy)2(5,5’d(CF3)bpy)]PF6 photocatalyst (1 mol%). The vial contents were then 
dissolved in anhydrous acetonitrile (0.2 M). Finally, the alkene was added (1.2 equiv). This 
solution was sparged under argon for 15 min. Separate solutions of substrate in acetonitrile (0.2 
M) were also prepared. For reactions formed directly from well-plates, 10 µL of each solution 
were deposited into a well to form the final reaction mixture. For reagent addition experiments, 
droplets were formed from substrate solution, and reagents were added on-chip (see Section 4.3.1 




General Procedure C: In-Droplet Reaction Screen Setup 
Following droplet generation, reactor tubing (100 µm i.d., 360 µm o.d.) containing droplets was 
wrapped around a 100 x 50 mm glass recrystallization dish and placed on top of our 25 LED array 
light setup (see Figure 3.11 for photoreactor details) for irradiation.  Droplet reactions were run at 
a flow rate of 200 nL/min in an oscillatory manner by programming a syringe pump to alternate 
between refill and infusion modes at 10 min intervals, yielding a total residence time of 1 h (Figure 
4.14).  Following irradiation, droplet samples were characterized by ESI-MS analysis.   
 
Figure 4.14. Continuous flow setup for in-droplet reaction screens. 
 
General Procedure D: Flow Scale-up (0.01 mmol) Setup 
We selected 9 of our droplet reactions to perform 0.01 mmol scale-up in flow to provide sufficient 
material for product isolation. Reactions were set up according to General Procedure B.  These 
reactions were carried out in the same PFA tubing (100 um i.d., 360 o.d.) and run in a continuous 
stream (non-droplet format) at a flow rate of 400 nL/min, providing a residence time of 15 min.  
 219 
Irradiation was performed using the 25 LED array setup described in Chapter 3.  Purification was 
performed using an HPLC-MS (Agilent) with an eluent of 50% MeCN/ H2O (50% to 100% MeCN/ 
H2O across 30 min).   
General Procedure E: Flow Scale-up (0.1 mmol) Setup 
We selected 9 of our droplet reactions to perform 0.1 mmol scale-up in flow (Figure 4.15). 
Reactions were set up according to General Procedure B.  These reactions were carried out in PFA 
tubing (0.03’’ i.d., 1/16’’ o.d., 100 µL internal volume) and run in a continuous stream (non-droplet 
format) at a flow rate of 300 nL/min, providing a residence time of 30 min.  Irradiation was 
performed using the 25 LED array setup described in Chapter 3.  Purification was performed using 
flash chromatography on SiO2 with an eluent of 70% ethyl acetate (spiked with 1% acetic 
acid)/hexanes (20% to 70% ethyl acetate/hexanes gradient across 20 min).   
 
Figure 4.15. Continuous flow setup for 0.1 mmol scale-up reactions. 
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4.4.4 Compound Characterization  
 
N-(1-(3,4-difluorophenyl)-1-(4-methoxyphenyl)propan-2-yl)acetamide (4.5) 
The reaction was run according to General Procedures B and E on 0.1 mmol scale.  The crude 
reaction was purified by column chromatography (20% to 70% ethyl acetate in hexanes; 1% spiked 
acetic acid in ethyl acetate) to afford the title compound (10 mg, 31%) as a light yellow foam.  Rf 
= 0.20 (ethyl acetate/hexanes 7:3 with 1% acetic acid in ethyl acetate; UV). 1H NMR (700 MHz, 
CDCl3) δ 7.16 – 7.10 (m, 2H), 7.06 (qd, J = 9.4, 3.5 Hz, 2H), 7.02 (s, 1H), 6.87 – 6.78 (m, 2H), 
5.19 (s, 1H), 4.82 – 4.74 (m, 1H), 3.77 (d, J = 3.1 Hz, 3H), 3.75 (d, J = 9.3 Hz, 1H), 1.86 – 1.81 
(m, 3H), 1.13 – 1.06 (m, 3H).  13C NMR (176 MHz, CDCl3) δ 169.3, 158.5, 150.8 (d, J = 12.7 Hz), 
149.7 (d, J = 12.3 Hz), 149.4 (d, J = 13.2 Hz), 148.3 (d, J = 12.6 Hz), 139.4, 133.3, 129.1, 123.6, 
117.3 (d, J = 17.0 Hz), 116.9 (d, J = 17.4 Hz), 114.2, 56.5, 55.2, 47.7, 23.3, 20.1.  The acquired 
















1H NMR (700 MHz, CDCl3) for 4.5 
 






The reaction was run according to General Procedures B and E on 0.1 mmol scale.  The crude 
reaction was purified by column chromatography (20% to 70% ethyl acetate in hexanes; 1% spiked 
acetic acid in ethyl acetate) to afford the title compound (16 mg, 35%) as a light yellow foam.  Rf 
= 0.24 (ethyl acetate/hexanes 7:3 with 1% acetic acid in ethyl acetate; UV).  1H NMR (500 MHz, 
CDCl3) δ 8.17 (d, J = 8.6 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.73 – 7.66 (m, 2H), 7.59 (s, 1H), 7.51 
– 7.39 (m, 3H), 7.30 (d, J = 8.3 Hz, 2H), 6.80 (dd, J = 6.3, 3.9 Hz, 2H), 6.51 (t, J = 54.2 Hz, 2H), 
6.03 (s, 1H), 5.12 – 5.02 (m, 1H), 4.72 (d, J = 10.2 Hz, 1H), 3.81 (s, 3H), 3.73 (d, J = 1.2 Hz, 3H), 
1.27 (d, J = 6.5 Hz, 3H).  13C NMR (176 MHz, CDCl3) δ 160.5, 158.3, 142.8 (t, J = 27.6 Hz), 
137.4, 134.1, 134.1, 133.7, 132.0, 129.5, 128.9, 127.2, 126.0, 125.5, 125.2, 124.3, 123.2, 116.9, 
114.0, 111.0 (t, J = 233.9 Hz), 55.2, 51.7, 48.5, 39.3, 20.5.  19F NMR (471 MHz, CDCl3) δ -110.14 
(dd, J = 1476.3, 54.1 Hz), -110.14 (dd, J = 862.4, 54.5 Hz).   
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1H NMR (500 MHz, CDCl3) for 4.6
 
13C NMR (176 MHz, CDCl3) for 4.6 
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The reaction was run according to General Procedures B and E on 0.1 mmol scale.  The crude 
reaction was purified by column chromatography (20% to 70% ethyl acetate in hexanes; 1% spiked 
acetic acid in ethyl acetate) to afford the title compound (10 mg, 27%) as a light yellow foam.  Rf 
= 0.25 (ethyl acetate/hexanes 7:3 with 1% acetic acid in ethyl acetate; UV). 1H NMR (500 MHz, 
CDCl3) δ 7.37 – 7.31 (m, 2H), 7.16 (dd, J = 8.3, 2.2 Hz, 1H), 6.73 (d, J = 7.8 Hz, 1H), 6.71 – 6.66 
(m, 2H), 5.95 – 5.89 (m, 2H), 5.13 (d, J = 9.2 Hz, 1H), 4.76 (d, J = 6.4 Hz, 1H), 3.70 (d, J = 10.3 
Hz, 1H), 1.83 (s, 3H), 1.11 (d, J = 6.6 Hz, 3H).  13C NMR (176 MHz, CDCl3) δ 169.2, 148.1, 
146.7, 142.3, 134.9, 132.4, 130.6, 130.5, 130.2, 126.9, 121.3, 108.5, 108.2, 101.1, 57.1, 47.3, 23.4, 



















1H NMR (500 MHz, CDCl3) for 4.7 
 




3-acetamido-4-(4-cyanophenyl)-4-(4-methoxyphenyl)butan-2-yl acetate (4.8) 
The reaction was run according to General Procedures B and E on 0.1 mmol scale.  The crude 
reaction was purified by column chromatography (20% to 70% ethyl acetate in hexanes; 1% spiked 
acetic acid in ethyl acetate) to afford the title compound (5 mg, 13%) as a light yellow foam.  Rf 
= 0.22 (ethyl acetate/hexanes 7:3 with 1% acetic acid in ethyl acetate; UV).  A 1:1.5 ratio of 
diastereomers (minor diastereomer 4.8A and major diastereomer 4.8B) was observed by 1H and 
13C NMR.  1H NMR (700 MHz, CDCl3) δ 7.57 – 7.54 (m, 2H, 8A), 7.55 – 7.52 (m, 2H, 8B), 7.43 
(d, J = 7.8 Hz, 2H, 8A), 7.40 – 7.35 (m, 2H, 8B), 7.25 – 7.22 (m, 2H, 8B), 7.07 (d, J = 8.1 Hz, 2H, 
8A), 6.87 – 6.83 (m, 2H, 8B), 6.83 – 6.80 (m, 2H, 8A), 5.43 (d, J = 10.3 Hz, 1H, 8A), 5.29 (d, J = 
5.0 Hz, 1H, 8B), 5.27 (s, 1H, 8A), 5.14 (d, J = 10.3 Hz, 1H, 8B), 4.90 (t, J = 11.0 Hz, 1H, 8A), 
4.83 (d, J = 5.3 Hz, 1H, 8B), 4.74 (d, J = 6.6 Hz, 1H, 8A), 3.94 (d, J = 11.8 Hz, 1H, 8A), 3.85 (d, 
J = 11.2 Hz, 1H, 8B), 3.76 (d, J = 1.7 Hz, 3H, 8B), 3.75 (d, J = 1.8 Hz, 3H, 8A), 2.14 (d, J = 1.8 
Hz, 3H, 8A), 1.96 (d, J = 1.8 Hz, 3H, 8B), 1.85 (d, J = 1.8 Hz, 3H, 8A), 1.81 (d, J = 1.8 Hz, 3H, 
8B), 1.18 – 1.16 (m, 3H, 8A), 1.16 – 1.13 (m, 3H, 8B).  13C NMR (176 MHz, CDCl3) δ 170.6, 
170.0, 169.8, 169.4, 158.9, 158.9, 147.5, 147.4, 132.4, 132.3, 131.9, 131.6, 128.8, 128.7, 128.7, 
128.5, 118.8, 118.7, 114.7, 114.6, 110.5, 110.4, 70.2, 70.1, 55.2, 55.2, 54.3, 53.9, 53.3, 52.1, 23.2, 









1H NMR (700 MHz, CDCl3) for 4.8A and 4.8B 
 






The reaction was run according to General Procedures B and E on 0.1 mmol scale.  The crude 
reaction was purified by column chromatography (20% to 70% ethyl acetate in hexanes; 1% spiked 
acetic acid in ethyl acetate) to afford the title compound (7 mg, 15%) as a light yellow foam.  Rf 
= 0.23 (ethyl acetate/hexanes 7:3 with 1% acetic acid in ethyl acetate; UV).  1H NMR (700 MHz, 
CDCl3) δ 7.57 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 7.9 Hz, 2H), 6.80 – 6.74 (m, 2H), 6.72 (s, 1H), 5.67 
(d, J = 9.2 Hz, 1H), 5.45 (t, J = 9.2 Hz, 1H), 4.40 (d, J = 9.1 Hz, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 
3.53 (d, J = 1.8 Hz, 3H), 1.90 (d, J = 1.9 Hz, 3H).  13C NMR (176 MHz, CDCl3) δ 172.2, 169.8, 
149.0, 148.4, 143.9, 131.4, 129.5 (q, J = 32.6 Hz),  128.6, 125.7 (q, J = 3.7 Hz), 124.0 (q, J = 272.0 
Hz), 120.5, 111.3, 111.2, 55.9, 55.8, 55.0, 53.2, 52.3, 23.1.  19F NMR (471 MHz, CDCl3) δ -62.59. 
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1H NMR (700 MHz, CDCl3) for 4.9
 
13C NMR (176 MHz, CDCl3) for 4.9 
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The reaction was run according to General Procedures B and E on 0.1 mmol scale.  The crude 
reaction was purified by column chromatography (20% to 70% ethyl acetate in hexanes; 1% spiked 
acetic acid in ethyl acetate) to afford the title compound (25 mg, 68%) as a light yellow foam.  Rf 
= 0.19 (ethyl acetate/hexanes 7:3 with 1% acetic acid in ethyl acetate; UV).  1H NMR (700 MHz, 
CDCl3) δ 7.24 (d, J = 6.6 Hz, 2H), 7.17 (d, J = 4.4 Hz, 1H), 6.86 (d, J = 8.3 Hz, 2H), 6.74 (d, J = 
4.5 Hz, 1H), 5.33 (d, J = 9.2 Hz, 1H), 5.00 (q, J = 8.4 Hz, 1H), 4.34 (d, J = 9.4 Hz, 1H), 3.78 (d, J 
= 2.6 Hz, 3H), 1.80 (d, J = 2.7 Hz, 3H), 1.29 (d, J = 6.5 Hz, 3H).  13C NMR (176 MHz, CDCl3) δ 




1H NMR (700 MHz, CDCl3) for 4.10
 





The reaction was run according to General Procedures B and E on 0.1 mmol scale.  The crude 
reaction was purified by column chromatography (20% to 70% ethyl acetate in hexanes; 1% spiked 
acetic acid in ethyl acetate) to afford the title compound (7 mg, 20%) as a light yellow foam.  Rf 
= 0.26 (ethyl acetate/hexanes 7:3 with 1% acetic acid in ethyl acetate; UV).  1H NMR (700 MHz, 
CDCl3) δ 7.82 (t, J = 9.6 Hz, 2H), 7.64 (d, J = 7.5 Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.47 (d, J = 
8.8 Hz, 1H), 7.34 (t, J = 7.3 Hz, 1H), 7.14 (t, J = 7.9 Hz, 1H), 7.10 (d, J = 8.4 Hz, 2H), 6.84 – 6.78 
(m, 2H), 4.90 (s, 1H), 4.28 – 4.21 (m, 1H), 4.01 (dd, J = 13.3, 4.1 Hz, 1H), 3.78 (d, J = 2.5 Hz, 
3H), 1.85 (d, J = 2.5 Hz, 3H), 1.78 (s, 3H). 13C NMR (176 MHz, CDCl3) δ 170.1, 157.9, 141.0, 
139.5, 135.1, 130.9, 129.2, 128.5, 127.3, 127.0, 125.0, 125.0, 125.0, 124.9, 114.1, 55.2, 49.0, 47.0, 
27.7, 23.4. 
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1H NMR (700 MHz, CDCl3) for 4.11
 








Chapter 5: Synthesis and Derivatization of Ir(III)+ Polypyridyl Complexes using 
Microwave Heating 
Portions of this chapter have been published in Timothy M. Monos, Alexandra C. Sun, Rory C. 
McAtee, James J. Devery III, Corey R. J. Stephenson, J. Org. Chem. 2016, 81, 6988-6994. 
5.1 Introduction 
5.1.1 Preparation and Applications of Heteroleptic Ir(III)+ Polypyridyl Complexes 
The development of visible light-mediated redox catalysis is an energy conscious response to 
the multifaceted challenges of chemical sustainability.255 In this context, photoabsorbing Ru(II) 
and Ir(III) polyimine complexes have been widely applied in organic light emmiting diodes 
(OLEDs) 256 ,  organic synthesis 257 , 258 , polymer synthesis 259 , 260 , oxygen sensors 261  and bio-
analytical devices262. The field of photoredox catalysis has adopted Ru(II) and Ir(III) complexes 
in preference to other metals263,264 due to the fact that these complexes are bench stable solids with 
highly efficient photophysical properties and tunable reactivity. Such characteristics have enabled 
these complexes to be used in the exploration of small molecule synthesis257,258, natural product 
synthesis265,266,267 and multi-catalytic technologies268,269,270,271 in an effort to develop safe and 
sustainable synthetic methods.  
     Among the variety of known polypyridyl Ir(III) complexes272, the cationic, heteroleptic Ir(III) 
complexes represent a relatively new class of photosensitizers. The ligand scaffold (Figure 5.1A) 
is a combination of two cyclometalating ligands [(C^N) = arylpyridine] and one dative ligand 
[(N^N) = bipyridine] that give rise to a substitutionally inert, photoexcitable species.273 Such 
heteroleptic complexes were originally developed by Bernhard, Malliaras, and coworkers, to 
improve upon Ru(II) and neutral Ir(III)-based electroluminescent materials. 274 , 275  Ir(III)+ 
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chromophores exhibit superior chemical stability, as well as a higher quantum yield, than the 
corresponding Ru(II) materials. This boost in performance has been attributed to the improved 
photophysical characteristics of ligand field stabilization energy (LFSE) and decreased non-
radiative quenching tendencies.276 
 
Figure 5.1. (A) Comparison of the archetypical Ru and Ir polyimine complexes and (B) orthogonal 
tuning of Ir(III)+ redox behavior based on ligand choice. 
 
     A significantly notable characteristic of the Ir(III)+ heteroleptic complexes is the spatial 
separation of redox events that allow for individual, redox tuning. Specifically, the HOMOs are 
understood to exist between the Ir metal center and the C^N ligand, and the LUMOs are separately 
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located on the N^N ligand (Figure 5.1B). Bernhard and Malliaras experimentally demonstrated 
this phenomenon by comparing the redox events of various fluorinated Ir(III)+ complexes. In this 
manner, incorporation of fluorine substituents on the C^N ligand increased the oxidation potential 
by 100 mV while the reduction potential was minimally affected.275 This phenomenon was 
observed previously by King and Watts, who detected two separate metal-to-ligand charge transfer 
(MLCT) emission peaks from the excitation of Ir(ppy)2(bpy)
+ – one emission peak corresponding 
to the MLCT–N^N transition (major process) and the second corresponding to the MLCT–C^N 
transition (minor process).277 These results support the notion that the HOMOs and LUMOs are 
spatially separated and that orthogonal electrochemical modulation is possible through the 
independent variation of the C^N and N^N ligand electronics.278  
 
Figure 5.2. Synthesis of Ir(III)+ complexes 
Despite the great utility of these compounds, synthetic methods for their production are time 
and energy intensive. These requirements can limit the screening diversity of catalysts during 
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project development, thus minimizing the actual benefits of this design aspect. By convention, 
there are two methods for producing Ir(III)+ polypyridyl complexes (Figure 5.2). Both of these 
methods rely on the initial synthesis of an [(C^N)2Ir-μ-Cl]2 dimer. From this intermediate, a dative 
bipyridyl ligand can be introduced by either cracking the dimer through silver salt metathesis279, 
or by an additional reflux step with the dative ligand.280 In both cases, these multi-step processes 
require between 12 and 24 hours, totaling more than 48 hours for the synthesis of a single complex.     
 We have alleviated the time and energy requirements necessary for the synthesis of 
heteroleptic Ir(III)+ complexes through microwave heating. Microwave heating utilizes polar 
solvents for highly efficient internal temperature regulation281,282,283,284,285, allowing for rapid 
temperature equilibration and in many cases, enhanced reaction kinetics.286,287 Microwave heating 
has proven beneficial in a number of contexts including transition metal catalysis284, continuous 
flow processing288, and combinatorial chemistry.281 These reports bolster this technique as a bona 
fide method for reliably heating, scaling, and conducting synthetic operations in a reasonable time 
frame.289 In this report, we detail the application of microwave heating towards the synthesis of 
heteroleptic Ir(III)+ complexes in a high yielding, operationally simple protocol, which can be 
completed in 3 hours.  
     We identified the benefits of microwave heating in the application of organometallic Ir(III)+ 
complex synthesis because of the canonically chosen reaction solvent, ethylene glycol. Ethylene 
glycol is one of the best solvents for microwave heating, boasting a “heating” factor quotient (tanδ) 
of 1.350. This quotient is calculated by the ratio of the dielectric loss factor ( " ) – which indicates 
heating efficiency – over the dielectric constant ( ' ) – which describes the polarization of the 
molecule – and indicates the possibility of microwave excitation (Equation 1). For example, these 
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values range from ethylene glycol to non-polar solvents such as toluene (1.350 and 0.040, 








=                                 
Equation 1. Heating Factor Quotient 
Additionally, we sought microwave heating as an optimal tool for catalyst synthesis because the 
reaction course from IrCl3•xH2O to Ir(C^N)2(N^N)
+ displayed diagnostic color and solubility 
changes. The organometallic Ir complexes were differentially colored and soluble in ethylene 
glycol, whereas the IrCl3•xH2O was an insoluble black powder.
291 We later followed this with a 
formal optimization of the two ligation processes.  
 
Figure 3. tanδ Values (heating factor) for common solvents in organic synthesis 
5.1.2 Synthesis of Transition Metal-Based Nanohoop Complexes 
Cycloparaphenylenes (CPPs), also referred to as carbon nanohoops, represent a unique class 
of compounds that possess strikingly distorted phenylene moieties and radially oriented π-systems.  
The [n]CPPs are composed of n benzene rings linked end-to-end at the para positions, which results 
in a rigid, three dimensional, fully sp2 hybridized cylindrical molecular structure.  Initially 
designed as building blocks for the size-selective growth of carbon nanotubes, [n]CPPs have 
garnered significant synthetic interest since their seminal preparation in 2008 by Jasti, Bertozzi, 
and co-workers.292,293,294 The bent cyclic geometries of [n]CPPs have given rise to a wealth of 
novel, unexpected electronic and photophysical properties, which show significant promise for 
 241 
future materials science applications. 295 , 296   [n]CPPs possess unique electronic properties, 
including a HOMO–LUMO energy gap that decreases as the number of phenylenes in the hoop 
are reduced, as well as a red-shifting fluorescence associated with decreasing size.297,298  This trend 
is opposite to that observed for the linear paraphenylene species, in which the HOMO–LUMO 
energy gap decreases with increased chain length, due to extended conjugation.  In fact, [n]CPPs 
have narrower HOMO–LUMO gaps than even the longest linear paraphenylene species, thereby 
highlighting their potential in the design of novel organic semiconductors.  Additionally, the 
presence of a radially oriented π-system provides a hydrophobic, electron-rich cavity that enables 
effective host-guest interactions with electron poor guest substrates such as C60.
299  Given the 
combination of these unique chemical properties, [n]CPPs have been investigated as 
biocompatible fluorophores for targeted live cell imaging, as well as electronic materials that are 
tunable by functionalization or guest uptake.300,301,302 
The development of novel redox active ligands is critical in the design of highly efficient and 
selective transition metal complexes for applications including small molecule activation, 
photocatalysis, and photovoltaics.  Since many redox active ligands utilized in chemical catalysis 
are derived from flat, linear aromatic scaffolds, the incorporation of three dimensional, cyclic 
aromatic ligands into metal-ligand frameworks would offer new avenues for catalyst design and 
reactivity.  In 2017, Jasti and co-workers reported the first synthetic method for accessing 2,2’-
bipyridyl (bipy)-embedded nanohoops in a size selective and scalable manner (Figure 3.4).303  
They were able to demonstrate the successful synthesis of both a homoleptic Pd(II) nanohoop 
dimer and a Ru(II) nanohoop complex. These bipyridyl-containing CPP nanohoops show promise 
as a new class of ligands for the construction of cylindrical coordination cages, as well as transition 
metal photosensitizers with supramolecular capabilities.  
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Figure 5.4. Current examples of 2,2’-bipy-embedded nanohoop transition metal complexes 
Given the prevalence of heteroleptic Ir(III)+ polypyridyl complexes in photocatalysis and 
photovoltaics, we aimed to explore the synthesis of iridium-based transition metal complexes 
containing the 2,2’-bipy-embedded CPP ligand.  We envision that the introduction of CPP 
nanohoops into common iridium photosensitizers could unlock new opportunities for tuning the 
electronic and photophysical properties of these transition metal complexes to facilitate catalysis.  
At the same time, the incorporation of a nanohoop ligand framework could potentially generate a 
chiral environment for supramolecular host-guest interactions to enable asymmetric catalysis.  We 
have been able to utilize our reported microwave synthetic procedure304 to synthesize a library of 
heteroleptic Ir(III)+ polypyridyl nanohoop complexes.  Additionally, we have carried out initial 
studies on the electronic and photophysical properties of these complexes using cyclic 
voltammetry and UV-vis spectroscopy.   
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5.2 Results and Discussion 
5.2.1 Microwave-Assisted Synthesis of Common Ir(III)+ Photocatalysts and Analogs 
      In our initial studies, we investigated the generation of the [Ir(dF(CF3)ppy)2Ir-μ-Cl]2 dimeric 
species en route to [Ir(dF(CF3)ppy)2(dtbbpy)]PF6. We highlight the synthetic process with this 
C^N ligand because we sought a robust cyclometallation protocol capable of utilizing either 
electron deficient or electron rich C^N ligands, while notably the cyclometallation of electron poor 
arylpyridines was expected to be more difficult. Heating a mixture of IrCl3•xH2O and 2 equivalents 
of 2-(2,4-difluorophenyl)-5-(trifluoromethyl)pyridine (L1) in ethylene glycol with microwave 
irradiation provided [(dF(CF3)ppy)2Ir-μ-Cl]2 in 40% yield, after 1 hour (Figure 5.5, Entry 1).  This 
reaction was visibly heterogeneous, consisting of amorphous green solids which were attributed 
to unreacted IrCl3.
291  Increasing the equivalents of L1 provided a slight increase in yield to 52% 
(Entry 2). The highest yield of the [(dF(CF3)ppy)2Ir-μ-Cl]2 dimer (59%) was obtained with 8 
equivalents of the cyclometalling L1 ligand after 1 hour of reaction time  (Entry 3). Extending the 
reaction time or changing the reaction temperature (250 °C, in triethylene glycol monoethyl ether) 
failed to increase dimer yield and only resulted in dimer decomposition (Entry 4 and Entry 5). 
Under identical reaction conditions, the [(ppy)2Ir-μ-Cl]2 dimer was isolated in 84% yield (Entry 
6), thus supporting our original hypothesis on the difference in reactivity among 2-arylpyridine 
derivatives.  While the use of 8 equivalents of L1 or L2 is seemingly excessive, the high ligand 
concentration is thought to neutralize the stoichiometric HCl generated during cyclometallation. 
Additionally, the mass balance of 2-phenylpyridine ligands could be recovered by an organic 
extraction following the reaction. 
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Figure 5.5. Optimization of reaction conditions 
The second step of the one-pot sequence was performed by simply opening the microwave 
reaction vial, adding 4,4'-di-tert-butyl-2,2'-bipyridine (L3) and recapping for another irradiation 
cycle. Notably, this avoided the addition of silver salts279 or exogenous base (K2CO3)
280  in order 
to facilitate the second ligation event. Conversion of the dimeric [(dF(CF3)ppy)2Ir-μ-Cl]2 complex 
to [Ir(dF(CF3)ppy)2(dtbbpy)]PF6 was successfully accomplished using 1.5 equivalents of the N^N 
ligand L3 and microwave heating for 30 minutes, followed by anion metathesis with ammonia 
hexafluorophosphate to give a 96% isolated yield (Entry 3, Step 2). Conversion of the [(ppy)2Ir-




Figure 5.6. Scope of Ir(III)+ complexes synthesized. Reaction conditions: (1) 1.0 equiv IrCl3•xH2O (50 
mg or 100 mg), 8.0 equiv cyclometalating ligand, in ethylene glycol (5 mL) and microwave irradiation (200 
°C) for 50 min. (2) 1.5 equiv dative ligand was added to the reaction solution followed by microwave 
irradiation (200 °C) for 30 min. 
 
With optimized conditions in hand, we explored the scope of our method for the preparation 
of synthetically useful and known heteroleptic Ir(III)+ complexes (Figure 5.6).273 The conditions 
proved efficient for generating the Ir(III)+ complex 5.1 with 2-phenylpyridine (L2) as the C^N 
ligand and 4,4'-di-tert-butyl-2,2'-bipyridine (L3) as the N^N ligand. Alternative difluoro and 
monofluoro 2-phenylpyridines gave the corresponding iridium complexes in 60-95% yield when 
partnered with the dative 4,4'-di-tert-butyl-2,2'-bipyridine and 2,2'-bipyridine ligands (5.2, 5.3, 5.4, 
5.5). Ligand solubility in ethylene glycol influenced the overall efficiency of the reaction. A 
moderate decrease in reaction yield was observed when the partially soluble L1 as well as 
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phenanthroline ligands were used as cyclometallating and dative ligands, respectively (5.6, 5.7, 
5.8).  
 
Figure 5.7. Gram-scale preparation of [Ir(ppy)2(dtbbpy)]PF6 
To demonstrate the utility of this process, a gram scale preparation of [Ir(ppy)2(dtbbpy)]PF6 
was performed (Figure 5.7). Satisfyingly, a 78% (1.12 grams) isolated yield of complex 5.1 was 
obtained without derivation from the optimized conditions. Notably, this reaction could be 
performed start to finish in less than 5 hours, demonstrating a substantial advance over currently 
existing methods. This reaction showcases the practicality of the method towards catalyst 
derivatization efforts.   
     In conclusion, we have reported an operationally simple, time efficient, and scalable microwave 
heating method for the preparation of heteroleptic Ir(III)+ complexes, an important class of 
photosensitizers for organic synthesis and light emitting materials. We envision that microwave 
heating can provide a direct replacement for conventional heating methods in the synthesis of 
metal-imine complexes. Importantly, this method is ideal for metal complex diversification, 
wherein uniquely functionalized complexes can be synthesized from a common [(C^N)2Ir-µ-Cl]2 
intermediate, in a synthetic process that is directly streamlined and capable of completion with 
minimal time at the bench.    
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5.2.2 Synthesis of Ir(III)+ Polypyridyl Nanohoop Complexes 
In our initial studies, we have prepared a library of Ir(III)+ polypyridyl complexes containing 
both bipy-8-CPP and bipy-9-CPP nanohoop ligands.  Both bipy-CPP ligands were synthesized 
according to procedures reported by Jasti et al.49  To investigate the feasibility of appending the 
nanohoop ligand onto an Ir(III)+ polypyridyl framework, we began by synthesizing three 
[(C^N)2Ir-μ-Cl]2  dimers derived from common Ir photocatalysts (Figure 5.8) using our reported 
microwave method.  Addition of the bipy-8-CPP nanohoop ligand (1.5 equiv), followed by 30 min 
of microwave irradiation at 200°C, resulted in the successful formation of Ir(III)+ bipy-CPP 
complexes 5.9, 5.10, and 5.11 (66-78% isolated yields).   
 
Figure 5.8. Synthesis of Ir(III)+ bipy-8-CPP and bipy-9-CPP complexes 
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We were able to validate generation of the desired heteroleptic Ir(III)+ nanohoop complexes using 
NMR spectroscopy and HRMS.  X-ray crystallographic structures were also obtained for 
complexes 5.19 and 5.10, showcasing successful incorporation of the nanohoop ligand (Figure 
5.9).  At the same time, we expanded upon our library to include heteroleptic Ir complexes(III)+ 
containing the bipy-9-CPP ligand, yielding the synthesis of complexes 5.11, 5.12, and 5.13.  X-
ray crystallographic data was acquired for compound 5.12.   
 
Figure 5.9. X-ray crystallographic data for select Ir(III)+ nanohoop complexes 
Based on our x-ray crystallographic data, we observed that in complexes 5.9, 5.10, and 5.12, 
the pyridyl group of one of the cyclometallating 2-phenylpyridine (ppy) ligands was positioned at 
an orientation that pointed inwards toward the nanohoop.  Additionally, all three structures 
contained dichloromethane solvent molecules that had co-crystallized within the nanohoop.  This 
led us to propose that the appendage of functionality (e.g. hydrogen bond donors/acceptors) at the 
2-position of the cyclometallating ligand could potentially lead to interactions between the 
complex and small molecule substrates, docked within the nanohoop, in a supramolecular host-
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guest fashion.  To test this hypothesis, we have synthesized several Ir(III)+ nanohoop derivatives 
(Figure 5.10) that contain both hydrogen bond donor and acceptor functionalities, including 
carboxylic acid, amide, and ketone moieties (5.17, 5.18, 5.19).  Ongoing efforts have been targeted 
towards the isolation and characterization of our expanded scope of nanohoop complexes.  
 
Figure 5.10. Synthesis of Ir(III)+ bipy-9-CPP complexes 
In order to investigate the photophysical properties of our Ir(III)+ nanohoop complexes, UV-
vis experiments were performed to measure the absorbances of complexes 5.9–5.14 (Figure 5.11).  
Absorbance of these complexes were measured in acetonitrile (10 µM).  The measured maximum 
absorbances for complexes 5.9–5.14 were observed to be between 318 – 344 nm, with complexes 
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bearing more electron deficient ligand substituents being more blue-shifted.  This phenomenon 
can be rationalized by the presence of electron withdrawing groups (e.g. fluorine and 
trifluoromethyl groups) that lower HOMO energies, resulting in larger HOMO–LUMO gaps and 
greater absorbance energies (more blue-shifted).  In comparison with the photocatalyst 
[Ir(dF(CF3)ppy)2(dtbbpy)]PF6 , which exhibits a higher maximum absorbance value of 476 nm,
38 
these Ir nanohoop complexes are observed to be more blue-shifted, with maximum absorbances 
prevalent in the near UV region.  
 
Figure 5.11. UV-vis Spectroscopy Data for Select Ir(III)+ Nanohoop Complexes 
Having investigated the photophysical properties of these complexes, we next turned to study 
their electrochemical properties via cyclic voltammetry (CV).  Our CV data (Figure 5.12) were 
reported relative to the ferrocenium/ferrocene redox couple.  The cyclic voltammograms of 
complexes were collected at scan rates of 100 mV/s in acetonitrile.  CV experiments revealed that 
complexes 5.12, 5.13, 5.14 underwent reduction at -0.92 V, -0.90 V, and -0.80 V, respectively, 
with reduction potentials decreasing for more electron deficient complexes.  Varying levels of 
reversibility were observed in the reduction waves of these complexes, with complex 5.12 
exhibiting the highest level of reversibility.  On the other hand, all three complexes, including the 
bipy-9-CPP nanohoop ligand demonstrated irreversible oxidation potentials of over 1.8 V, which 
suggests potential decomposition of the nanohoop ligand upon oxidation.  Ongoing experiments 
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have been focused on optimizing CV experimental parameters to more effectively measure redox 
potentials while preventing decomposition of the analyte.  
 
Figure 5.12. Cyclic voltammetry data for select Ir(III)+ nanohoop complexes 
5.3 Experimental Methods 
5.3.1 General Information and Experimental Procedures 
All reagents were obtained from commercial suppliers and used without further purification 
unless otherwise noted. IrCl3•xH2O was purchased from Pressure Chemical, NH4PF6 was 
purchased from Oakwood Products, Inc. and all ligands were obtained from Sigma-Aldrich unless 
otherwise specified.  Microwave heated reactions were carried out in sealed microwave flasks (2-
5 mL [CG-4920-01] or 10-20mL [CG-4920-02], Chemglass) and heated by a Biotage Initiator+ 
microwave synthesizer with a Robot Eight automated sampler. Temperature and pressure were 
monitored by an infrared sensor on the surface exterior of the vial. Pressure was monitored by a 
pressure transducer situated at the top of the vial.  NMR spectra were obtained on a 700 MHz 
Varian VNMRS spectrometer and a 500 MHz Varian VNMRS spectrometer.  1H and 13C NMR 
chemical shifts are reported in ppm relative to the residual acetone (δ 2.09) solvent peak.37 
Reactions were monitored by thin layer chromatography (TLC) using silica TLC plates obtained 
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from EMD Millipore; silica gel 60 F254, glass-backed, 250 μm, and were visualized with ultraviolet 
light.   
General Procedure for C^N ligand synthesis38 
2-(2,4-difluorophenyl)-5-(trifluoromethyl)pyridine. 
To a three-necked, 100 mL round bottom flask charged with a magnetic stir bar were added 2-
chloro-5-(trifluoromethyl)pyridine (3.1 g, 17.0 mmol, 0.9 equiv), 2,4-difluorophenylboronic acid 
(3.0 g, 19.0 mmol, 1.0 equiv), 2 M aqueous sodium carbonate (4.03 g, 38.0 mmol, 2.0 equiv), 
benzene (23 mL), and toluene (17 mL).  The mixture was degassed by sparging with N2 for 15 
min.  Then Pd(PPh3)4 (0.505 g, 0.437 mmol) was added to the reaction mixture and degassing was 
continued for another 15 min.  The reaction mixture was heated to reflux for 48 h to generate a 
yellow solution with yellow precipitate.  The progress of the reaction was monitored by TLC (85% 
ethyl acetate in hexanes).  Upon completion of the reaction, the mixture was cooled to room 
temperature and then extracted with dichloromethane (4 x 20 mL), washed with brine (3 x 20 mL), 
and dried over Na2SO4.  Solvent was removed under reduced pressure to give a dark brown oil 
which solidified at room temperature. The crude product was purified by flash chromatography 
using 100% dichloromethane to afford a yellow oil, which crystallized at room temperature.  The 
yellow oil was further dried in vacuo to afford the pure ligand in 77% yield (3.81 g, 14.7 mmol) 
as white crystals. 1H NMR chemical shifts match literature values.38 
2-(4-fluorophenyl)pyridine. 
To a three-necked, 100 mL round bottom flask charged with a magnetic stir bar were added 2-
chloropyridine (2.00 g, 17.61 mmol, 1.0 equiv), 4-fluorophenylboronic acid (2.96 g, 21.14 mmol, 
1.2 equiv), triphenylphosphine (0.46 g, 1.76 mmol, 0.1 equiv), 2 M aqueous potassium carbonate 
(6.55 g, 47.39 mmol), and dimethoxyethane (20 mL).  The mixture was degassed with N2 for 15 
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min.  Then 2.5 mol% Pd(OAc)2 (0.1 g, 0.441 mmol) was added to the reaction mixture and 
degassing was continued for another 15 min.  The reaction mixture was heated to reflux for 18 h 
to generate an orange solution with orange precipitate.  The progress of the reaction was monitored 
by TLC (10% ethyl acetate/hexanes).  Upon completion of the reaction, the mixture was cooled to 
room temperature and then extracted with dichloromethane (4 x 20 mL), washed with brine (3 x 
20 mL), and dried over Na2SO4.  Solvent was removed under reduced pressure, and the crude 
product was purified by flash chromatography (0-5% ethyl acetate in hexanes) on a 30 g silica 
column. The pure ligand was obtained in 55% yield (1.68 g, 9.7 mmol) as a white solid. 1H NMR 
chemical shifts match literature values.38  
General Procedure A for the Synthesis of Heteroleptic Ir(C^N)(N^N)2 Complexes  
(100 mg scale)  
To a Chemglass microwave vial (size 2-5 mL) equipped with a magnetic stir bar were added 
IrCl3•xH2O (50 or 100 mg, 1.0 equiv), cyclometalating ligand (8.0 equiv), and ethylene glycol (5 
mL, 32 or 64 μM).  The vial was sealed and pre-stirred for 1 min prior to heating under microwave 
irradiation (200 oC, 50 min) at atmospheric pressure.*  Upon allowing the mixture to cool to room 
temperature, the dative ligand was added (1.5 equiv), and the vial was heated under microwave 
irradiation (200 oC, 30 min) at atmospheric pressure.  After cooling to room temperature, the 
reaction mixture was diluted with DI H2O (25 mL) and extracted with hexanes (3 x 20 mL).  The 
aqueous portion was collected and heated to 75 oC for 15 min to remove remaining organic solvent.   
Aqueous ammonium hexafluorophosphate (2.0 g in 20 mL DI H2O) was added to the mixture, and 
the mixture was cooled in an ice bath.  The resulting precipitate was collected and washed with 
cold DI H2O (10 mL) and cold diethyl ether (10 mL).  Finally, the precipitate was taken up in 
acetone and dried in vacuo to afford the desired product. 
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Procedure for the 500 mg scale synthesis of [Ir(ppy)2(dtbbpy)]PF6 
The general procedure A was followed, using IrCl3‧H2O (500 mg, 1.6 mmol, 1.0 equiv), 2-
phenylpyridine (1.8 μL, 12.6 mmol, 8.0 equiv), and ethylene glycol (15 mL) to obtain a bright 
yellow solution with yellow solids.  2a was synthesized using 4,4'-di-t-butyl-2,2'-bipyridine (636 
mg, 2.36 mmol, 1.5 equiv) to afford a homogeneous orange solution. 2a was obtained in 78% yield 
(1.12 g, 1.22 mmol) as a yellow solid after recrystallization with acetone and diethyl ether at low 
temperatures. 
Procedure for the 500 mg scale synthesis of [Ir(dF(CF)3ppy)2(dtbbpy)]PF6 
The general procedure A was followed, using IrCl3‧H2O (500 mg, 1.6 mmol), 2-(2,4-
difluorophenyl)-5-(trifluoromethyl)pyridine (3.28 g, 12.6 mmol), and ethylene glycol (15 mL).  
The reaction mixture was sonicated before microwave irradiation to increase homogeneity of the 
solution. A bright orange solution with green amorphous solids was obtained. 2g was synthesized 
using 4,4'-di-t-butyl-2,2'-bipyridine (636 mg, 2.36 mmol) to afford an orange solution with green 
solids.  The reaction mixture was diluted with DI H2O (100 mL) and extracted with hexanes (3 x 
75 mL) and ethyl acetate (4 x 75 mL).  The ethyl acetate extract was collected, filtered to remove 
unreacted IrCl3 solids, dried over Na2SO4, and concentrated in vacuo to afford an orange oil with 
yellow solids.  DI H2O (75 mL) was combined with the mixture to generate a yellow solution with 
free-flowing yellow solids.  Aqueous ammonium hexafluorophosphate (10.0 g in 100 mL DI H2O) 
was then added to the mixture, and the whole was cooled in an ice bath.  The resulting yellow 
precipitate was collected and washed sequentially with cold DI H2O (4 x 25 mL) and hexanes (4 
x 25 mL).  Finally, the precipitate was taken up in acetone and dried in vacuo to afford a mixture 
of yellow solids and an orange oil. 2g was obtained in 50% yield (883 mg, 0.79 mmol) as a light 
yellow solid after recrystallization with acetone and diethyl ether at low temperatures.   
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5.3.2 Compound Characterization  
Characterization of Heteroleptic Ir(III)+ Complexes 
[Ir(ppy)2(dtbbpy)]PF6 (5.1): 1H-NMR (Acetone-d6, 700 MHz): δ 8.88 (s, 2H), 8.23 (d, J = 8.2 Hz, 
2H), 8.03 - 7.92 (m, 3H), 7.88 (d, J = 7.6 Hz, 2H), 7.78 (d, J = 5.7 Hz, 2H), 7.70 (d, J = 5.7 Hz, 
2H), 7.12 (t, J = 6.5 Hz, 2H), 7.02 (t, J = 7.4 Hz, 2H), 6.90 (t, J = 7.3 Hz, 2H), 6.33 (d, J = 7.5 Hz, 
2H), 1.40 (s, 13H).13C-NMR (Acetone-d6, 176 MHz): δ 167.88 (s), 163.97 (s), 155.89 (s), 151.00 
(s), 150.18 (s), 149.02 (s), 144.03 (s), 138.55 (s), 131.53 (s), 130.31 (s), 125.48 (s), 124.89 (s), 














[Ir(Fppy)2(bpy)]PF6 (5.2): 1H-NMR (Acetone-d6, 500 MHz): δ 8.91 (d, J = 8.2 Hz, 2H), 8.37 (td, 
J = 8.0, 1.4 Hz, 2H), 8.28 (d, J = 8.2 Hz, 2H), 8.21 (d, J = 5.3 Hz, 2H), 8.11 - 7.97 (m, 4H), 7.87 
(d, J = 5.8 Hz, 2H), 7.81 - 7.73 (m, 2H), 7.22 (t, J = 6.6 Hz, 2H), 6.87 (td, J = 8.8, 2.5 Hz, 2H), 
5.98 (dd, J = 9.5, 2.5 Hz, 2H). 13C-NMR (Acetone-d6, 176 MHz):  δ 166.48 (s), 164.40 (s), 162.96 
(s), 155.92 (s), 153.51 (d, J = 5.8 Hz), 150.78 (s), 149.28 (s), 140.51 (s), 139.91 (s), 139.06 (s), 
128.74 (s), 127.22 (d, J = 9.3 Hz), 124.97 (s), 123.68 (s), 120.11 (s), 117.40 (d, J = 17.8 Hz), 














[Ir(Fppy)2(dtbbpy)]PF6 (5.3): 1H-NMR (Acetone-d6, 700 MHz): δ 8.94 (s, 2H), 8.28 (d, J = 8.2 
Hz, 2H), 8.13 - 7.96 (m, 4H), 7.82 (d, J = 5.5 Hz, 2H), 7.77 (dd, J = 5.8, 1.7 Hz, 2H), 7.19 (t, J = 
6.2 Hz, 2H), 6.87 (td, J = 8.8, 2.5 Hz, 2H), 5.97 (dd, J = 9.5, 2.5 Hz, 2H), 1.45 (s, 18H). 13C-NMR 
(Acetone-d6, 176 MHz): δ 166.66 (s), 164.46 (s), 164.29 (s), 163.02 (s), 155.81 (s), 154.08 (d, J = 
5.6 Hz), 150.37 (s), 149.07 (s), 140.50 (s), 138.99 (s), 127.20 (d, J = 9.3 Hz), 125.66 (s), 123.56 














[Ir(dFppy)2(bpy)]PF6 (5.4): 1H-NMR (Acetone-d6, 700 MHz): δ 8.94 (s, 2H), 8.62 (d, J = 8.9 Hz, 
2H), 8.41 (d, J = 8.7 Hz, 2H), 8.19 (d, J = 5.8 Hz, 2H), 7.94 - 7.70 (m, 4H), 6.87 (t, J = 10.3 Hz, 
2H), 5.97 (d, J = 7.9 Hz, 2H), 1.43 (s, 18H). 13C-NMR (Acetone-d6, 176 MHz): δ 167.83 (s), 
165.33 (d, J = 18.6 Hz), 163.85 (d, J = 12.6 Hz), 163.19 (d, J = 12.7 Hz), 161.70 (d, J = 13.2 Hz), 
156.00 (s), 155.77 (d, J = 6.9 Hz), 151.09 (s), 145.72 (d, J = 4.7 Hz), 137.18 (s), 126.81 (s), 126.03 
(s), 125.23 (d, J = 34.6 Hz), 124.11 - 124.03 (m), 123.90 (d, J = 20.9 Hz), 122.91 (s), 122.67 (s), 
















[Ir(dFppy)2(dtbbpy)]PF6 (5.5): 1H-NMR (Acetone-d6, 500 MHz): δ 8.96 (s, 2H), 8.41 (d, J = 8.4 
Hz, 2H), 8.09 (dd, J = 14.1, 6.8 Hz, 4H), 7.90 (d, J = 5.6 Hz, 2H), 7.77 (dd, J = 5.8, 1.7 Hz, 2H), 
7.24 (t, J = 6.7 Hz, 2H), 6.86 – 6.70 (m, 2H), 5.80 (dd, J = 8.5, 2.2 Hz, 2H), 1.43 (s, 18H). 13C-
NMR (Acetone-d6, 176 MHz): δ 164.62 (s), 164.33 (d, J = 12.4 Hz), 163.91 (d, J = 7.0 Hz), 162.87 
(d, J = 12.6 Hz), 162.14 (d, J = 13.1 Hz), 160.67 (d, J = 12.9 Hz), 155.68 (s), 155.25 (d, J = 6.4 
Hz), 150.44 (s), 149.59 (s), 139.71 (s), 127.89 (s), 125.80 (s), 124.10 (s), 123.61 (d, J = 19.9 Hz), 















[Ir(dF(CF)3ppy)2(bpy)]PF6 (5.6): 1H-NMR (Acetone-d6, 700 MHz): δ 8.90 (d, J = 8.2 Hz, 2H), 
8.62 (d, J = 8.9 Hz, 2H), 8.41 (d, J = 7.4 Hz, 4H), 8.31 (d, J = 5.3 Hz, 2H), 7.98 (s, 2H), 7.87 - 
7.73 (m, 2H), 6.87 (t, J = 10.9 Hz, 2H), 5.97 (d, J = 8.3 Hz, 2H). 13C-NMR (Acetone-d6, 176 
MHz): δ 167.66 (d, J = 6.2 Hz), 165.26 (d, J = 12.6 Hz), 163.80 (d, J = 12.3 Hz), 163.18 (d, J = 
12.7 Hz), 161.69 (d, J = 13.1 Hz), 155.98 (s), 155.21 (d, J = 6.8 Hz), 151.48 (s), 146.20 (d, J = 
4.4 Hz), 140.71 (s), 137.29 (s), 129.17 (s), 126.87 (s), 125.72 (s), 125.63 - 125.31 (m), 125.31 - 
125.22 (m), 125.14 (s), 123.98 (s), 123.90 (d, J = 21.0 Hz), 122.90 (s), 121.35 (s), 119.81 (s), 















[Ir(dF(CF)3ppy)2(dtbbpy)]PF6 (5.7): 1H-NMR (Acetone-d6, 700 MHz): δ 8.94 (s, 2H), 8.62 (d, J 
= 8.9 Hz, 2H), 8.41 (d, J = 8.7 Hz, 2H), 8.19 (d, J = 5.8 Hz, 2H), 7.94 - 7.70 (m, 4H), 6.87 (t, J = 
10.3 Hz, 2H), 5.97 (d, J = 7.9 Hz, 2H), 1.43 (s, 18H).13C-NMR (Acetone-d6, 176 MHz): δ 167.83 
(s), 165.33 (d, J = 18.6 Hz), 163.85 (d, J = 12.6 Hz), 163.19 (d, J = 12.7 Hz), 161.70 (d, J = 13.2 
Hz), 156.00 (s), 155.77 (d, J = 6.9 Hz), 151.09 (s), 145.72 (d, J = 4.7 Hz), 137.18 (s), 126.81 (s), 
126.03 (s), 125.23 (d, J = 34.6 Hz), 124.11 - 124.03 (m), 123.90 (d, J = 20.9 Hz), 122.91 (s), 
122.67 (s), 121.37 (s), 114.44 (d, J = 17.9 Hz), 99.31 (d, J = 27.1 Hz), 99.09 (s), 99.08 (s), 35.70 















 [Ir(dF(CF)3ppy)2(phen)]PF6 (5.8): 1H-NMR (Acetone-d6, 500 MHz): δ 9.02 (d, J = 8.3 Hz, 2H), 
8.69 (d, J = 5.1 Hz, 2H), 8.62 (d, J = 8.6 Hz, 2H), 8.46 (s, 2H), 8.35 (d, J = 8.8 Hz, 2H), 8.16 (dd, 
J = 8.3, 5.1 Hz, 2H), 7.87 (s, 2H), 6.99 - 6.85 (m, 2H), 6.08 (dd, J = 8.4, 2.2 Hz, 2H). 13C-NMR 
(Acetone-d6, 176 MHz): δ 167.69 (d, J = 6.9 Hz), 165.24 (d, J = 12.9 Hz), 163.77 (d, J = 12.7 Hz), 
163.15 (d, J = 13.0 Hz), 161.66 (d, J = 13.1 Hz), 154.67 (d, J = 7.1 Hz), 152.33 (s), 146.75 (s), 
146.46 (d, J = 4.6 Hz), 139.72 (s), 137.19 (s), 131.91 (s), 128.63 (s), 127.34 (s), 127.12 (s), 125.33 
(s), 125.13 (s), 124.28 (s), 123.76 (d, J = 20.9 Hz), 123.69 - 123.55 (m), 122.74 (s), 121.19 (s), 
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